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Preface 
This Thesis describes the data obtained during the research work performed at the 
Instituto Gulbenkian de Ciência under the scientific supervision of Dr. Miguel P. 
Soares. 
It is organized in 4 chapters and two appendixes, preceded by an abstract written 
both in Portuguese and English. A state of the art introductory review on the 
subject is provided in Chapter 1. In Chapters 2, 3 and Appendix 1 the original 
observations obtained during the research period are presented and discussed. 
Chapter 5 consists of a general discussion aiming at integrating the results 
presented in the previous chapters. Appendix 2 is a review manuscript published 
during this time on a relevant topic for this Thesis. 
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Sumário 
A inflamação é uma resposta protetora iniciada por células da imunidade 
inata, em resposta a uma infeção ou lesão dos tecidos, cujo objetivo é eliminar a 
fonte de infeção ou o estímulo danoso. A resposta inflamatória desempenha um 
papel essencial na ativação da imunidade adaptativa. É regulada a vários níveis, 
de modo a minimizar o grau de danos infligidos aos tecidos. As células 
apresentadoras de antigénio (CAA) constituem um desses níveis de regulação, 
uma vez que controlam a ativação das células T auxiliares (TA), estabelecendo a 
ponte entre imunidade inata e adaptativa. A resposta gerada pelas células TA é 
geralmente protetora. No entanto, em algumas circunstâncias, que não se 
compreendem ainda totalmente, pode tornar-se patológica, como acontece na 
esclerose múltipla (EM) e no seu modelo animal encefalomielite autoimune 
experimental (EAE). Desta forma, seria de esperar que mecanismos que limitem a 
ativação e/ou reativação de células TA previnam a patogénese da neuroinflamação 
autoimune. Esta Tese descreve dois desses mecanismos: o primeiro é controlado 
pelo fator de transcrição, Fator 2 relacionado com o NF-E2 (Nrf2) e o segundo é 
controlado por um dos genes que aquele regula, o gene da enzima heme 
oxigenase-1 (Hmox1/HO-1). O Nrf2 regula a resposta celular ao stress oxidativo, 
enquanto a HO-1 é uma enzima que cataboliza grupos hémicos gerando monóxido 
de carbono (CO), ferro e biliverdina. Tanto o Nrf2 como a HO-1 foram previamente 
implicados na redução da resposta inflamatória, incluindo a que se encontra 
presente na neuroinflamação autoimune. 
O objetivo desta Tese foi compreender o papel do Nrf2 e da HO-1 na 
regulação da neuroinflamação autoimune. Para isso, estudámos o papel da 
expressão do Nrf2 e da HO-1 na patogénese da EAE. Investigámos ainda, de um 
ponto de vista terapêutico, o impacto da indução farmacológica da expressão da 
HO-1 e da administração exógena de um dos seus produtos, o CO. 
Ratinhos com disrupção funcional do gene que codifica o Nrf2 (Nrf2-/-) 
desenvolvem uma forma de EAE mais severa do que ratinhos com o gene intacto 
(Nrf2+/+). Este aumento de severidade é repetido quando se transferem leucócitos 
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encefalitogénicos adotivos de ratinhos Nrf2-/- vs. Nrf2+/+ para ratinhos naïve. A 
expressão da interleucina (IL)-12 está aumentada em células dendríticas (CD)  
Nrf2-/- vs. Nrf2+/+ no estado basal e após estimulação com LPS. Quando expostas a 
péptidos derivados da mielina, CD Nrf2-/- promovem a diferenciação de células TA, 
reativas contra a mielina, em células TA tipo 1 (TA1), que produzem interferão (IFN)-
. O efeito encefalitogénico dos leucócitos Nrf2-/- vs. Nrf2+/+ é suprimido quando a 
atividade da IL-12/23p40 é neutralizada com um anticorpo monoclonal. O mesmo 
se verifica quando leucócitos encefalitogénicos adotivos de ratinhos Nrf2-/- vs. 
Nrf2+/+ são transferidos para ratinhos naïve, com disrupção funcional do recetor do 
IFN- (Ifngr1-/-). O Nrf2 inibe a produção de IL-12 em CD através de um mecanismo 
que envolve a expressão da HO-1. No entanto, ratinhos com disrupção do gene 
que codifica a HO-1, especificamente em CD desenvolvem uma forma de EAE 
semelhante à observada em ratinhos controlo. Em suma, a expressão do Nrf2 em 
CD contraria a patogénese da neuroinflamação autoimune através de um 
mecanismo que inibe a produção de IL-12 em CD, prevenindo assim a 
diferenciação de células TA1. Este efeito protetor não parece ser mediado pela 
expressão da HO-1 em CD. 
No entanto, ratinhos com disrupção funcional sistémica do gene da HO-1 
(Hmox1-/-) desenvolvem uma forma de EAE mais severa do que ratinhos com o 
gene intacto (Hmox1+/+). A indução da HO-1 pela administração de protoporfirina IX 
de cobalto (CoPPIX), após o aparecimento dos sinais clínicos, resulta na melhoria 
da progressão da doença, e este efeito desaparece em ratinhos Hmox1-/-, o que 
indica que o CoPPIX atua via HO-1 para suprimir a progressão da EAE. O efeito 
protetor da indução farmacológica da HO-1 está associado a uma inibição da 
expressão do complexo principal de histocompatibilidade classe II (CPHII) em 
células apresentadoras de antigénio, incluindo CD, macrófagos e microglia, e na 
consequente redução da acumulação, proliferação e função efetora das células 
TA1 e T CD8+ no sistema nervoso central. A administração exógena de CO simula 
este efeito, o que sugere que este gás contribui para a ação protetora da HO-1 em 
EAE. Em suma, o gene da HO-1 controla a severidade da EAE e a indução 
farmacológica da sua expressão regula negativamente a expressão do CPHII em 
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CAA, regulando assim a resposta T e a severidade da EAE, supostamente via 
produção de CO, podendo vir a ser usado para tratar a EM. 
No seu conjunto, os resultados apresentados nesta Tese revelam que a 
expressão do Nrf2 e a indução farmacológica da expressão da HO-1 
desempenham um papel na regulação de CAA, com impacto na resposta T que 
está na origem da neuroinflamação autoimune, previamente subestimado. Estes 
dados revelam a importância do Nrf2 e da HO-1 no controlo da neuroinflamação 
autoimune através da modulação de células da imunidade inata e 
consequentemente da imunidade adaptativa.  
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Abstract 
Inflammation is a protective response generated by innate immune cells, upon 
infection and/or tissue injury, and aims at clearing the source of infection or noxious 
stimuli. It is required for activation of adaptive immunity. Inflammation has several 
layers of regulation in order to minimize the degree of tissue damage. Antigen-
presenting cells (APC) constitute one layer of regulation as they initiate the 
activation of T helper (TH) cells, bridging innate and adaptive immunity. The TH cell 
response generated is usually protective, although in certain circumstances, that 
are not completely understood, can also become pathological, as occurs in multiple 
sclerosis (MS) and in its mouse model, experimental autoimmune 
encephalomyelitis (EAE). Thus, mechanisms restraining TH cell activation and/or 
reactivation should prevent the pathogenesis of autoimmune neuroinflammation. In 
this Thesis we describe two of such mechanisms: one controlled by the 
transcription factor NF-E2-related factor 2 (Nrf2) and another controlled by one of 
its downstream genes Heme oxygenase-1 (Hmox1), which encodes the enzyme 
HO-1. Nrf2 is a transcription factor that regulates cellular responses to oxidative 
stress, while HO-1 catabolizes heme into carbon monoxide (CO), iron, and 
biliverdin. Both, Nrf2 and HO-1 have been implicated in dampening inflammatory 
reactions, including autoimmune neuroinflammation. 
The aim of this Thesis was to understand the role(s) of Nrf2, and its 
downstream gene Hmox1, in the regulation of autoimmune neuroinflammation. For 
this, we studied the role of Nrf2 and Hmox1 expression in the pathogenesis of EAE. 
Further, we investigated the impact of pharmacological induction of HO-1 
expression and exogenous CO administration from a therapeutic point of view. 
Nrf2-deficient (Nrf2-/-) mice develop a more severe form of EAE, as 
compared to wild type (Nrf2+/+) counterparts. This is recapitulated when 
encephalitogenic leukocytes from Nrf2-/- vs. Nrf2+/+ mice are adoptively transferred 
into naïve recipients. Expression of interleukin (IL)-12 is increased in resting and 
LPS-activated Nrf2-/- vs. Nrf2+/+ dendritic cells (DC). When “pulsed” with myelin-
derived peptides, Nrf2-/- DC favor the differentiation of myelin-reactive TH cells 
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towards a TH1 phenotype, producing IFN-. The encephalitogenic effect of Nrf2-/- vs. 
Nrf2+/+ leukocytes is suppressed when IL-12/23p40 activity is blocked using a 
monoclonal antibody. This is also the case when encephalitogenic leukocytes are 
adoptively transferred into naïve recipients lacking the IFN--receptor. Nrf2 inhibits 
IL-12 production in DC via a mechanism that involves the expression of HO-1. Mice 
carrying a deletion of the Hmox1 gene specifically in DC develop a similar form of 
EAE vs. wild type controls. Therefore, expression of Nrf2 in DC counters the 
pathogenesis of autoimmune neuroinflammation via a mechanism that inhibits IL-12 
production in DC, preventing encephalitogenic TH1 cell differentiation. This 
protective effect does not seem to be mediated by the expression of HO-1 in DC. 
However, mice with systemic deletion of Hmox1 (Hmox1-/-) also develop a 
more severe form of EAE, as compared to control mice (Hmox1+/+). Induction of 
HO-1, by cobalt protoporphyrin IX (CoPPIX) administration after EAE onset, 
reversed EAE progression and this effect was abrogated in Hmox1-/- mice, 
indicating that CoPPIX acts via HO-1 to suppress EAE progression. The protective 
effect of HO-1 induction was associated with inhibition of expression of MHC class 
II by DC, macrophages and microglia, and thus inhibition of accumulation, 
proliferation, and effector function of TH and TC cells within the CNS. Exogenous 
CO mimicked these effects, suggesting that CO contributes to the protective action 
of HO-1. Therefore, HO-1 controls the severity of EAE and its pharmacological 
induction negatively regulates the expression of MHC class II in APC and thus, the 
T cell response and severity of EAE. If, as we suggest, this effect is attributable to 
the production of CO, then treatment of MS might be possible through the 
therapeutic administration of CO. 
In conclusion, the results presented in this Thesis reveal that Nrf2 
expression, and pharmacological induction of HO-1, play a previously 
underappreciated role in the regulation of APC, with impact on the TH cell response 
at the core of autoimmune neuroinflammation. These data reveals the importance 
of Nrf2 and HO-1 in controlling autoimmune neuroinflammation, via modulation of 
innate immune cells and consequently adaptive immunity. 
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Chapter 1 
 
General Introduction 
  
2 
 
1. The immune response 
Immunity comprises a set of mechanisms that provide host protection to infection, 
and it can be subdivided into innate and adaptive immunity1. 
 
1.1. Innate immunity and inflammation 
Innate immunity is the first line of defense against infection and is characterized by 
the recognition of microorganisms, through germline encoded receptors, which 
detect evolutionarily conserved molecular patterns expressed by microbes. It is 
composed by a diverse set of cells and soluble mediators. Innate immune cells 
have hematopoietic origin, including dendritic cells (DC), macrophages (Mø), 
neutrophils, mast cells, basophils, eosinophils, NK cells and  T cells1. Soluble 
mediators include collectins, ficolins and pentraxins2. 
Innate immune cells express multiple germline encoded receptors called 
pattern-recognition receptors (PRRs) with specificity to a large number of molecular 
structures shared among classes of pathogenic and commensal microorganisms, 
named pathogen-associated molecular patterns (PAMPs)1,3. Only a specific class of 
PAMPs, viability-associated PAMPs (VitaPAMPs), appears to induce immune 
responses4. PRRs can also recognize molecules released by injured or dying cells, 
termed damage-associated molecular patterns (DAMPs), such as adenosine 
triphosphate (ATP), potassium ions, uric acid, high-mobility group box 1 protein 
(HMGB1) and members of the S100 calcium-binding family of proteins2. However, it 
is not clear whether innate immune activation by DAMPs empower these cells with 
the ability to activate adaptive immunity (see section 1.2)2. 
PRRs include Toll-like receptors (TLRs), C-type lectin receptors (CLRs), 
NOD-like receptors (NLRs) and RIG I-like receptors (RLRs)3,5. PRRs can be 
classified into secreted, transmembrane or cytosolic. Secreted PRRs include 
collectins, ficolins and pentraxins. These bind to microbial cell surfaces and activate 
the complement system5, which consists of a series of circulating inactive proteins, 
many being proteases, that become themselves activated by proteolytic cleavage in 
sequential reactions, releasing effector peptides. The complement cascade can be 
initiated by three major pathways: Alternative, Classical and Lectin6. The Alternative 
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pathway is spontaneously and continuously activated and plays a crucial role in 
immune surveillance7. The Classical and Lectin pathways of complement activation 
are induced when antibodies bind to their corresponding antigen or when mannan-
binding lectin binds mannose residues on the surface of microorganisms, 
respectively6. The process by which a microorganism is bound by a complement 
component facilitating its phagocytosis is called opsonization. Triggering of the 
complement cascade generates pro-inflammatory mediators, antimicrobial 
compounds, and anaphylactic peptides, and can lead to assembly of the multimeric 
protein membrane attack complex (MAC) that forms a cytolitic pore in the cell 
membrane6. 
Transmembrane PRRs comprise TLRs and CLRs located in cellular 
membranes and endosomes5. TLRs are the best characterized class of PRRs and 
are expressed in a cell-specific manner8. Cell-surface TLRs recognize PAMPs 
accessible on the cell surface, such as lipopolysaccharide (LPS) of Gram-negative 
bacteria (TLR4), while endosomal TLRs detect microbial nucleic acids such as 
double-stranded RNA (dsRNA; TLR3) or unmethylated CpG sequences common in 
bacterial and viral DNA (TLR9)8. CLRs localize in the outer membrane and detect 
carbohydrate components on fungal cell walls9.  
Cytosolic PRRs consist of NLRs and RLRs5. NLRs detect degradation 
products of peptidoglycans (a cell wall component of bacteria) and other microbial 
products, as well as several forms of stress and non-infectious crystal particles10. 
RLRs are expressed by virtually all cell types and detect viral nucleic acids11. 
Recognition of PAMPs or DAMPs by PRRs triggers the activation of specific 
signal transduction pathways and ultimately leads to the expression of effector 
molecules12,13 (Fig.1). These comprise cytokines, chemokines, vasoactive amines, 
lipid mediators and products of several proteolytic cascades, such as the 
complement system2. 
Tissue-resident innate immune cells play a crucial role in detecting the 
presence of pathogens as well as tissue injury1. Engagement of PRRs in tissue 
resident Mø and mast cells leads to their activation and initiation of inflammation, a 
response aimed at clearing pathogens and restoring tissue homeostasis2. In 
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Figure 1. Signal transduction pathways triggered by PRR engagement. TLR engagement 
leads to homo or heterophylic interactions and to the TLR-specific recruitment of the 
intracellular signaling adaptor molecules: myeloid differentiation primary response gene 88 
(MyD88), TIR-domain-containing adaptor protein-inducing IFN- (TRIF), TRIF-related adaptor 
molecule (TRAM) and TIR-associated protein (TIRAP)8. TIRAP and TRAM are adaptor 
molecules that allow MyD88 and TRIF recruitment, respectively. The adaptors recruited are 
specific for the TLR triggered, i.e. TLR4 can recruit the four adaptors, while TLR3 only TRIF 
and TLR9 only MyD8812. TLR signaling via MyD88 culminates in the activation of MAPK and 
NF-B and via TRIF in the activation of NF-B and IRF-312,13. CLRs (i.e. Dectin-1, DNGR1, 
Dectin-2) signal, either directly or by recruiting adaptor proteins, via spleen tyrosine kinase 
(Syk) leading to the activation of MAPK, NF-B and NF-AT12,13. NLRs activate MAPK and NF-
B as well as IRF-3 (NOD2) and IRF-7 (NOD1). NLR family members such as NLRP3 and 
NLRC4 form multiprotein complexes, the inflammasomes, leading to the activation of pro-
inflammatory caspases, generating active cytokines from inactive precursors10. RLRs (e.g. RIG-
I and MDA5) lead to the activation of NF-B, IRF-3 and IRF-712,13. 
addition, DC activation by PRR is crucial for the generation of adaptive immunity, as 
discussed in detail below (see section 1.1.1 and 1.2.1.2). 
The inflammatory response is revealed clinically by four classical signs 
described by Celsus in AD40 as “calor, rubor, tumor and dolor”. However, it is 
currently believed that asymptomatic inflammatory responses of lower magnitude 
occur more frequently than appreciated and play a central role in maintaining tissue 
homeostasis2. Presumably, inflammation, or a related process termed para-
inflammation, sharing many effector molecules, plays a critical physiological role in 
restoring homeostasis after mild cellular stress and tissue dysfunction, occurring in 
many instances irrespectively of infection2. 
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The kinetics of the inflammatory response comprises three distinct phases: 
initiation, amplification and resolution, each characterized by the expression of 
different mediators. PRR engagement triggers the initiation phase of the 
inflammatory response resulting in the coordinated delivery of circulating 
leukocytes, mainly neutrophils, and plasma proteins at a site of microbial infection 
or injury, while providing a physical barrier that prevents spreading of the infectious 
or noxious agent. Neutrophils gain access to the tissue through the endothelium 
and are activated via PRRs14. This leads to the release of the toxic contents of their 
granules such as reactive oxygen and nitrogen species (ROS and RNS, 
respectively), proteinase 3, cathepsin G and elastase14. If these toxic molecules are 
not sufficient to eliminate the infection, an additional layer of control is provided via 
activation of adaptive immunity (see section 1.2). This is called the amplification 
phase. 
While inflammatory mediators can eliminate the infection, they also cause 
tissue damage to the infected host. Once the infectious agent has been cleared, or 
the cause of tissue injury eliminated, a phase of repair and healing ensues, and this 
is called resolution. It avoids the development of pathological states characterized 
by chronic inflammation and activation of adaptive immunity, avoiding irreversible 
tissue damage. Failure in resolution of inflammation leads to the development of 
immune-mediated inflammatory diseases, acting as major causes of mortality and 
morbidity worldwide15. These include autoimmune diseases, such as multiple 
sclerosis (MS) in which tissue damage occurs within the central nervous system 
(CNS) (see section 2).  
During the resolution phase of an inflammatory response, apoptosis of 
neutrophils is triggered, while that of neighboring parenchyma cells is avoided. 
Recognition of apoptotic cells switches the cytokine and lipid mediators produced 
by resident Mø from a pro- to anti-inflammatory profile16,17. Examples include the 
anti-inflammatory cytokines interleukin (IL)-1016 and transforming growth factor 
(TGF)-17 as well as lipid mediators, such as lipoxins, resolvins and protectins18. 
Numerous other mechanisms contribute to the dampening of inflammation including 
but not limited to: i) inhibition of the major signal transduction pathways triggered by 
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PRRs, ii) suppression of innate immune responses by adaptive immune cells, iii) 
suppression by regulatory T cells (TREG), iv) control of lymphocyte expansion and 
promotion of cell death, and v) expression of anti-inflammatory stress-responsive 
genes (see section 3.3 and 3.3.1). 
 
1.1.1. Dendritic cells (DC) 
The main function of DC is the recognition of pathogens and the subsequent 
priming of adaptive immune responses, against specific antigens expressed by 
those pathogens19. Nonetheless, DC are also critical in suppressing immune 
responses, maintaining peripheral tolerance and tailoring T cell responses, 
according to the pathogen encountered20,21. 
DC are the most efficient antigen-presenting cells (APC) in the immune 
system22, capturing, processing and presenting antigens in the context of major 
histocompatibility complex (MHC) to T cells19. DC have the unique ability among all 
other APC of activating naïve T cells, bridging innate and adaptive immune 
systems, and are therefore called professional APC23. Other cells, such as Mø and 
B cells, can act as APC but mainly to reactivate primed T cells and thus only 
amplify the response23. Antigen presentation by DC can either be immunogenic or 
tolerogenic20,21. When immunogenic, DC trigger T cell proliferation and 
differentiation into distinct effector subsets (see section 1.2.1.2; Fig.2b), while 
tolerogenic DC promote T cell deletion, anergy or regulatory function20 (Fig.2a). The 
DC maturation status, DC subset, environment and the balance between pro- and 
anti-inflammatory gene expression determines whether a DC-T cell interaction will 
be immunogenic or tolerogenic21. 
DC are defined phenotypically by their specific morphology, characterized 
by the presence of dendrites, as well as by the surface expression of MHC class II 
and of the integrin cluster of differentiation (CD)11c24. Nevertheless, DC constitute 
an heterogeneous population composed of many functional subsets based on their 
location, surface marker expression and whether or not they are present during 
homeostasis24,25. All DC subsets are thought to have a common hematopoietic 
origin and to reside in tissues, such as the skin and mucosal surfaces, where they 
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Figure 2. DC maturation status dictates the result of the DC-T cell 
interaction. (a) Under homeostatic conditions, DC display an immature 
phenotype, expressing low levels of MHC class II and costimulatory 
molecules (e.g. CD40, CD80 and CD86)28. They are characterized by a 
high endocytic and phagocytic capacity28, sampling antigens and 
migrating to lymph nodes or the spleen thereafter where they present 
antigens to T cells19,21. Here, immature DC-T cell interactions result in 
suboptimal priming, favoring T cell tolerance21. (b) Signals such as 
PAMPs, DAMPs or pro-inflammatory cytokines can trigger DC 
maturation21. These signals cause a transient increase in antigen uptake 
and processing by DC, that subsequently decreases as DC mature, and 
is accompanied by the up-regulation of MHC class II and costimulatory 
molecules28. Mature DC present antigens via MHC class II for T cell 
receptor (TCR) recognition, providing costimulation, which will trigger T 
cell activation and proliferation19,28. Costimulation and secretion of a 
variety of cytokines will influence T cell differentiation into distinct effector 
TH cell subsets (see section 1.2.3)19,34. 
sample the environment and capture antigen, and in secondary lymphoid organs, 
such as the spleen and lymph nodes (LN)26. Splenic DC can be subdivided into 
plasmacytoid or conventional DC24. Plasmacytoid DC possess the unique feature of 
quickly secreting large amounts of type I interferons in response to PRR 
engagement27. Conventional DC can be further subdivided based on the surface 
expression of CD8 into CD8+ and CD8- cells24. These latter can be sub-
classified based on CD4 expression, but the physiologic relevance of this 
classification is still not clear24. 
In vivo, DC can exist in two states, immature and mature and only mature 
DC are able to prime immune responses28 (Fig.2b). A mature DC is defined by its 
ability to act in a immunogenic manner, i.e. to elicit an adaptive immune response, 
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upon presentation of antigen in the context of MHC molecules to naïve T cells28. 
Importantly, PAMPs, but not DAMPs can generate immunogenic DC. 
 
1.2. Adaptive immunity 
Adaptive immunity provides a highly specific response against infectious 
pathogens, while generating immunological memory, which refers to a quantitatively 
and qualitatively improved immune response upon subsequent exposure to the 
same antigen13. Contrary to innate immunity, the adaptive immune system relies on 
clonally expressed and highly specific antigen receptors, capable of recognizing 
virtually any antigen13. The high specificity and affinity of antigen receptors is due to 
somatic recombination and hypermutation of the genes encoding these receptors. 
These are composed of several segments that can be assembled in different 
combinations in a process called somatic recombination. In addition, a controlled 
program of creating point mutations in these genes generates high-affinity antigen 
receptor variants in a process called somatic hypermutation. 
Antigen receptors are called B cell- and T cell-receptors (BCR and TCR), 
when expressed on B and T cells, respectively, the two cell types that compose the 
cellular arm of the adaptive immune system1. B and T cell precursors originate in 
the bone marrow, with B cell precursors maturing in the bone marrow while T cell 
progenitors migrate to the thymus where they give rise to mature T cells. The 
adaptive immune system is also composed by a humoral arm, provided by soluble 
BCR, i.e. antibodies produced by activated B cells that differentiate into antibody-
producing plasma cells. Antibodies belong to different immunoglobulin (Ig) 
classes/isotypes that have different effector functions.  
B cells can be activated in a T cell-dependent or independent manner, 
resulting in differentiation into plasma cells that mediate the responses through 
antibody production. On the other hand, T cells mediate their function through the 
production of pro-inflammatory cytokines or cytotoxic activity. 
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1.2.1. T cells 
T cells can be subdivided into T cytotoxic (TC), helper (TH) and TREG cells1. TC are 
defined by the expression of the TCR co-receptor CD8 whereas TH and TREG by the 
expression of CD4. TC cells recognize antigens presented in the context of MHC 
class I while TH and TREG cells do so in the context of MHC class II molecules29. TC 
cells mediate defense, mainly against viral infections and tumors, by virtue of their 
direct cytotoxic effect exerted on target cells in an antigen-specific manner30. TH 
cells orchestrate immune responses against a wide range of pathogens, help B 
cells produce antibodies, enhance and maintain TC cell responses, regulate Mø 
function31. TREG suppress immune responses to control autoimmunity and adjust the 
magnitude and persistence of the response31. 
 
1.2.1.1. TH and TREG cell lineages 
There are at least four CD4+ T cell lineages: TH1, TH2, TH17, and TREG (Fig.3). TH1, 
TH2 and TH17 are important for eradicating intracellular pathogens, helminths and 
extracellular bacteria/fungi, respectively31. In addition, TH2 cells contribute to allergic 
responses, whilst TH1 and TH17 play an important role in the pathogenesis of 
autoimmune diseases, such as MS (see section 2)31. TREG cells suppress immune 
responses and maintain peripheral tolerance (see section 1.3.2)32. There are 
several described populations of regulatory T cells, such as Tr1, Th3, but the best 
characterized are TREG, defined by the surface expression of IL-2 receptor  chain 
(CD25) and the transcription factor forkhead box P3 (Foxp3)31,33. TREG can be 
subdivided in two subsets based on how they are generated. Natural TREG (nTREG) 
are generated in the thymus, expressing Foxp3 constitutively, while inducible TREG 
(iTREG) are generated in the periphery by the induction of Foxp3 expression upon 
antigen encounter32 (see section 1.2.1.2). 
Two other TH cell phenotypes may be considered as lineages, i.e. TH9 and 
follicular helper T (TFH) cells. TH9 cells are derived from TH2 cells in the presence of 
TGF- and it is unclear whether they constitute a new lineage or are the result of 
adaptation of TH2 cells to a change in the microenvironment during an ongoing 
immune response31,34. TFH cells reside in B cell follicles where they provide help to 
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Figure 3. Generation of effector TH and iTREG cell subsets. Cytokines play critical roles in the 
differentiation and effector functions of TH1, TH17, TH2 and iTREG cells. Upon TCR activation 
triggered by DC, naïve CD4+ T cells differentiate into distinct lineages in the context of different 
combinations of cytokines. The differentiation process involves the activation of specific STAT 
proteins and up-regulation of lineage-specific transcription factors. Each lineage then secretes a 
specific pattern of cytokines. 
B cells. TFH can secrete TH1, TH2 and TH17 signature cytokines, which raises 
questions as to whether this is a bona fide T cell lineage or an adaptation of these 
subsets to the environment in B cell follicles31,34. 
Effector TH and iTREG cell lineages produce specific patterns of cytokines 
that relate to the particular function of that lineage (Fig.3). For TH1 cells, interferon 
(IFN)- is the signature cytokine. TH1 cells also produce lymphotoxin31,35 as well as 
high levels of IL-2 and tumor necrosis factor (TNF)31,35. TH1 cytokines are potent 
activators of Mø, which deal with intracellular pathogens36. TH2 cells secrete IL-4, 
IL-5 and IL-13 as signature cytokines31,35. They also produce IL-10, TNF, modest 
amounts of IL-2 and some can produce IL-931. TH2 cytokines are critical for IgE 
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production, eosinophil recruitment and clearance of extracellular parasites30,35,37. 
TH17 cells are characterized by the production of IL-17A, IL-17F and IL-22 as well 
as high levels of IL-2131,38-40. These induce the recruitment of neutrophils and clear 
extracellular bacterial and fungal infections41. iTREG produce TGF-as signature 
cytokine and limit the magnitude of immune responses31,42. 
 
1.2.1.2. Effector TH and iTREG cell generation 
 Upon TCR engagement, a combination of cytokines is required for the 
differentiation of each TH cell subset and iTREG and generation of effector function: 
IL-12 and IFN- for TH1, IL-4 and IL-2 for TH2, TGF- and IL-6/IL-21/IL-23 for TH17 
and TGF-and IL-2 for iTREG31 (Fig.3). In all cases, the effector cytokines produced 
by a given lineage promote further differentiation into that subset, via a positive 
feedback loop that stabilizes lineage commitment. This appears to be the case for 
TH1 via the production of IFN-, for TH2 via the production of IL-4, for TH17 via the 
production of IL-21, and for iTREG via the production of TGF-31At later stages of T 
cell differentiation, TCR-independent cytokine production can also be induced by IL-
18 for TH1, IL-7/ thymic stromal lymphopoietin (TSLP)/IL-33 for TH2 and IL-1 for 
TH1731. 
Cytokines and costimulatory molecules produced by innate immune cells, 
and in particular by DC, play a critical role in determining CD4+ T cell differentiation 
towards TH1, TH2, TH17 or iTREG. IL-12 produced by DC is necessary and sufficient 
for TH1 differentiation both, in vitro43 and in vivo44, as demonstrated in the context of 
Toxoplasma gondii infection. Expression of the costimulatory molecule CD70 by DC 
also induces TH1 differentiation45,46. In addition, different subsets of DC can induce 
specific TH cell lineages. Splenic CD8+ DC that localize preferentially in the T cell 
rich areas of the spleen secret high levels of IL-12, driving TH cell activation towards 
a TH1 phenotype24,47,48. In contrast, CD8- DC are localized in the marginal zone of 
the spleen and do not generally secrete much IL-12, secreting preferentially IL-10, 
and as such, inducing TH2 responses24,47,48. The contribution of DC-derived 
cytokines for the differentiation of other TH cell lineages is less clear. Whether 
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cytokines necessary for TH2, TH17 and iTREG differentiation are DC-derived is still 
poorly defined24. In addition, other innate immune cells can influence TH cell 
differentiation by producing cytokines that favor commitment towards specific 
lineages. T cells promote TH17 responses via the production of IL-21, basophils 
TH2 via the production of IL-4 and NK cells TH1 via the production of IFN-34. 
 
1.2.1.3. Molecular mechanisms of effector TH and iTREG cell generation  
Signaling by several cytokines, including IL-12, IFN-, IL-4, IL-6, IL-21, IL-23 and IL-
2 trigger the activation of signal transducer and activator of transcription (STAT) 
proteins and the expression of transcription factors essential for TH and iTREG cell 
lineage commitment31. In addition, these cytokines are also involved in active 
suppression of alternative lineage fates. This occurs via the regulation of genes 
promoting lineage commitment, while repressing alternative lineage genes, 
therefore rendering subsets mutually exclusive. STAT-4, T-box transcription factor 
(T-bet) and Eomesodermin are important for TH1 differentiation, STAT-5 and trans-
acting T cell-specific transcription factor (GATA) 3 for TH2, STAT-3, retinoic acid 
receptor-related orphan receptor (ROR) t and  for TH17, and STAT-5 and Foxp3 
for iTREG31 (Fig.3). These transcription factors bind directly to regulatory DNA 
regions, such as promoters, enhancers, insulators and locus control regions of the 
effector cytokine genes, i.e. T-bet for Ifng, GATA3 for Il4 and Il13 and RORt for 
Il17a and Il17f 31, inducing gene activation, repression or epigenetic modifications, 
thus regulating gene expression31. This phenomenon is well characterized for TH1 
lineage commitment, where the transcription factor T-bet promotes IFN- 
transcription49 by chromatin remodeling at the Ifng gene promoter locus50. 
There is a great degree of plasticity between CD4+ T cell lineages. Several 
examples have been described, for example for iTREG and TH17 differentiation 
plasticity51. Briefly, TGF-β induces both Foxp3 and RORt in naïve CD4+ T cells, 
but Foxp3 is dominant and antagonizes RORt function unless IL-6 is present52. 
Thus, an inflammatory environment alters the balance between iTreg and TH17 
differentiation towards the TH17 lineage. TH17 differentiation in vitro also shows a 
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STAT4- and T-bet-dependent plasticity towards TH1 and in vivo during chronic 
inflammation TH17 cells convert to IFN-producers
34,53-55. TH2 cells can produce 
both IL-4 and IFN- upon a viral infection in vivo56 and IL-10 can be induced in TH1 
cells during infection, generating cells that produce both IL-10 and IFN-57,58. These 
observations suggest that CD4+ T cell lineage commitment in vivo is probably not 
as rigid as it appears from in vitro studies. There is flexibility in the secretion of 
cytokines among TH and iTREG lineages, according to the trigger and phase of the 
immune response, conferring adaptability to this response. However, the plasticity 
appears not to be random but to follow well-defined rules. 
 
1.3. Immune tolerance 
The immune system maintains a delicate balance between responding to non-self, 
pathogen-derived, antigens, while acquiring and maintaining a state of tolerance to 
the body’s self-antigens, commensal microorganisms and foreign innocuous 
antigens59. The disturbance of this balance can lead either to pathologic tolerance 
in detriment of immunity, resulting in chronic infections and tumors, or a pathologic 
failure of tolerogenic mechanisms resulting in autoimmune diseases, such as MS59 
(see section 2). Immune tolerance is maintained by central and peripheral 
mechanisms. Central tolerance operates in the thymus and in the bone marrow to 
eliminate self-reactive immature T and B cells, respectively59, while peripheral 
tolerance operates once mature T and B cells emigrate from the thymus or bone 
marrow, and controls auto-reactive T and B cells in the periphery60. 
 
1.3.1. Central T cell tolerance in the thymus 
During T cell development in the thymus, thymocytes are selected by thymic APC 
presenting self-antigens representing the diversity of peripheral tissues61. Positive 
selection is the process by which thymocytes that are able to establish intermediate 
affinity interactions with a peptide-MHC complex receive survival signals, while 
those with no or very low affinity undergo apoptosis61,62. Negative selection consists 
in the elimination by apoptosis of thymocytes with high affinity for self-antigens61. 
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This process aims at purging the mature T cell repertoire from self-reactive T cells 
with a high affinity towards self-antigens, as to prevent the development of 
autoimmune diseases, such as MS (see section 2).  
However, central tolerance mechanisms are not 100% effective and as a 
consequence, self-reactive T cells escape and are found in the peripheral T cell 
repertoire of healthy individuals61,62. Peripheral tolerance mechanisms are thus 
essential to control the activation of these auto-reactive T cells and prevent T cell 
driven autoimmunity, such as occurs in MS (see section 2). 
 
1.3.2. Peripheral T cell tolerance 
Peripheral tolerance mechanisms comprise inactivation of auto-reactive T cells by 
deletion, induction of anergy or suppression by TREG cells21,60. iTREG cells play a 
pivotal role in the maintenance of peripheral tolerance63, via a mechanism involving 
the production of IL-10 and TGF-β. The suppressive activity of nTREG is thought to 
rely also on cell/cell-contact and inhibitory surface molecules targeting DC and T 
cell activation64. Several mechanisms have been suggested and can be grouped 
into: 1) suppression by cytolysis, acting via granzyme secretion or the TNF-related 
apoptosis inducing ligand death receptor 5 (TRAIL-DR5) pathway; 2) metabolic 
disruption, acting via IL-2-deprivation-mediated apoptosis or through the release of 
adenosine nucleosides and 3) modulation of DC maturation or function, acting via 
the costimulatory molecule cytotoxic T-lymphocyte antigen 4 (CTLA4)64. Whether 
these mechanisms are redundant, or not, remains to be established. What is clear 
from the autoimmune phenotype associated with Foxp3 inactivation, in both mice 
and humans, is that TREG cells are essential in maintaining immune homeostasis 
preventing autoimmune diseases, such as MS33. 
 
2. Multiple sclerosis (MS) 
MS is the most prevalent chronic autoimmune inflammatory disease targeting the 
CNS65-67. It is the leading cause of neurological disability in young adults, affecting 
about one in 1000 individuals in Western countries and more than one million 
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people worldwide. Notably, it is two to three times more prevalent in women than in 
men67. 
It is a heterogeneous disease in terms of clinical symptoms, as well as 
progression (Fig.4a). Symptoms include defects in sensation and in the motor, 
autonomic, visual and cognitive systems67,68. In the early stages, around 85-90% of 
the individuals have a relapsing-remitting disease course (RR-MS), with slow-
progressing disability, characterized by recurrent unpredictable episodes of 
neurological deficits followed by periods of remission where the symptoms 
disappear partially or completely67,68 (Fig.4a). However, with time, about 50% of the 
individuals with RR-MS develop a progressive form of disease with cumulative and 
incapacitating disability, called secondary progressive multiple sclerosis (SP-
MS)67,68 (Fig.4a). 10-15% of the MS patients present at diagnosis a progressively 
worsening form of disease, called primary progressive (PP-MS)67,68 (Fig.4a). 
2.1. Pathology 
MS pathology is clinically and histologically heterogeneous66. It has become 
increasingly recognized that MS may not refer to a single disease, but rather to a 
composite of several pathological processes manifested in different clinical 
 
Figure 4. Progression of clinical disability in MS. (a) In PP-MS clinical disability increases cumulatively 
from the onset of MS. In patients with RR-MS, after onset of disease, sporadic clinical relapses are followed 
by periods of remission, until disease progression turns SP-MS where clinical disability increases cumulatively 
with no recovery. (b) In RR-MS acute white matter demyelination predominates at initial stages of the disease 
and declines with time, while grey matter demyelination is present from the beginning but increases in SP-
MS.(c) In RR-MS acute axonal damage prevails in the first phase of the disease and is partially reversible. 
Brain atrophy starts from the onset of the clinical symptoms but increases in later stages of MS. Adapted from 
Siffrin et al. (2010) Trends Neurosc. 
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phenotypes that encompass RR-MS and SP-MS67 (Fig.4a). MS is characterized by 
lesions in the white matter of the CNS composed of myelinated axons, as visualized 
by magnetic resonance imaging. These lesions are usually characterized by 
perivascular lymphocyte, Mø and antibody-producing plasma cell infiltration. They 
present signs of demyelination, oligodendrocyte injury and death, axonal damage 
and loss, as well as an increase in microglia and astrocytes, i.e. glial scar69. 
Antibody deposition and complement activation have also been reported69. It is 
widely accepted that T cells are at the core of the pathogenesis of MS65,69 (see 
section 2.4.3.2). Immunosuppression studies support this notion, as neurological 
deficits associated with MS improve with treatment70 and in particular with 
monoclonal antibodies targeting T cells71. 
The classical view of MS pathology emphasized the importance of CNS 
lesions in the white matter, leading to demyelination and oligodendrocyte loss, but 
recent evidence from histology and advanced MRI techniques revealed that grey 
matter (part of the CNS consisting of neuronal cell bodies and dendrites, glial cells 
and vasculature) pathology, causing neuronal death, is present from the earliest 
stages of MS (Fig.4b). In fact, cortical lesions tend to have fewer infiltrating 
leukocytes and more prominent neuronal degeneration than white matter lesions. 
Another feature of grey matter pathology is atrophy, which worsens more rapidly 
than white matter atrophy and correlates with disability66 (Fig.4c). The current view 
is that MS pathology is complex, involving both immune and degenerative 
mechanisms66,67. Immune mechanisms target both white and grey matter and 
neurodegenerative processes include loss of axons in lesions, diffuse damage to 
white matter distant from areas of visible active lesions, and involvement of both 
deep and cortical grey matter67,72. 
The mechanisms underlying the heterogeneity of MS manifestations are still 
not clear, but the different localization and types of lesions among individuals with 
MS, as well as the different contributions of the immune and degenerative 
processes controlling MS pathogenesis could be part of the explanation. 
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2.2 Ethiology 
The exact cause of MS is unknown, but epidemiological studies indicate that 
genetic and environmental factors, and their interaction, play a determinant role in 
disease predisposition66,73,74. 
 
2.2.1. Genetic factors 
The case for genetic factors is strongly suggested by the observation of disease 
clustering in families and concordance rate studies in twins. Mono and dizygotic 
twin studies show a 5% concordance rate for the first and 25-40% for the latter, in 
both cases superior to the 0,1% prevalence of MS observed in Western 
populations74,75. In addition, genome-wide linkage analysis, candidate gene and 
genome-wide association studies revealed several genes that confer susceptibility 
to MS. The human leukocyte antigen (HLA) locus confers a dominant risk of 
developing MS, in particular the HLA-DRB1 gene74. HLA-DRB1*1501 is the main 
susceptibility allele, and risk conferred by this allele can still be increased or 
reduced depending on whether individuals carry in trans (in another chromosome) 
the alleles HLA-DRB1*0801 or HLA-DRB1*1401, respectively. In the HLA class I 
region, alleles that confer moderate to high risk (HLA-A*0301) or protection (HLA-
A*0201 and HLA-C*05) have also been reported74. In addition, 49 other genes have 
alleles that confer a small risk to MS. These include, but are not limited to, 
immunological genes important in T cell responses that encode: cell adhesion 
molecules, costimulatory molecules, cytokines, cytokine receptors and signal 
transducers of these cytokine receptors76. Among these are polymorphisms in the 
human IL12A (IL12p35), IL12B (IL12/23p40), IL12RB176 and IFNG77 genes, 
suggesting a pathogenic role for TH1 cells in autoimmune neuroinflammation (see 
section 2.4.3.2). 
Given the above, MS is considered a polygenic disease where many genes 
have small contributions to disease predisposition, and the pathologic outcome will 
depend on the genetic background of the individual and its interaction with post-
genomic regulatory events, such as gene rearrangement, epigenetic modifications, 
RNA editing and splicing, and with environmental factors73,74 (Fig.5). 
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Figure 5. Factors that confer susceptibility to MS. The onset of MS results 
from genetic factors, responsible for a modest disease risk, and their interaction 
with post-genomic regulatory and environmental factors. For a matter of 
simplification only some of the factors in each category are mentioned. Adapted 
from Oksenberg et al. (2010) Nat. Rev. Neurol. 
2.2.2. Environmental factors 
The contribution of environmental factors to the pathogenesis of MS is revealed by 
the observation that monozygotic twins have only 25-40% instead of 100% 
concordance in MS development, with concordance rates differing by latitude. 
Migration, latitude, and month of birth all influence disease prevalence, further 
supporting a role for the environment in MS risk73. Reduced sunlight exposure is a 
candidate risk factor for the increase in MS prevalence with latitude. Sunlight is 
required for Vitamin D synthesis and low levels Vitamin D are common in 
individuals with MS, correlating negatively with relapse rate and disability. 
Preliminary studies also suggest high-dose Vitamin D supplementation may reduce 
MS relapses66,73. However, sunlight and Vitamin D seem to have independent 
effects on MS susceptibility66,73 (Fig.5). 
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Several viral and bacterial infections have also been suggested to act as risk 
factors in MS, being the most compelling evidence provided for Epstein Bar virus 
(EBV) infection66. However, as for other infectious triggers a causal relationship is 
still missing66. Infection can trigger autoimmunity by several processes such as: i) 
molecular mimicry, ii) bystander activation or iii) epitope spreading. Molecular 
mimicry is the process by which autoreactive T cells cross-react with a microbial 
epitope sharing sequence or structural homology with a self-antigen78. Bystander 
activation refers to the non-antigen specific activation of autoreactive T cells by the 
inflammatory environment triggered, for instance, by an infection78. Epitope 
spreading refers to the development of reactivity to epitopes distinct from, and non-
cross-reactive with, the disease-inducing epitope that is promoted during chronic 
inflammation78 (see section 2.4.1; Fig.5). 
 
2.3. Experimental models of MS 
Much of the current understanding of the pathogenesis of MS is driven from its 
animal models. As it is still not clear whether MS is the result of an autoimmune 
response, a response to infection, or a combination of the two, the animal models 
available reflect this, with two types available: autoimmune and viral79,80. We will 
only discuss the autoimmune model, experimental autoimmune encephalomyelitis 
(EAE), as viral models fall out of the scope of this Thesis. 
 
2.3.1 Experimental autoimmune encephalomyelitis (EAE) 
The gold standard to study the autoimmune ethiology of MS is EAE81,82. The 
pathological mechanisms involved in producing the acute lesion of EAE share 
similarities with those of MS, making it a suitable model to understand the 
immunological basis of MS79. EAE can be actively induced in susceptible inbred 
mouse strains by immunization with spinal cord homogenate, myelin basic protein 
(MBP), proteolipid protein (PLP) or peptides from encephalitogenic regions of MPB, 
PLP or myelin oligodendrocyte glycoprotein (MOG)83 in complete Freund’s adjuvant 
(CFA)79,80. Depending on the mouse genetic strain and encephalitogen used, the 
profile of disease can vary from acute monophasic to chronic progressive or 
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relapsing-remitting79. MOG is located at the surface of the myelin sheath and is a 
minor myelin component68,80. When immunized with the MOG35-55 peptide in 
conjunction with Pertussis toxin (PTx) administration, C57BL/6 mice develop a 
chronic progressive EAE after an asymptomatic period of 10 to 20 days80,83. PTx 
facilitates T cell access to the CNS, presumably via TLR4-mediated induction of 
adhesion molecules in the endothelium of the blood-brain barrier84. In addition, PTx 
contributes to the break of T cell tolerance, promoting clonal expansion and 
cytokine production by T cells79,80. This immunization model promotes the activation 
of TH cells, specifically of the TH1 and TH17 lineages79,80. CNS lesions are located 
predominantly in the spinal cord, leading to a classical EAE manifestation, that is a 
progressive ascending paralysis starting from the tail and reaching the forelimbs in 
the more severe stages79. 
Alternatively, EAE can be induced by adoptive transfer of TH cells from 
immunized donors to naïve mice85. Adoptive transfer of different TH cell lineages 
can cause autoimmune neuroinflammation65,86 but of major importance are TH1 and 
TH17 lineages87,88. TH1- and TH17-driven EAE have functional and pathogenic 
differences89,90. TH1-induced EAE causes classical EAE, in which infiltrating cells 
are mostly of monocytic origin and lesions are restricted to the spinal cord89. 
Instead, TH17 cells cause atypical EAE that manifest as an axial rotatory movement 
that starts as a subtle head tilt and in more severe states leads to rotation over the 
longitudinal axis. The infiltrate is granulocytic and the lesions locate predominantly 
to the brain, brainstem and cerebellum89. In addition, the ratio of TH1 vs. TH17 cells 
determines the localization of the lesions91. Only when IL-17-secreting TH cells are 
in excess over IFN--producing cells, do EAE lesions localize to the brain, 
suggesting that IFN- signaling has a protective role in the brain, while pathogenic 
in the spinal cord91,92. Functional differences between TH1 vs. TH17 EAE are also 
illustrated by the fact that treatment with IFN- improves TH1 while worsening TH17-
induced pathology91. 
Several CD4+ TCR transgenic mouse models recognizing specific myelin-
derived peptides (MBPAc1-9, PLP139-151, MOG35-55) including a “humanized mouse” 
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model expressing a TCR specific for human MBP in the context of HLA-DR2 have 
been generated79,80. Importantly, in these models, development of spontaneous 
EAE occurs with variable incidence93-96. MBPAc1-9 CD4+ TCR transgenic develop 
spontaneous EAE with a frequency of 14%93. EAE incidence increases to 100% 
when MBPAc1-9 CD4+ TCR transgenic are crossed with recombination activating 
gene (Rag1)-deficient mice93, in which endogenous TCR recombination is 
suppressed. This reveals that the remaining polyclonal T cell repertoire of Rag1-
competent MBPAc1-9 CD4+ TCR transgenic mice exerts a potent regulatory effect 
over pathogenic anti-MBPAc1-9 TCR transgenic TH cells. This regulatory effect was 
later found to be mediated by nTREG cells97,98. In a similar manner, MOG35-55 TCR 
transgenic mice (2D2) develop EAE at a frequency of 4%, but have a spontaneous 
incidence of optic neuritis of 30%96. Whether spontaneous incidence of EAE or 
higher incidence of optic neuritis increases when TREG are deleted in 2D2 mice is 
likely to be the case, but this remains to be tested. Interestingly, for a significant 
proportion of individuals with MS, optic neuritis is the first clinical manifestation of 
the disease99. 
TC cells also play a pathogenic role in MS and EAE and models based on TC 
cells exist as well. In these models, EAE is induced either by adoptive transfer of 
activated myelin-specific TC cells or by generation of CD8+ TCR transgenic 
mice80,100. EAE manifestation is different from TH cell-mediated EAE, but resembles 
many features of MS80,100. 
Each of the animal models discussed above reproduces only part of the 
heterogeneous pathological features seen in MS, and to recapitulate the whole 
spectrum of the disease and understand its pathogenesis they need to be analyzed 
in combination79,80. 
 
2.4. Pathogenesis 
While the triggering event in MS pathogenesis is not clear, it is widely accepted that 
an autoimmune TH cell response against myelin components is central to this 
process65,68. Presumably, myelin-specific autoreactive TH cells that escape deletion 
in the thymus, become activated in the periphery and cross the blood-cerebral 
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Figure 6. Peripheral activation and CNS invasion by TH cells. TH cells are primed in the 
periphery by DC presenting myelin epitopes (1). TH cells cross the BCB barrier either in the 
choroid plexus or the meningeal venules (2); the TH cells are reactivated within the subarachnoid 
space by DC expressing myelin epitopes (3). Reactivated TH cells trigger activation of distal 
microglial cells and blood vessels (4). Activated TH cells adhere to and cross the activated 
endothelium of the BBB, enter the perivascular space and are reactivated by perivascular DC 
(5). TH cells enter the parenchyma and, together with activated Mø and microglial cells, secrete 
soluble mediators that cause demyelination (6). Adapted from Goverman (2009) Nat. Rev. 
Immunol. 
spinal fluid (CSF) or blood-brain barrier (BCB and BBB, respectively) to be 
reactivated in the CNS by resident APC65 (Fig.6).T cell reactivation triggers effector 
function that initiates recruitment of innate and adaptive immune cells65 (Fig.5). This 
establishes an inflammatory environment, causing damage to CNS-resident cells, 
such as oligodendrocytes and neurons, leading to demyelination and axonal 
damage and ultimately to development of focal lesions and neurological 
symptoms65 (Fig.6). 
 
 
 
23 
 
2.4.1. Antigenic specificity and epitope spreading 
What is the exact antigen against which the TH cell response is triggered is a 
pressing question in MS and despite considerable effort no definitive answer has 
been reached yet. Several lines of evidence suggest that this antigen could be part 
of the myelin sheath. An indirect but consistent observation is that TH cells from 
individuals with MS are restricted to MS-associated HLA class II molecules and 
reactive with several myelin epitopes, such as MBP, PLP and MOG, and the avidity 
of these cells is higher for those demonstrated to be able to induce EAE68. Even 
though the antigenic specificity does not differ from healthy individuals, the 
frequency of primed T cells specific for encephalitogenic epitopes is increased in 
MS individuals68. In some patients, a transient increase in MBP-reactive T cells 
correlates with higher disease activity68. In addition, MS-associated HLA class II 
molecules are overrepresented in individuals with MS and a small but substantial 
increase in the frequency of high-avidity TH cell lines recognizing myelin epitopes 
that are weak HLA binders was reported in MS patients68. 
Although this data supports the hypothesis that the antigen in MS is a myelin 
component, it is possible that the relevant antigen is a pathogen-derived epitope or 
even another constituent of the CNS. TH cell responses against several other non-
myelin proteins occur in MS individuals including: 2’,3’-cyclic nucleotide 3’ 
phosphodiesterase, -B-crystallin, S100protein and transaldolase-H68. Lipid 
components are also candidate antigens in MS, as T cell responses against 
gangliosides are found increased in individuals with PP-MS68. However, it is not 
known which is the disease-inducing antigen and which antigens are the result of 
epitope spreading, reported in individuals with MS101. In EAE, epitope spreading 
has been extensively characterized and is the major functional cause of disease 
progression68,102. It starts in the inflamed CNS103 where DC are the main APC 
responsible for epitope spreading103-105. DC are found in MS lesions106 and 
individuals with MS, have higher levels of blood-derived myeloid DC expressing the 
activation makers CD40 and CD80, and the pro-inflammatory cytokines IL-12 and 
TNF107. In EAE, DC present in the CNS have been shown to activate naïve myelin-
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specific T cells that were recruited to the inflamed tissue and to contribute to their 
differentiation into TH17 cells108. 
 
2.4.2. Break of peripheral tolerance and CNS invasion 
The ability of myelin-specific TH cells to infiltrate the CNS requires these cells to be 
previously activated in the periphery. CNS antigens are continuously transported to 
cervical LN via CSF drainage65. In transgenic mice expressing a specific TCR for 
either MBP or PLP and developing EAE spontaneously, the first MBP and PLP-
specific T cell responses occur in the CNS-draining cervical LN109,110 (Fig.6). This 
suggests that myelin-specific antigens are presented here by APC and that 
peripheral tolerance mechanisms must operate in CNS-draining cervical LN to 
prevent activation of naïve myelin-specific TH cells65. However, under some 
conditions, not clearly understood at the moment, presentation of myelin epitopes 
leads to activation of myelin-specific TH cells65 (Fig.6). The reason why under 
specific circumstances, APC present myelin antigens in an immunogenic manner is 
not clear, but could involve molecular mimicry and/or bystander activation, such as 
provided by a concomitant infection, triggering a pathologic autoimmune response 
(see section 2.2.2). 
Once activated in CNS-draining cervical LN, myelin-specific TH cells access 
to the CNS is limited by two barriers: the BCB and the BBB65 (Fig.7). The BCB is 
constituted by epithelial cells and surrounds the choroid plexus (where CSF is 
produced) and the meningeal venules, while the BBB is composed by endothelial 
cells (EC) and surrounds parenchymal venules65 (Fig.7). The cells forming both 
barriers are united by tight junctions and limit CNS access to memory T cells that 
play an immunosurveillance role in the CNS65. This is thought to occur mainly by 
cells that cross the BCB into the subarachnoid space, as epithelial cells of the BCB 
are the only ones that express constitutively the adhesion molecules necessary for 
transmigration of activated T cells111. In the context of EAE, leukocytes, and in 
particular T cells, are thought to cross the BCB barrier first (Fig.6). CC-chemokine 
ligand 20 (Ccl20) is constitutively expressed by epithelial cells of the choroid plexus, 
and its receptor CC-chemokine receptor 6 (Ccr6), expressed on TH17 promotes the 
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Figure 7. Routes of entry of activated T cells in the CNS. (a) Activated T cells that cross the 
BCB, through EC of meningeal venules, enter the subarachnoid space, between the arachnoid 
and pial membranes where CSF circulates65. They can also enter the subarachnoid space by 
migrating from blood vessels into the stroma of the choroid plexus and then crossing the BCB 
(b). Alternatively, they can cross the EC layer joined by tight junctions at the BBB of post-
capillary venules that penetrate the brain parenchyma, entering the perivascular space. This 
space is the region between the basement membrane connected to the blood vessel EC and the 
glial limitans, which is composed of astrocyte feet and microglial cells65 (a). Adapted from 
Goverman (2009) Nat. Rev. Immunol. 
migration of these cell into the CNS112. Both DC and Mø are present in the CSF of 
healthy individuals113 and DC are sufficient to reactivate primed T cells in the CNS 
and induce EAE114. Mø depletion inhibits EAE, supporting a role for these cells in 
disease initiation115. Nevertheless, it has not been excluded by this study whether 
the effect is also mediated by DC, as the method used for Mø depletion is based on 
the phagocytic capacity of cells and thus, also eliminates DC116. 
T cell reactivation in the CNS leads to proliferation and secretion of pro-
inflammatory cytokines. These activate EC of the BBB that induce the expression of 
chemokines and adhesion molecules facilitating perivascular infiltration65 (Fig.6). 
The transition of T cells from the perivascular space into the CNS parenchyma is 
dependent on chemokines produced by parenchyma cells in the CNS65. The degree 
of ensuing CNS inflammation is not determined by the ability of T cells to invade the 
CNS parenchyma, but by the relative strength of T cell reactivation by resident APC 
in the CNS65. 
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Figure 8. Effector mechanisms of CNS damage. TH17 cells infiltrate the CNS and induce the 
secretion of  chemokines that recruit Mø, neutrophils and more T cells (TH17, TH1 and TC cells). 
TH17 can also kill neurons by direct contact. All these cells produce cytokines that activate 
infiltrating Mø, microglia, neutrophils and astrocytes, leading to the production of pro-
inflammatory mediators (i.e. ROS, chemokines and cytokines) and sustaining neuroinflammation. 
ROS can damage myelin via oxidation of lipids. Plasma cells secrete anti-myelin antibodies that 
opsonize myelin for phagocytosis by Mø. TC cells can kill neurons and oligodendrocytes via 
several cell-cell contact mechanisms. 
2.4.3. Cellular and soluble effectors of CNS damage 
Effector cells and molecules in MS are directly responsible for the damage imposed 
to parenchyma cells in the CNS. Cellular effectors include innate immune cells, i.e. 
Mø/microglia, and adaptive immune cells, such as TH1 and TH17, TC and B cells. 
Soluble mediators comprise antibodies, complement activation components and 
ROS. 
 
2.4.3.1. Innate immune cellular effectors 
Mø/microglia contribute to autoimmune neuroinflammation by guiding and activating 
T cells and establishing an inflammatory milieu in the CNS117 (Fig.8). They become 
potent APC and secrete pro-inflammatory mediators, such as IL-1, IL-6, TNF, nitric 
oxide (NO) and ROS117 (see section 2.4.3.3). The production of ROS as a result of 
microglia activation can promote neuronal damage and reactive microgliosis (i.e. 
response of microglia to neural tissue damage) at sites of lesion117. Other innate 
immune cells such as  T cells, NK and mast cells have also been implicated in 
autoimmune neuroinflammation. However, their role is still not clear, with some 
studies suggesting a pathogenic and others a protective role in EAE118. 
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2.4.3.2. Adaptive immune cellular effectors 
The cytokine profile of pathogenic TH cells in MS is still an area of controversy. In 
EAE, TH1, TH17 and TH9 cells can cause autoimmune neuroinflammation65,86. 
Among these, TH1 and TH17 cells seem to play a predominant role. However, the 
signature cytokines of these T cell lineages, i.e. IFN-and IL-17 are not the critical 
factors that determine T cell encephalogenicity as revealed by genetic ablation of 
either cytokine in mice119,120. Instead GM-CSF produced by TH cells is necessary for 
TH cell encephalogenicity121. In addition, IL-23, T-bet and STAT-4 also appear to be 
critical122-125. It is unclear, however, whether these molecules contribute to a 
common, yet undefined pathway, or act in a synergistic manner to promote 
encephalitogenicity. Nevertheless, both TH1 and TH17 cells seem to contribute to 
autoimmune neuroinflammation, since disease develops in the absence of 
molecules essential for the induction of each lineage, as revealed for Il12p35100, 
Ifng119, Ifngr126, Il17a and Il17f 120. Supporting a role for these cells in EAE and MS 
is the following set of observations: 1) Adoptive transfer of TH1 or TH17 cells is 
sufficient to induce EAE87,88; 2) increased levels of IFN- and IL-17 are detected in 
the CNS of animals undergoing EAE and in MS lesions127-130; 3) mice deficient in 
Il23p19, a cytokine required for TH17 function are resistant to EAE131 and 4) IFN- 
administration exacerbates MS132, while IFN- neutralization ameliorated the 
pathology133. 
TH17 cells are thought to constitute the first wave of cells to enter the CNS 
via a mechanism involving Ccr6, expressed on TH17 cells, and its ligand Ccl20, 
expressed on epithelial cells of the choroid plexus112. Once in the CNS, TH17 cells 
promote further recruitment of TH1 and TH17 cells, monocytes and neutrophils in a 
Ccr6-Ccl20 independent manner112. In the CNS of mice undergoing EAE, IL-17A-
expressing cells convert into IFN--producers and become the major source of this 
cytokine134. This conversion is dependent on IL-23134, possibly explaining why 
Il23p19-deficient mice are resistant122, while Il12p35 remain susceptible to EAE100. 
This could also explain why IL-23 is required to initiate disease but not in the 
effector phase135. 
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The exact role of TH1 and TH17 cells in the development of MS lesions is not 
clearly established but it is thought to rely on the differential pattern of chemokine 
and cytokine production89,136 (Fig.8). TH1 cells induce the expression of CXCL9, 
CXCL10 and CXCL11 that attract preferentially inflammatory monocytes, while 
TH17 cells recruit preferentially neutrophils via CXCL1 and CXCL2136. IFN- 
produced by TH1 cells induces the expression of MHC class II and adhesion 
molecules on APC, promoting TH cell reactivation in the CNS. IFN-also activates 
microglia/Mø and astrocytes to secrete pro-inflammatory mediators136 (Fig.8). The 
mechanisms by which TH1 cells cause tissue damage in vivo are not fully 
elucidated. TH1 cells are capable of inducing programmed cell death of antigen-
presenting astrocytes via a mechanism that relies on MHC class II and IFN-89. 
Human oligodendrocytes are sensitive to IFN--induced apoptosis and IFN-
expression co-localizes with apoptotic oligodendrocytes in MS lesions137. 
TH17 cells acquire cytotoxic potential in vitro only after converting to IFN--
producing cells89. TH17 cells can induce severe, localized, and partially reversible 
fluctuations in neuronal intracellular calcium concentration as an early sign of 
neuronal damage138 (Fig.8). 
Evidence for a pathogenic role for TC cells in the context of autoimmune 
neuroinflammation139 includes the observation that under conditions where TH cell 
depletion fails to improve MS, combined depletion of TH and TC cells inhibits 
disease progression140. A higher frequency of TC cells recognizing myelin proteins 
is present in individuals with MS compared to healthy controls141 and T cell receptor 
analysis of TC cells from MS lesions reveals clonal expansion, which is consistent 
with recognition of cognate antigen142,143. Further supporting this notion, EAE can 
be induced by adoptive transfer of TC cells144,145. Interestingly, EAE in Cd8 knockout 
mice presents reduced mortality but increased relapse, suggesting that TC cells 
might also play an immunoregulatory role in promoting periods of remission146. 
Although the pathogenicity of TC cells is established, the effector 
mechanisms by which these cells contribute to lesion formation remain to be 
determined. TC cells can exert cytotoxic effects in a MHC class I-restricted manner. 
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As such, TC cells can kill neurons in vitro via cell contact-dependent mechanisms 
involving TNF receptor superfamily member 6 ligand (FasL), leukocyte function-
associated antigen 1, and CD40147, as well as oligodendrocytes by release of 
perforin148 (Fig.8).  
Self-reactive B cells are also important in the pathogenesis of MS. B cells 
and plasma cells are found in MS lesions149 and B-cell depletion studies revealed a 
decrease in inflammatory activity in MS150. In EAE, B-cell deficient mice fail to 
develop EAE if immunized with the MOG protein151. 
 
2.4.3.3. Soluble effectors: antibodies, complement components and ROS 
A pathogenic role for antibodies has been established by several lines of evidence. 
Up to 50% of the lesions in individuals with MS are characterized by abundant 
antibody deposition69. Clinical trials using plasmapheresis, a technique that 
removes soluble components from the serum, can reverse severe neurological 
deficits152. Antibodies against CNS components such as MOG, MBP peptides, -B-
crystallin and amyloid68, as well as against lipids of the myelin sheath, such as 
sulfatides, cerebrosides and phospholipids have all been found in the brain and/or 
CSF of individuals with MS153. In addition, in the CSF of MS patients there is 
oligoclonal distribution, i.e. only some clones are represented, suggesting there is 
antigen-driven clonal selection154. 
Antibodies can promote demyelination by opsonization of myelin for 
phagocytosis and via activation of the complement cascade (Fig.8). In MS lesions 
where antibodies are found, deposition of terminal components of the complement 
cascade are also present155. In addition, mice deficient for early components of the 
complement cascade develop attenuated EAE, suggesting that complement-
mediated opsonization is involved in demyelination156.  
ROS are products of normal cellular metabolism that play a physiological 
role in numerous cellular processes157. They are generated by the mitochondrial 
respiratory chain during aerobic respiration and include superoxide anion (O2-), 
hydrogen peroxide (H2O2), hydroxyl radical (OH∙) and organic peroxides, as 
products of the biological reduction of molecular oxygen158,159. ROS are also 
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produced by Mø160 and neutrophils161. Normally, ROS are quenched by antioxidant 
mechanisms of the cell that comprise enzymes, such as catalase or superoxide 
dismutases (Table 1), and soluble molecules, such as glutathione and 
thioredoxin157,162 (Table 1). Whenever the rate of production of free radicals, 
exceeds the capacity of the protective antioxidant mechanisms, oxidative stress 
ensues. This can lead to damage of lipids, proteins and DNA157,163, causing 
mutations and epigenetic alterations. 
Individuals with MS have lower concentrations of antioxidants in the serum, 
compared to healthy individuals, and MS lesions show reduced levels of 
antioxidants and several markers of oxidative damage163. This is suggestive that 
antioxidant depletion results from continued exposure to ROS. Oxidative stress is 
thought to contribute to the formation and persistence of MS lesions. In the brain 
parenchyma, ROS contribute to tissue damage mediating myelin phagocytosis, 
oligodendrocyte damage and axonal injury164,165 (Fig.8). Furthermore, dietary intake 
of exogenous antioxidants, including flavonoids and -lipoic acid, reduces the 
clinical signs of EAE166,167. This supports the notion of a role for oxidative stress in 
the effector damage during EAE and MS. 
Adaptive responses to oxidative stress can counter oxidative damage, such 
as occurs in the CNS during MS and EAE. These rely on the activation of 
transcription factors that include nuclear factor erythroid (NF-E) 2-related factor 2 
(Nrf2)157. 
 
3. The Nrf2 cytoprotective pathway 
Nrf2 is an evolutionarily conserved basic leucine-zipper (bZip) transcription factor 
expressed by worms, insects, fish, birds and mammals but not by plants or fungi. 
Activation of Nrf2 mediates cellular adaptive responses to oxidative stress162. Nrf2 
contains a conserved Cap ‘n’ Collar (CNC) domain (Fig.9) that defines a family of 
transcription factors that, in mice and humans, includes Nrf1, Nrf2, and Nrf3168,169. 
Broad-Complex, Tramtrack, and Bric-a-brac (BTB) and CNC homology (Bach) 1 
and Bach2 are more distantly related family members containing an additional BTB 
domain, acting as transcriptional repressors168,169. A naturally-occurring truncated 
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isoform of Nrf1 as well as a caspase-cleaved form of Nrf2 may also function as 
transcriptional repressors168,169. 
Nrf2 is activated by changes in the redox status of the cell in response to 
oxidants (remove electrons from another reactant) and electrophiles (accept a pair 
of electrons to make a new covalent bond). Nrf2 activation restores homeostasis by 
up-regulating a diverse set of cytoprotective genes (see section 3.2)162,168. Thus, 
Nrf2 influences the sensitivity to physiologic and pathologic processes affected by 
oxidative and electrophilic stress, such as those imposed by exposure to 
environmental toxicants and inflammation (see section 3.3)162. This is illustrated by 
increased sensitivity of Nrf2-deficient (Nrf2-/-) mice to diverse oxidative insults. 
When exposed to xenobiotic electrophiles, or chemicals that generate oxidative 
stress, Nrf2-/- mice display higher amount of DNA, lipid and protein oxidation, tissue 
damage and inflammation, as compared to wild-type animals169. Nrf2-/- mice are 
also more sensitive to a number of inflammatory diseases, such as sepsis, systemic 
lupus erythrematosus, pulmonary diseases, colitis, rheumatoid arthritis and 
EAE162,169,170. Compounds that activate the Nrf2 pathway, e.g. curcumin and 
sulforaphane, act as therapeutic agents in several experimental models of toxicity, 
neurodegeneration and inflammation-driven diseases (see section 3.3)162,169. 
Clinical studies have also determined the therapeutic value of pharmacologic 
induction of the NRF2 pathway in the treatment of inflammatory lung diseases, 
neurodegeneration and preeclampsia169. 
In humans, analysis of disease-associated DNA polymorphisms also 
supports a protective role for NRF2171. DNA polymorphisms that reduce NRF2 
expression are associated with skin vitiligo, chronic gastritis, peptic ulcer, ulcerative 
colitis and adult respiratory distress syndrome169. These observations suggest that 
individuals bearing these polymorphisms have a reduced antioxidant response and 
are at increased risk for diseases related to oxidative stress169. 
Nrf2 binds to the antioxidant response element (ARE) with the consensus 
sequence TGACnnnGC168, present in enhancer elements in the promoter regions of 
cytoprotective genes172. Nrf2 forms heterodimers with small musculo-aponeurotic 
fibrosarcoma oncogene (Maf) proteins (MafF, MafG and MafK) and binds to the 
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Figure 9. Structural domains of Nrf2 and its inhibitor Keap1. In the Nrf2 protein are shown the relative 
positions of the 6 functional domains, Nrf2-ECH homology (Neh) 1-6168,169. Neh1 contains the bZip DNA binding 
and heterodimerization domain through which Nrf2 binds its transcriptional partners, including small Maf 
proteins168,169. Nrf2 is negatively regulated by Keap1 that interacts with the Neh2 domain168,169. The Neh3 domain 
binds to chromodomain helicase DNA binding protein 6 that functions as a transcriptional co-activator168,169. Neh4 
and Neh5 act synergistically to bind the transcriptional co-activator CREB binding protein (CBP)168,169. Finally, the 
Neh6 domain controls the Keap1-independent negative regulation of Nrf2168,169. In the Keap1 protein are shown 
the N-terminal region (NTR), the BTB domain, the intervening region (IVR), the Kelch domain and the C-terminal 
region (CTR). The BTB is the domain through which Keap1 homodimerizes and the Kelch domain through which 
it binds Nrf2168. In the BTB and IVR domains are present reactive cysteines C151, C273 and C288 through which 
Keap1 senses redox changes168,169. 
ARE, recruiting the general transcriptional machinery and inducing the expression 
of ARE-driven cytoprotective genes (see section 3.2)162,172. 
 
3.1. Regulation of the Nrf2 pathway 
Nrf2 is regulated mainly at the post-transcriptional level by the Kelch-like ECH 
associated protein (Keap1)168,169, a cysteine-rich protein, containing 25 or 27 
cysteine residues in mice and humans (Fig.9). Ten of these residues are predicted 
to be reactive with oxidants or electrophiles, breaking the disulfide bond between 
two adjacent cysteines, which allows Keap1 to sense redox changes and triggers 
the activation of the Nrf2 pathway168,169 (Fig.9). Nrf2 also contains four evolutionarily 
conserved cysteine residues, suggesting that it could react directly with oxidants or 
electrophiles, but the physiological relevance of this is still an open question168. 
Under homeostasis, Nrf2 is sequestered in the cytoplasm by Keap1, 
targeting Nrf2 for proteolysis by the 26S proteasome (Fig.10a). Under oxidative 
stress, this association is modified, leading to diminished rates of proteolysis of Nrf2 
and enhanced nuclear accumulation. Nrf2 heterodimerizes with small Maf proteins 
and drives the transcription of ARE-regulated genes (Fig.10b). 
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Figure 10. Nrf2 regulation by Keap1. (a) In homeostasis, Keap1 is 
tethered to the actin cytoskeleton and localizes in the cytoplasm168,169. It 
binds Cul3, which forms a core E3 ubiquitin ligase complex through 
association with Ring-box1 protein (Rbx1)168,169. Keap1 negatively 
regulates Nrf2 activity via cytoplasmic sequestration and targeting of 
Nrf2 for proteasomal degradation, acting as an E3 ubiquitin ligase 
substrate adaptor for the Cul3-Rbx1 complex168,169. Nrf2-Keap1 
interaction is thought to occur via the “hinge and latch” mechanism, with 
a high-affinity and a low-affinity motif, within the Neh2 domain of Nrf2 
interacting with a separate Kelch repeat domain in the Keap1 
homodimer. Both motifs are required for the Nrf2 repression by Keap1. 
(b) Oxidants and electrophiles react with cysteines in Keap1, leading to 
a conformational change and release of the weaker interaction with the 
low affinity motif of Nrf2. Failure of Nrf2 to interact simultaneously with 
both Kelch repeat domains enables it to “escape” ubiquitination by 
Cul3-Rbx1, reducing its degradation rate168,169. This impairs newly 
transcribed Nrf2 from binding Keap1, allowing for Nrf2 nuclear 
translocation and transcriptional regulation. Phosphorylation of Nrf2 by 
several kinases also affects its nuclear accumulation. Nuclear export is 
mediated by the exportin chromosome region maintenance (CRM1). 
Some inducers of the Nrf2 pathway can stabilize Nrf2 by dissociating the 
Keap1-Cul3 complex, thus leading to the inhibition of Nrf2 ubiquitination. Other 
inducers of the pathway may target Keap1 for Cul3-mediated ubiquitination168,169. It 
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has also been suggested that the nuclear translocation of Nrf2 is redox regulated, 
fine-tuning the speed, magnitude and duration of the antioxidant response169. It is 
possible that these mechanisms are not mutually exclusive and just reflect inducer 
and/or cell type-specific regulatory mechanisms. 
Although the main form of Nrf2 regulation relies on the modulation of Keap1-
dependent Nrf2 degradation, there is also a mechanism of Keap1-independent Nrf2 
degradation. The Neh6 domain may contain a redox-insensitive degron (a specific 
sequence of amino acids that directs the starting place of degradation)168,169. 
Glycogen synthase kinase (GSK) 3 and the -transducin repeat containing E3 
ubiquitin protein ligase regulate the activity of the Neh6 degron in a Keap1-
independent manner168,169. In addition, Nrf2 is also regulated at the transcriptional 
and translational levels. There is an ARE in the Nrf2 promoter, suggesting Nrf2 
regulates its own transcription in a positive feedback loop168,169. At the translational 
level, Nrf2 mRNA contains a redox-sensitive internal ribosomal entry site in the 5’-
UTR, increasing Nrf2 translation upon redox imbalance168,169. These levels of 
regulation may function in concert with increased Nrf2 stability to provide a robust 
long-term response to inducers. 
The Nrf2-Keap1 signal transduction pathway interacts at multiple levels with 
other signal transduction pathways. These include phosphorylation of Nrf2, by a 
number of protein kinases that regulate its activity, e.g. protein kinase C, MAPK, 
GSK3 tyrosine kinase Fyn, protein kinase-like endoplasmic reticulum kinase and 
casein kinase II168,169 (Fig.10a). Nrf2 can also compete for ARE binding with MafK 
and with transcription factors, such as Nrf1, Nrf3, Bach1, activating transcription 
factor (ATF)-1, ATF-4, JunD, c-Jun, c-Fos and Fra1169. Nrf2 binding to ATF-3, 
proliferator-activated receptor (PPAR)-, ROR, estrogen-related receptor 
estrogen receptor , the chromatin remodeling factor brahma-related gene 1 and 
the transcriptional co-repressor silencing mediator of retinoic acid and thyroid 
hormone receptor also modulates Nrf2-driven gene expression169. Finally, there is 
cross-regulation with the AhR, NF-B, p53 and Notch pathways at the 
transcriptional level173. 
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3.2. Transcriptional regulation of cytoprotective genes 
Nrf2 has an estimate of 600 target genes arguing for the central role of this 
transcription factor in the cytoprotective response to oxidative stress (Table 1). 
These genes encode proteins: acting as direct antioxidants, inactivating oxidants, 
increasing the levels of glutathione synthesis and regeneration, stimulating NADPH 
synthesis, enhancing toxin export through the multidrug-response transporters, 
enhancing recognition, repair and removal of damaged proteins, elevating 
nucleotide excision repair, regulating the expression of other transcription factors, 
receptors and molecular chaperones and dampening inflammation162,168 (Table 1).  
The heme oxygenase-1 (Hmox1) gene, encoding the heme-catabolizing 
enzyme HO-1 (see section 3.2.1), is a Nrf2-regulated gene that acts in a salutary 
Name Gene Function 
Glutathione S- transferases Gstt1 Detoxify electrophiles by the conjugation 
with glutathione. 
Metallothioneins 
 
Mt1 
Mt2 
Bind heavy metals preventing heavy 
metal-mediated oxidative stress. 
Thioredoxins Trn1 Quench reactive oxygen species 
undergoing reversible oxidation. 
Peroxiredoxins 
 
Prdx1 
 
Degrade enzymatically hydrogen and 
organic peroxides and peroxynitrite. 
Catalase Cat 
 
Catalyses the conversion of hydrogen 
peroxide into H2O and O2. 
Superoxide dismutases Sod2 Catalise the dismutation of superoxide 
anion into H2O2 and O2. 
NAD(P)H:quinone oxidoreductases Nqo1 
Nqo2 
Catalyze the two-electron reductions of 
quinones and derivatives. 
-glutamyl cysteine ligase Gclm 
Gclc 
Catalyzes the rate-limiting step in the 
biosynthesis of glutathione. 
Glutathione peroxidases Gpx1 Detoxify cellular hydrogen and organic 
peroxides by oxidizing glutathione. 
Heme oxygenase-1 
 
Hmox1 Catabolizes heme into CO, biliverdin and 
labile Fe. 
Ferritin H chain Fth Sequesters and oxidizes labile Fe 
stopping it from being a Fenton reactor. 
CD36 antigen 
 
Cd36 Cell surface receptor of several ligands: 
i.e. oxidized lipoproteins. 
Table 1. Nrf2-regulated genes and their functions. Examples or Nrf2-regulated genes that are involved in: 1) 
providing direct antioxidants (i.e. Mt and Trn); 2) encoding enzymes that directly inactivate oxidants, (e.g. Gstt1, 
Prdx, Cat, Sod, Hmox1, Fth and Nqo), 3) increasing the levels of glutathione synthesis and regeneration, (i.e. 
Gpx1, Gsr, Gclm and Gclc) and 4) dampening inflammation, i.e. Cd36162,168.  
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Figure 11. Regulation of Hmox1 transcription by the Nrf2 pathway. (a) In 
homeostasis Bach1 in heterodimer with small Maf proteins binds to the ARE in 
the enhancers of the Hmox1 promoter repressing its transcription. (b) Upon 
oxidative stress and/or an increase in heme levels the DNA-binding activity of 
Bach1 is inhibited and its nuclear export via CRM1 and proteolysis promoted. 
This allows Nrf2-small Maf heterodimers to bind the ARE and drive Hmox1 
transcription. 
manner in a number of immune-mediated inflammatory diseases, including 
autoimmune neuroinflammation174-176 (see section 3.3.1). This suggests that the 
salutary effects of Nrf2 exerted in autoimmune neuroinflammation, and presumably 
in other immune-mediated inflammatory diseases (see section 3.3), could be 
mediated, at least in part, via the expression of HO-1. 
HO-1 is regulated mainly at the transcriptional level, with its rate of 
transcription being induced by a variety of signal transduction pathways that 
culminate in the activation of Nrf2 (Fig.11), as well as other transcription factors, 
such as NF-B, AP-1 and heat shock factor177. 
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Several cis-acting (acting on the same chromosome) regulatory elements have 
been identified in the Hmox1 promoter, including upstream enhancer regions, E1 
and E2, which play a major functional role in the redox-dependent induction of HO-
1, as they contain several ARE178.  
Nrf2 binding to these ARE, in association with small Maf proteins, leading to 
transcription of Hmox1, is dependent on release of the transcriptional repressor 
Bach1 from the ARE179 (Fig.11). Under homeostasis, HO-1 expression is repressed 
by Bach1-small Maf protein heterodimers (Fig.11a), but upon oxidative stress, 
Bach1-mediated repression of HO-1 is relieved (Fig.11b). Bach1 can sense ROS 
and heme, which inhibits its binding to the ARE and promotes nuclear export and 
degradation by the 26S proteasome178 (Fig.11b). Other levels of regulation of HO-1 
have also been described, including post-transcriptional regulation by mRNA 
stabilization and post-translational regulation by cleavage of HO-1180. 
 
3.2.1. HO-1 and the products of heme catabolism 
HO-1 is the enzyme responsible for the first and rate-limiting enzymatic step in the 
catabolism of heme (Fe protoporphyrin IX), generating equimolar amounts of 
biliverdin, carbon monoxide (CO) and labile Fe181 (Fig.12). HO-1 is one of two 
evolutionarily conserved isozymes, HO-1 and HO-2, encoded in mice and humans 
by the Hmox1/HMOX1 and Hmox2/HMOX2 genes, respectively. Hmox genes are 
evolutionarily conserved and ubiquitously expressed in most living organisms 
including bacteria, algae, plants, insects and mammals, suggesting that the need 
for heme catabolism appeared early in evolution182. HO-2 is a non-inducible 
enzyme183, while HO-1 is inducible by a wide variety of oxidative stress-related 
stimuli184 including hypoxia, shear stress, ROS, heavy metals, cytokines, e.g. TNF, 
IL-1, TLR ligands, such as LPS, and its substrate, heme177,178. 
HO-1 provides cellular protection against oxidative stress, preventing 
programmed cell death, and thus providing beneficial effects in many inflammatory 
conditions185. In support of this notion are the observations that cells lacking HO-1 
expression are highly sensitive to oxidative stress, which leads to exacerbated 
cellular toxicity186. In addition, induction of HO-1 expression or HO-1 over-
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expression prevents oxidative stress-mediated toxicity in a variety of cell 
types187,188. 
Mice with a disruption of the Hmox1 gene (Hmox1-/-) die in utero at high 
frequency, presumably due to lack of protection against the oxidative stress 
generated during embryonic development189-191. Moreover, the embryos that survive 
to term display a chronic inflammatory condition that progresses with age and can 
cause premature death189. Hmox1-/- mice show increased sensitivity to a number of 
inflammatory pathologies (see section 3.3.1), in which oxidative injury is a common 
pathologic denominator. These include but are not limited to: graft rejection192, 
atherosclerosis193, ischemia-reperfusion injury194, septic shock195,196 and 
malaria197,198. In addition, pharmacological induction of HO-1 or administration of 
the end products of its activity can exert therapeutic effects in a variety of 
inflammatory diseases176. 
In humans, HMOX1 deficiency is extremely rare and leads to the 
development of an inflammatory syndrome that can cause premature death199. This 
is characterized by massive EC damage, growth failure, anemia, tissue Fe 
deposition, lymphadenopathy, leukocytosis and increased sensitivity to oxidant 
injury199. In addition, the human HMOX1 promoter has a (GT)n microsatellite 
polymorphism that alters the levels of HO-1 expression and has been associated 
with the incidence and/or progression of a variety of diseases200. Lower numbers of 
GT repeats within this polymorphic sequence have been associated with higher 
inducibility of HO-1 expression in response to stress stimuli and individuals with this 
allele seem to be less likely to develop a series of pathologies than individuals with 
a higher number of (GT)n repeats200. These pathologies overlap broadly with those 
in which the outcome is exacerbated in mice that lack HO-1 or in wild type mice, in 
which HO-1 activity is inhibited pharmacologically176,200. This illustrates further the 
crucial role of HO-1 in the prevention of oxidative damage associated with 
inflammation (see section 3.3.1). 
Heme, the substrate of HO activity, consists of a protoporphyrin IX ring with 
a central Fe ion. It exists as a prosthetic group of hemoproteins, an evolutionarily 
conserved strategy that allows to incorporate Fe into the tertiary structure of 
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Figure 12. Heme catabolism by HO-1. Heme catabolism by HO-1 involves 
cleavage of the protoporphyrin IX ring, generating equimolar amounts of 
biliverdin, CO and labile Fe. The Fe2+ released by this reaction is then stored by 
FtH. Biliverdin is converted by biliverdin reductase into the antioxidant bilirubin . 
All three end products of heme catabolism, that is, biliverdin/bilirubin, CO and 
Fe/FtH, are cytoprotective. Adapted from Gozzelino et al. (2010) Annu. Rev. 
Pharmacol. Toxicol. 
proteins180. It is an abundant compound in mammals and plays a physiological role 
for oxygen and mitochondrial electron transport as an essential prosthetic group of 
hemoglobin, myoglobin and cytochromes180. However, when released from the 
heme pockets of hemoproteins, heme can be highly toxic as it may react with H2O2 
to generate OH∙ via the Fenton chemistry, leading to oxidative stress201,202. Due to 
the pro-oxidant properties of non-protein bound heme, the enzymatic synthesis and 
degradation of this molecule must be tightly controlled180. 
Heme degradation by HO generates biliverdin, which is converted into 
bilirubin by biliverdin reductase203 (Fig.12). Bilirubin is a lipophilic tetrapyrrole, 
abundant in blood plasma and bile that exists uniquely in mammals and can be 
toxic at high concentrations204. However, it also appears to be one of the most 
abundant endogenous antioxidants in mammals and accounts for the major 
antioxidant activity in human serum205. 
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Another product of heme catabolism by HO is CO (Fig.12), a gaseous 
transmitter that modulates cellular signal transduction206. CO binds to Fe atoms in 
heme and/or sulfur clusters contained in a variety of proteins, e.g. guanylyl cyclase, 
cytochromes, peroxidases, catalase, nitric oxide synthases and phosphatases207. 
Presumably, when this occurs, the conformational structure of these proteins is 
modified in a manner that modulates their biological activity208. 
Heme degradation by HO unlocks a third product, labile Fe from the 
protoporphyrin IX ring (Fig.12). Labile Fe can be deleterious as it catalyzes the 
generation of ROS through the Fenton chemistry, promoting oxidative stress209. 
Labile Fe up-regulates the expression of an Fe-transporter pump that removes it 
from cells210. In addition, labile Fe induces the expression of the Fe-sequestering 
protein FtH211 (Fig.12), which associates with ferritin L chain and forms a multimeric 
protein complex with exceedingly high Fe storage capacity212. FtH has ferroxidase 
activity that oxidizes Fe2+ into Fe3+, which can limit the availability of labile Fe to 
promote the generation of ROS via the Fenton chemistry212. 
 
3.3. Regulation of immune-mediated inflammatory diseases by Nrf2 
Nrf2 confers protection against inflammatory-mediated injury162,169,170, as illustrated 
by the phenotype associated with deletion of the Nrf2 allele in mice. Namely, Nrf2-/- 
mice display a shortened lifespan as compared to wild type (Nrf2+/+) mice, 
presumably due to the development of a lupus-like autoimmune syndrome 
characterized by multi-organ damage, intravascular immune complex deposition, 
and the development of severe glomerulonephritis213,214. In addition, aged Nrf2-/- 
mice develop immune-mediated hemolytic anemia215. Nrf2-/- mice also develop over 
time (10 month after birth) widespread astrogliosis, along with vacuolar 
leukoencephalopathy216. 
Genetic disruption of the Nrf2 allele increases susceptibility to a variety of 
experimental models of immune-mediated inflammatory diseases in mice, including 
septic shock, colitis, lung inflammation, leading to acute respiratory distress 
syndrome, asthma and emphysema217-219 as well as diseases targeting the CNS, 
such as EAE170,220,221 (Table 2). This is associated with increased expression of 
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several pro-inflammatory genes, suggesting that Nrf2 regulates the immune 
response during EAE. Furthermore, Dimethylfumarate, has also proved beneficial in 
EAE221,222, and more importantly in MS223,224, acting via the Nrf2 pathway221,222. 
The regulatory role of Nrf2 in these experimental models of disease is 
thought to be mediated by two mechanisms: 1) Activation of the cellular antioxidant 
and detoxifying machinery, providing cytoprotection and tissue damage control162 
and 2) Suppression of pro-inflammatory signaling pathways restraining the 
expression of pro-inflammatory mediators, including but not limited to cytokines, 
chemokines and cell adhesion molecules170 (Table 2). 
Nrf2 inhibits the expression of pro-inflammatory mediators, acting in distinct 
processes of the inflammatory response. This effect can be mediated by binding of 
Nrf2 to the promoter regions of Nrf2-dependent pro-inflammatory mediators, in a 
manner that would block their transcription, or more likely, given that Nrf2 is a 
transcriptional activator, relying on the interference of Nrf2 with pro-inflammatory 
signaling pathways. An effect of Nrf2 on a promoter has been suggested for VCAM-
1 regulation, in a study where Nrf2 overexpression strongly inhibited VCAM-1 
promoter activity and Keap1 reversed this effect170. Negative regulation of pro-
inflammatory mediators by Nrf2 can also act indirectly through cytoprotection and 
tissue damage control, thus limiting release of DAMPs and sustained expression of 
pro-inflammatory mediators. 
Pathology Pro-inflammatory mediators up-regulated 
Septic shock Cytokines (IL-1, TNF, IL-6, etc.), chemokines and adhesion molecules 
 
Asthma Cytokines (IL-4, IL-13) 
 
Colitis Cytokines (IL-1, IL-6, IL-12/23p40 and TNF) 
 
Colitis Cytokines (IL-1 and TNF) and adhesion molecules (ICAM-1) 
 
EAE Cytokines (Ifng, Il1b, Tnf and Il12) and chemokines (Cxcl13 and Cxcl9) 
Table 2. Genetic ablation of Nrf2 leads to increased expression of pro-inflammatory mediators in diverse 
pathologies. Example of diseases where genetic ablation of Nrf2 has been shown to exacerbate pathology and to 
be associated with increased expression of pro-inflammatory mediators. 
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Expression of many inflammatory mediators, associated with the onset of 
inflammatory reactions, such as chemokines, cytokines, and cell-adhesion 
molecules, is regulated by the transcription factor nuclear factor-kappa B (NF-B). 
NF-B constitutes a family of transcription factors that contain a conserved Rel 
homology domain responsible for dimerization and DNA binding173,225. It can be 
subdivided into two groups based on the presence, (RelA/p65, RelB, and c-Rel), or 
absence (p100 and p105) of a transactivation domain. In homeostasis, NF-B is 
located in the cytoplasm associated with its negative regulator IB, which hides the 
nuclear-localization sequence and DNA-binding domain of NF-B, preventing 
transcription173. Upon triggering of a signal transduction pathway that leads to NF-
B activation, IB is phosphorylated by IB kinases (IKK), allowing the release and 
nuclear translocation of NF-B173. In addition, phosphorylation of NF-B can modify 
its transcriptional activity, of which the best characterized example is RelA 
phosphorylation at S276 by protein kinase A226. 
Nrf2-/- mice have increased NF-B activation when compared with wild type 
(Nrf2+/+) mice, as demonstrated in the context of traumatic brain injury, LPS and 
TNF administration and infection by respiratory syncytial virus173,225. In keeping with 
this notion, pharmacological inducers of the Nrf2 pathway repress NF-B 
activation173,225. The mechanism via which Nrf2 inhibits NF-B activation is not 
clearly elucidated173,225, but is thought to involve the inhibitor of NF-B, IB via a 
mechanism targeting the upstream IKK kinase activity responsible for IB 
phosphorylation and leading to its degradation and activation of NF-B225. As the 
NF-B pathway can be activated by ROS, via IB phosphorylation227, it is plausible 
that the increased levels of ROS observed in Nrf2-/- mouse embryonic fibroblasts 
(MEF)228 account for the heightened IB phosphorylation. This would suggest that 
the inhibitory effect of Nrf2 on this pathway relies on the expression of antioxidant 
genes and maintenance of the redox-status of the cell by preventing ROS-mediated 
NF-B activation. In keeping with this notion, it has been demonstrated that 
maintenance of the cellular levels of glutathione is important217. In addition, several 
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Nrf2-dependent genes that contribute to redox homeostasis have been shown to 
regulate NF-B activity, including Trn, Nqo1 and Hmox1. In particular, HO-1 
modulates NF-B activation via a mechanism that relies on its end products 
bilirubin and free Fe229,230 and that does not involve IB phosphorylation, targeting 
the phosphorylation of RelA, required for TNF-dependent NF-B activation230. 
 
3.3.1. Regulation of immune-mediated inflammatory diseases by HO-1 
Oxidative tissue damage associated with inflammation is thought to lead to the 
unlocking of heme from hemoproteins, generating non-protein bound heme, which 
has pro-oxidant and pro-inflammatory properties231. Thus, control of the non-protein 
bound heme levels by HO-1 should restrain inflammation and prevent further tissue 
damage, a notion consistent with the evidence that Hmox1 deletion in mice and 
humans is characterized by neutrophil activation, infiltration and oxidative tissue 
damage190,199,232. In addition, the deleterious effects of non-protein bound heme in 
inflammatory disease models have been illustrated by our laboratory in 
malaria197,198,233 and septic shock196. These studies show that enzymatic 
degradation of heme via HO-1 play a critical role in the prevention of programmed 
cell death, affording tissue damage control234. In addition, our laboratory has shown, 
in a septic shock model, that elevated non-protein bound heme levels, such as 
occur in Hmox1-/- mice, lead to tissue damage and release of DAMPs, i.e. 
HMGB1196. Thus, the cytoprotective effect of HO-1 appears to have a dual 
protective role, in that it sustains tissue/organ function, therefore inhibiting the 
release of DAMPs from dying cells185. This latter effect, presumably in combination 
with control of the pro-inflammatory non-protein bound heme levels, contributes to 
prevent unfettered inflammation and oxidative tissue damage. 
HO-1 has also immunoregulatory effects as demonstrated by Hmox1 
deletion in mice that develop an inflammatory syndrome with several immune 
abnormalities, such as splenomegaly, increased baseline IgM levels and increased 
production of pro-inflammatory cytokines by LPS-stimulated splenocytes235. This 
44 
 
immune phenotype has been dissected and immunomodulatory effects suggested 
both for innate and adaptive immune cells.  
Regulation of innate immune responses by HO-1 has been demonstrated in 
mice with myeloid-specific ablation of Hmox1 in that HO-1 is required for IRF3 
activation and the production of antiviral cytokines, e.g. IFN-175. Regulation of IFN-
 by HO-1 impacts TH cell responses and EAE, as IFN- blocks TH17 
differentiation175. This effect was suggested to be mediated by HO-1 expression in 
Mø, although the possible contribution of other myeloid cells has not been 
addressed. In Mø, HO-1 has also been shown to be up-regulated by LPS, leading 
to attenuation of the expression of pro-inflammatory genes, such as cytokines, i.e. 
TNF an IL-6236. However, it is not clear how relevant this effect is as Hmox1-/- or 
Hmox1+/+ peritoneal Mø produce similar pro-inflammatory cytokine levels in 
response to LPS in vitro185.  
Concerning the effects of HO-1 in DC, mouse immature DC express 
negligible levels of HO-1, inducing its expression upon activation185. Intriguingly, rat 
and human immature DC express HO-1 constitutively, downregulating its 
expression upon activation185. In any case, pharmacologic induction of HO-1 inhibits 
mouse, rat, and human DC activation and immunogenicity185. Recently, a study has 
suggested that the protective effects of Dimethylfumarate, in EAE and presumably 
MS, are mediated in part by HO-1 via the regulation of cytokine production in DC222. 
The effects of HO-1 in DC might impact adaptive immune responses. In 
addition, several observations in vitro suggest that HO-1 also inhibits T cell 
activation, proliferation and/or effector function185. HO-1 has also been suggested to 
suppress T cell responses by regulating TREG cell function185. However, analysis of 
TREG cells from Hmox1-/- and wild type mice revealed that HO-1 does not play a role 
in TREG cell development, peripheral maintenance and function in homeostasis237. 
 
3.3.1.1. Regulation of immune-mediated inflammatory diseases by the end  
products of heme-catabolism  
Biliverdin, CO and labile Fe play regulatory roles in several inflammatory diseases, 
having both cytoprotective, and immunoregulatory effects. Bilirubin, generated by 
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biliverdin reductase, is a potent antioxidant205. As ROS can trigger programmed cell 
death, bilirubin has cytoprotective effects, preventing NO or H2O2-mediated 
programmed cell death238. In addition, biliverdin/bilirubin are also immunoregulatory, 
inhibiting mouse and human TH cell activation in vitro239. In vivo, bilirubin 
suppresses T cell-driven inflammatory pathologies such as the rejection of 
transplanted organs240 or autoimmune neuroinflammation239. The immunoregulatory 
effects of biliverdin/bilirubin are mediated via inhibition of the transcription factors, 
NF-AT and NF-B, suppressing IL-2 production by TH cells240. 
CO is anti-apoptotic in a variety of cell types241. The cytoprotective effect of 
CO is mediated by a mechanism that prevents heme release from hemoproteins, 
e.g. hemoglobin, thus blocking its pro-oxidant effects436. In addition, CO interferes 
with the MAPK signaling pathway preventing apoptosis, as illustrated originally in 
Mø236 and thereafter in EC241,242. Regulation of the p38 MAPK signaling pathway by 
CO inhibits TNF production by Mø236 via a mechanism involving the production of 
mitochondrial ROS243. When exposed to CO, Mø shift the production of the pro-
inflammatory TNF to that of IL-10, a potent anti-inflammatory cytokine236. CO also 
induces production of another potent anti-inflammatory cytokine, TGF- by a 
pathway that involves stabilization of hypoxia-inducible factor 1, again via 
mitochondrial-generated ROS244. Production of mitochondrial-generated ROS in 
response to CO is also involved in the up-regulation of PPR-, which exerts anti-
inflammatory effects in Mø245. Other effects of CO in Mø include the interference 
with the molecular machinery involved in TLR signaling by two distinct mechanisms. 
First, CO enhances calveolin-1 binding to TLR4, inhibiting downstream signaling 
and production of pro-inflammatory cytokines246. Second, CO inhibits the activity of 
NADPH oxidase, reducing ROS formation, upon TLR ligation, consequently 
inhibiting TLR4 recruitment to lipid rafts247. Immunoregulatory effects of CO on 
adaptive immune cells have also been described. CO is able to inhibit TH cell 
activation248 and induce apoptosis in Jurkat T cells249. 
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Labile Fe, another end product of heme catabolism by HO-1, affords 
cytoprotection by inducing the expression of FtH250. The Fe storage ability of FtH 
underlies its ability to prevent TNF-mediated programmed cell death251. 
 
4. Aims of the Thesis 
The aim of the research work presented in this Ph.D Thesis was to understand 
whether and how the Nrf2 pathway and its downstream gene, Hmox1, regulate 
autoimmune neuroinflammation. For this, we studied the role of Nrf2 expression in 
the pathogenesis of autoimmune neuroinflammation (Chapter 2). Further, we 
investigated also the role of the expression of the Nrf2-dependent gene, Hmox1, in 
the pathogenesis of autoimmune neuroinflammation (Chapter 3 and Appendix 1). 
We also addressed the significance of induction of HO-1 expression and/or 
exogenous CO administration from a therapeutic point of view (Chapter 3). 
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1. Abstract 
The transcription factor NF-E2-related factor 2 (Nrf2) regulates cellular responses to 
oxidative stress. Here we investigated the mechanism underlying the protective 
effect of Nrf2 against autoimmune neuroinflammation. When immunized with myelin 
oligodendrocyte glycoprotein peptide 35-55 (MOG35-55), C57BL/6 Nrf2-deficient 
(Nrf2-/-) mice develop a more severe form of experimental autoimmune 
encephalomyelitis (EAE), as compared to wild type (Nrf2+/+) counterparts. This 
effect is also present when active immunization is bypassed in MOG35-55-specific T 
cell receptor transgenic (2D2) Nrf2-/- vs. Nrf2+/+ mice. Dendritic cells (DC) from   
Nrf2-/- vs. Nrf2+/+ mice express higher levels of IL-12, increasing the priming of 
myelin-reactive T helper type 1 (TH1) cells, that produce IFN-. The 
encephalitogenic effect associated with deletion of the Nrf2 allele is ablated once 
IL-12 activity is suppressed using an anti-IL-12/23p40 monoclonal antibody or when 
IFN- activity is suppressed by deletion of the IFN- receptor (Ifngr1-/-). Inhibition of 
IL-12 production in DC acts via the expression of heme oxygenase-1 (HO-
1/Hmox1). However, HO-1 expression in DC fails to control myelin-reactive TH1 cell 
priming or the pathogenesis of EAE, as demonstrated in mice carrying a deletion of 
the Hmox1 allele specifically in DC (CD11c-Cre/Hmox1∆/∆) vs. control Hmox1lox/lox 
mice. In conclusion, Nrf2 counters the pathogenesis of autoimmune 
neuroinflammation via a mechanism that involves the inhibition of IL-12 production 
by DC and thus preventing myelin-reactive TH1 cell priming. While the 
immunoregulatory effect of Nrf2 is mediated partially via the expression of HO-1, its 
overall protective effect against autoimmune neuroinflammation is not fully 
explained by the expression of HO-1 in DC. 
 
2. Introduction 
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory disease of the 
central nervous system (CNS), affecting about 1 in 1000 individuals in Europe and 
the US1. The pathogenesis of MS is triggered by the activation of myelin-reactive 
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CD4+ T helper (TH) cells that establish a chronic inflammatory response in the 
CNS2. Generation of inflammatory and cytotoxic mediators, by 
macrophages/microglia, in the CNS, causes oligodendrocyte damage, leading to 
demyelination and eventually to neuronal damage, responsible for the clinical 
outcome of MS3. 
Much of our current understanding of the mechanisms underlying the 
pathogenesis of MS was provided by analysis of its animal model, experimental 
autoimmune encephalomyelitis (EAE)4. In a similar manner to MS, the 
pathogenesis of EAE is driven by the activation of myelin-specific TH cells that 
establish focal inflammatory lesions in the CNS, responsible for the clinical signs of 
the disease2. Differentiation of naïve myelin-reactive TH cells towards an 
encephalitogenic TH type 1 (TH1) phenotype plays a central role in the pathogenesis 
of EAE as well as MS1,2. 
Presumably, myelin-reactive TH1 cell priming is triggered by dendritic cells 
(DC) in the CNS-draining LN2,5. Immunogenic DC can present myelin-derived 
peptides in the context of major histocompatibility complex (MHC) class II6, while 
expressing costimulatory molecules and producing cytokines that favor the 
differentiation of encephalitogenic TH1 cells7, characterized by the secretion of 
interferon (IFN)-8. The capacity of DC to drive myelin-reactive TH cell differentiation 
towards a TH1 phenotype relies on the production of interleukin (IL)-12p709,10. 
The encephalitogenic effect of IFN- produced by myelin-reactive TH1 cells 
is supported by the observation that: i) EAE is associated with high levels of IFN- 
production by CNS-infiltrating TH1 cells, which is also the case for active MS 
lesions11,12, ii) IFN- blocking antibodies suppress MS progression13 and iii) IFN- 
administration exacerbates MS progression14. The observation that despite the fact 
that Ifng15, Ifngr16 and Il12p3517-deficient mice fail to mount a TH1 response, these 
mice remain susceptible to EAE, led to the identification of TH17 cells, as another 
major player in the pathogenesis of autoimmune neuroinflammation18,19. 
The mechanisms underlying the encephalitogenicity of myelin-reactive TH1 
and TH17 cells are probably distinct20,21. TH1 elicit a classical form of EAE with 
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spinal cord lesions predominating over brain and associated with monocytic 
infiltrates, while TH17 induce an atypical form of EAE with brainstem and 
cerebellum lesions associated with granulocytic infiltrates20. When analyzed in 
conjunction, these forms of EAE recapitulate, to a large extent, the clinical 
symptoms of MS4. 
The pathologic outcome of autoimmune neuroinflammation reflects the 
extent of tissue injury imposed to oligodendrocytes and neurons by CNS-infiltrating 
encephalitogenic TH1 or TH17 cells22. Therefore, mechanisms inhibiting myelin-
reactive TH1 or TH17 cell priming should counter the pathogenesis of autoimmune 
neuroinflammation. Moreover, mechanisms conferring tissue-damage control in the 
CNS should also contribute to limit disease progression23. Presumably, these 
regulatory mechanisms are mediated by the expression of stress-responsive genes 
that modulate the pathogenic effect of myelin-reactive TH cells and/or that confer 
tissue-damage control in the CNS. We reasoned that some of these stress-
responsive genes may fall under the control of the nuclear factor erythroid (NF-E) 2-
related factor 2 (Nrf2), a master regulator of adaptive cellular responses to oxidative 
stress24,25. 
Nrf2 belongs to the Cap’n’collar basic leucine zipper family of transcription 
factors24,26 and responds to oxidative stress, sensed by its constitutive repressor 
Kelch-like ECH-associated protein 1 (Keap1)26. Accumulation of free radicals 
disrupts Keap1 interaction with Nrf227, overcoming the constitutive ubiquitination 
and degradation of Nrf2 by the 26s proteasome28. This allows for Nrf2 nuclear 
translocation and binding to antioxidant response elements (ARE) in the promoter 
of genes24 encoding antioxidant and detoxifying enzymes, that provide cellular 
adaptation to oxidative stress24. These oxidative stress-regulated genes include 
Hmox1, encoding the heme-catabolizing enzyme heme oxygenase-1 (HO-1)29 that 
confers protection against immune-mediated inflammatory diseases30, including 
autoimmune neuroinflammation31,32. 
Deletion of the Nrf2 allele in mice25 promotes the development of 
autoimmune diseases33-35, including autoimmune neuroinflammation36,37. The 
clinical relevance of these findings is supported by the observation that 
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polymorphisms reducing NRF2 expression38 are associated with increased severity 
of immune-mediated inflammatory diseases39-41. 
Here we report that Nrf2 restrains IL-12 production by DC, limiting myelin-
reactive TH1 cell priming and preventing TH1 cell-driven IFN- from participating in 
the pathogenesis of autoimmune neuroinflammation. While inhibition of IL-12 by 
Nrf2 acts via a mechanism involving the expression of HO-1 in DC, inhibition of 
myelin-reactive TH1 cell priming or EAE severity by Nrf2 act irrespectively of HO-1 
expression in DC. 
 
3. Results 
3.1 Nrf2 inhibits the pathogenesis of EAE 
We asked whether the onset and/or progression of EAE in MOG35-55-immunized 
C57BL/6 mice is associated with the expression of Nrf2-regulated genes, as 
assessed in the CNS at the onset and peak of disease by qRT-PCR. Expression of 
Hmox1, Ferritin h chain (Fth), Peroxiredoxin 1 (Prdx1), Superoxide dismutase 2 
(Sod2), Glutathione S-transferase, theta 1 (Gstt1), Glutathione peroxidase 1 (Gpx), 
Glutathione reductase (Gsr), Metallothionein (Mt1), Metallothionein 2 (Mt2), 
Thioredoxin 1 (Trn1), Nrf2 and Cd36 mRNA was induced at the onset and peak of 
EAE, as compared to naïve mice (Fig.1a). Expression of NADPH dehydrogenase 
quinone 1 (Nqo1) mRNA was induced only at the peak of EAE, while mRNA 
expression of Catalase (Cat), Glutamate-cysteine ligase modifier (Gclm) and 
catalytic (Gclc) subunits remained unchanged, as compared to naïve mice (Fig.1a). 
The level of expression of these genes varied in naïve mice (Suppl. Table 1), which 
impacts on their fold-induction, as assessed during EAE. Expression of a subset of 
these Nrf2 regulated genes, i.e. Hmox131,32, Mt1 and Mt242 has been shown to 
prevent the pathologic outcome of EAE, supporting the notion that Nrf2 exerts a 
protective effect against autoimmune neuroinflammation36,37. 
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To assess whether Nrf2 regulates the pathogenesis of autoimmune 
neuroinflammation, EAE was compared in wild type (Nrf2+/+) vs. Nrf2-deficient  
(Nrf2-/-) C57BL/6 mice, immunized with MOG35-55 in complete Freund's adjuvant 
(CFA), and receiving Pertussis toxin (PTx). EAE severity was higher in Nrf2-/- vs. 
Nrf2+/+ mice (Fig.1), illustrated by mean disease scores and incidence of mortality, 
without changes in disease incidence (Fig.1b,c,d). Immunization of Nrf2-/- vs. Nrf2+/+ 
 
Figure 1. Nrf2 inhibits the pathogenesis of EAE. (a) mRNA transcripts were 
quantified by qRT-PCR in the spinal cord before induction (naïve; white; n=16), at 
the onset (grey; n=11) or at the peak (black; n=12) of EAE in C57BL/6 mice 
immunized with MOG35-55 in CFA and receiving PTx. Data is shown as mean fold 
change of mRNA expression relative to naïve mice ± STD. Data was pooled from 
at least three independent experiments (n=3-6 mice/experiment). (b) Mean EAE 
score ± SEM in wild type (Nrf2+/+; white; n=13) and Nrf2-deficient (Nrf2-/-; black; 
n=17) C57BL/6 mice immunized with MOG35-55 plus CFA and receiving PTx. Data 
was pooled from three independent experiments with similar results. (c) Disease 
incidence in the same mice as (b). (d) Mortality in the same mice as (b). (e) Mean 
EAE score ± SEM in 2D2Nrf2+/+ (white, n=12) and 2D2Nrf2-/- (black; n=10) 
C57BL/6 mice receiving PTx. Data was pooled from two independent experiments 
with similar results. (f) Disease incidence in same mice as (e). (g) Mortality in same 
mice as (e). (*) p<0.05; (**) p<0.01; (***) p<0.001. 
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mice with a non-self-protein, i.e. ovalbumin (OVA) in CFA followed by PTx 
administration, did not lead to mortality (Suppl. Table 2). This suggests that Nrf2 
confers protection against activation of self-reactive T cells, such as myelin-reactive 
TH cells. 
Similar results were obtained in 2D2 TCR transgenic mice, in which TCR 
recognition is restricted to the MOG35-55 peptide, when presented in the context of 
MHC class II43. Consistent with previous reports43, 2D2 mice developed EAE in 
response to PTx administration, without active immunization (Fig.1e,f,g). Disease 
severity was higher in 2D2 mice lacking Nrf2 (2D2Nrf2-/-) vs. control (2D2Nrf2+/+) 
mice, as revealed by mean disease scores (Fig.1e). Disease onset occurred earlier 
in 2D2Nrf2-/- vs. 2D2Nrf2+/+ mice, while disease incidence (Fig.1f) and mortality 
(Fig.1g) were similar. 
The number of CNS-infiltrating leukocytes was similar in polyclonal TCR 
(Suppl. Fig.1a-h) or anti-MOG35-55 TCR transgenic (Suppl. Fig.2a-h) Nrf2+/+ vs.  
Nrf2-/- mice as assessed during EAE. There was an increase in the level of 
expression of MHC class II by the microglia (CD45lowCD11b+) (Suppl. Fig.1d) as 
well as a decrease in the number of CNS-infiltrating TH17 cells (Suppl. Fig.1f) in the 
CNS of Nrf2-/- vs. Nrf2+/+ mice. This accounts for a slightly higher TH1 (IFN-) to 
TH17 (IL-17A+) cell ratio in Nrf2-/- vs. Nrf2+/+ (Suppl. Fig.1g) as well as in 2D2Nrf2-/- 
vs. 2D2Nrf2+/+ (Suppl. Fig.2g) mice, which was not statistically significant. 
Expression of mRNA encoding a number of immune-related proteins was similar in 
the CNS of Nrf2+/+ vs. Nrf2-/- mice, as assessed by qRT-PCR at the onset of EAE 
(Suppl. Fig.3). There were no differences in the number of splenic macrophages, 
neutrophils, DC, TH1, TH17 and TREG cells from Nrf2+/+ vs. Nrf2-/- mice (Suppl. Fig.4), 
as assessed at the onset of EAE. 
 
3.2. The protective effect of Nrf2 is exerted in the immune system 
To determine further the mechanism via which Nrf2 limits EAE severity, leukocytes 
from immunized 2D2Nrf2-/- or 2D2Nrf2+/+ mice were adoptively transferred into sub-
lethally irradiated Nrf2+/+ or Nrf2-/- recipients. Leukocytes from 2D2Nrf2-/- vs. 
2D2Nrf2+/+ mice elicited higher EAE severity when adoptively transferred to Nrf2+/+  
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(Fig.2a-c) or Nrf2-/- (Suppl. Fig.5a-c) recipients, as illustrated by higher mean 
disease scores (Fig.2a and Suppl. Fig.5a). Leukocytes from immunized 2D2Nrf2-/- 
mice elicited an earlier onset of disease with similar disease incidence, as 
compared to 2D2Nrf2+/+ leukocytes (Fig.2b and Suppl. Fig.5b). Mortality was higher 
in mice receiving leukocytes from immunized 2D2Nrf2-/- vs. 2D2Nrf2+/+ mice, both 
for Nrf2+/+ (Fig.2c) and Nrf2-/- (Suppl. Fig.5c) recipients. EAE severity was not 
increased in Nrf2+/+ vs. Nrf2-/- recipient mice, adoptively transferred with leukocytes 
from 2D2Nrf2+/+ or 2D2Nrf2-/- mice, as illustrated by the mean disease scores 
(Fig.2d and Suppl. Fig.5d). Incidence of disease (Fig.2e and Suppl. Fig.5e) and 
mortality (Fig.2f and Suppl. Fig.5f) were similar when leukocytes from immunized 
2D2Nrf2+/+ or 2D2Nrf2-/- mice were adoptively transferred into Nrf2+/+ vs. Nrf2-/- mice. 
These observations reveal that the protective effect of Nrf2 is exerted via a 
mechanism controlling leukocyte encephalitogenicity. 
 
 
Figure 2. Nrf2 acts in leukocytes to inhibit the pathogenesis of EAE. (a) Mean EAE score ± SEM in Nrf2+/+ 
mice adoptively transferred with leukocytes from MOG35-55-immunized 2D2Nrf2+/+ (white; n=21) or 2D2Nrf2-/- 
(black; n=9) mice. (b) Disease incidence in the same mice as (a). (c) Mortality in the same mice as (a). (d) 
Mean EAE score ± SEM in Nrf2+/+ (white, n=21) and Nrf2-/- (black; n=13) mice adoptively transferred with 
leukocytes from MOG35-55-immunized 2D2Nrf2+/+ mice. (e) Disease incidence in the same mice as (d). (f) 
Mortality in the same mice as (d). Data was pooled from five independent experiments with similar results. (*) 
p<0.05; (**) p<0.01; (***) p<0.001. 
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3.3. Nrf2 regulates cytokine production by activated leukocytes 
To determine whether Nrf2 modulates the activation, proliferation and/or 
differentiation of myelin-reactive TH cells, proliferation and cytokine production were 
analyzed in draining LN leukocytes isolated from MOG35-55-immunized 2D2Nrf2+/+ 
vs. 2D2Nrf2-/- mice after MOG35-55 re-stimulation in vitro. Proliferation of 2D2Nrf2+/+ 
vs. 2D2Nrf2-/- leukocytes was similar, as assessed by carboxyfluorescein diacetate 
succinimidyl ester (CFSE) staining (Fig.3a,b). Production of IFN-, IL-17A and IL-13 
was higher in 2D2Nrf2-/- vs. 2D2Nrf2+/+ leukocytes, as assessed by ELISA (Fig.3c). 
There was no difference in the production of other cytokines involved in the 
pathogenesis of EAE, such as TNF, IL-10 or granulocyte macrophage colony-
stimulating factor (GM-CSF) (Fig.3c). Similar results were obtained in leukocytes 
isolated from the LN of MOG35-55-immunized Nrf2+/+ and Nrf2-/- mice, as assessed 
by [3H]-thymidine incorporation for TH cell proliferation (Fig.3d). Higher production of 
IFN- was confirmed in Nrf2-/- vs. Nrf2+/+ mice leukocytes, as assessed by ELISA 
(Fig.3e). Production of IL-17A and IL-13 were not modulated in Nrf2-/- vs. Nrf2+/+ 
leukocytes (Suppl. Fig.6). These observations suggest that Nrf2 inhibits the 
differentiation of myelin-reactive TH cells towards an IFN--producing TH1 
phenotype, irrespectively of TH cell proliferation. 
3.4. Nrf2 inhibits IL-12 production by DC 
We then asked whether Nrf2 regulates gene expression in DC. Steady state 
expression of mRNA encoding several Nrf2-regulated genes, such as Gsr (Fig.4e), 
Fth (Fig.4f), Nqo1 (Fig.4g), Hmox1 (Fig.4i) and Nrf2 itself (Fig.4h) was reduced in 
splenic DC (CD11c+MHCII+) from Nrf2-/- vs. Nrf2+/+ mice, as assessed by qRT-PCR. 
Steady state expression of mRNA encoding Gpx (Fig.4j) was increased in Nrf2-/- vs. 
Nrf2+/+ DC. Bacterial lipopolysaccharide (LPS) induced the expression of Gsr 
(Fig.4e) and Fth (Fig.4f), while reducing the expression of Hmox1 (Fig.4i)44 and Gpx 
(Fig.4j) in Nrf2+/+ DC, as compared to non-stimulated Nrf2+/+ DC. Expression of 
Nqo1 (Fig.4g) and Nrf2 (Fig.4h) remained unchanged in Nrf2+/+ DC exposed to 
LPS. Induction of Gsr (Fig.4e) and Fth (Fig.4f) in response to LPS was suppressed  
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Figure 3. Nrf2 inhibits the production of IFN- by MOG35-55-reactive leukocytes. (a) 
Proliferation (CFSE dilution profile) of LN (inguinal and popliteal) leukocytes isolated from 
MOG35-55-immunized 2D2Nrf2+/+ (open black line) and 2D2Nrf2-/- (filled grey) and re-
challenged in vitro with MOG35-55 (100 g/ml). Histogram represents cells from 
representative mice out of 3-4, in one out of two independent experiments. (b) Number of 
proliferating CD4+CFSElow cells from immunized 2D2Nrf2+/+ (n=4) or 2D2Nrf2-/- (n=3) mice, 
re-challenged in vitro with MOG35-55 (1, 10, 100 g/ml) or an anti-CD3 mAb (+; 0.5 g/ml). 
Data is shown as mean ± STD from individual mice (n=3-4) from two independent 
experiments. (c) Cytokine concentration in supernatants from LN leukocytes isolated from 
2D2Nrf2+/+ (n=11) or 2D2Nrf2-/- (n=11) mice immunized with MOG35-55 in CFA and cultured in 
vitro with MOG35-55 (+; 100 g/ml). Data is shown as mean ± SEM from three independent 
experiments, performed in triplicate (n=3-5 mice/group). (d) Proliferation ([3H]-thymidine 
incorporation) of LN leukocytes isolated from MOG35-55-immunized Nrf2+/+ or Nrf2-/- mice and 
cultured in vitro with MOG35-55 (1, 10, 100 g/ml) or anti-CD3 mAb (+; 0.5 g/ml). Data is 
shown as mean counts per minute (cpm) ± STD from individual mice (n=6) in two 
independent experiments with similar trend. (e) IFN- concentration in supernatants from 
leukocytes isolated from the 46 of MOG35-55-immunized Nrf2+/+ (n=8) or Nrf2-/- (n=8) mice 
cultured in vitro with MOG35-55 (+; 100 g/ml). Data is shown as mean ± STD from individual 
mice in two independent experiments (n=3-5 mice/group), with similar trend. 
57 
 
in Nrf2-/- DC. Expression of Nqo1 (Fig.4g) and Hmox1 (Fig.4i) were suppressed in 
Nrf2-/- vs. Nrf2+/+ DC. This suggests that Nrf2 regulates gene expression in naïve as 
well as LPS-activated splenic DC. 
 
Figure 4. Nrf2 regulates gene expression in DC. (a) Representative dot plots of 
splenic DC (CD11c+MHCII+) from (a) Nrf2+/+ and (b) Nrf2-/- mice, purified using anti-
CD11c magnetic beads. Representative dot plots of splenic (c) Nrf2+/+ and (d) Nrf2-/- DC 
sorted as CD11c+MHCII+TCR-IgM-CD19- cells. Expression of (e) Gsr, (f) Fth, (g) Nqo1, 
(h) Nrf2, (i) Hmox1 and (j) Gpx mRNA analyzed by qRT-PCR in splenic DC 
(CD11c+MHCII+TCR-IgM-CD19-) from Nrf2+/+ C57BL/6 mice as in (c) or Nrf2-/- as in  (d), 
cultured in presence (+) or absence (-) of LPS (100 ng/ml; 4h). Data is shown as mean 
fold change of mRNA expression relative to wild type (Nrf2+/+) naïve cells ± STD from 
four independent experiments with similar trend (n=3-4 pooled 
mice/genotype/experiment). 
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We then asked whether Nrf2 modulates the immunogenic effect of DC, in 
particular related to their capacity to produce IL-12, required to prime myelin-
reactive TH1 cells. Expression of Il12/23p40 mRNA was increased in naïve splenic 
Nrf2-/- vs. Nrf2+/+ DC as well as in response to LPS in vitro, as assessed by qRT-
PCR (Fig.5a). This effect was confirmed for IL-12/23p40 protein expression by 
ELISA in splenic Nrf2-/- vs. Nrf2+/+ DC exposed in vitro to different toll like receptor 
agonists, including LPS (TLR4), Poly(I:C) (TLR3) or CpG (TLR9)(Fig.5b). 
Production of IL-12p40 protein was also higher in Nrf2-/- vs. Nrf2+/+ Flt3 ligand 
(Flt3L)-derived bone marrow DC, stimulated in vitro with LPS or Poly(I:C) but not 
with CpG (Suppl. Fig.7). Expression of Il12p35 mRNA in response to LPS was also 
higher in splenic Nrf2-/- vs. Nrf2+/+ DC, as assessed by qRT-PCR (Fig.5c). This was 
also the case for IL-12p70, resulting from IL-12/23p40 and IL-12p35 
heterodimerization, as assessed by ELISA (Fig.5d). Expression of Il23p19 mRNA 
remained unchanged in Nrf2-/- vs. Nrf2+/+ DC, both at steady state and after LPS 
stimulation, as assessed by qRT-PCR (Suppl. Fig.8). IL-23 protein was 
undetectable in cell culture supernatants from splenic DC, as assessed by ELISA. 
These observations demonstrate that Nrf2 inhibits the production of IL-12 in DC. 
Induction of IL-6 expression in response to LPS was abolished in splenic DC 
from Nrf2-/- vs. Nrf2+/+ mice (Fig.5e), which is in keeping with the notion that Nrf2 
controls Il6 transcription in other cell types45. Induction of TNF expression by LPS 
was also reduced in splenic Nrf2-/- vs. Nrf2+/+ DC (Fig.5f). 
Expression of surface molecules regulating DC immunogenicity, including 
MHC class II, CD40, CD80, CD86 and CD70 was similar in splenic Nrf2-/- vs. Nrf2+/+ 
DC, both at steady state or after LPS stimulation (Suppl. Fig.9a). The same is true 
for splenic DC analyzed at the onset of EAE in Nrf2+/+ vs. Nrf2-/- mice (Suppl. 
Fig.9b). This demonstrates that Nrf2 inhibits IL-12 production by DC, while 
promoting IL-6 and TNF production, suggesting that Nrf2 might inhibit TH1 priming, 
a process which requires the production of IL-12 by DC9,10. 
 
 
 
59 
 
3.5. Nrf2 inhibits TH1 priming by DC 
We hypothesized that expression of Nrf2 in DC inhibits the differentiation of naïve 
myelin-reactive TH cells towards an IFN--secreting TH1 phenotype (Fig.3c,e). Naïve 
2D2Nrf2+/+ or 2D2Nrf2-/- TH cells were primed in vitro with MOG35-55-pulsed splenic 
Nrf2+/+ or Nrf2-/- DC, activated or not by LPS. Cytokines were measured by ELISA in 
cell culture supernatants after re-challenge with an anti-CD3 monoclonal antibody 
(mAb). 2D2 TH cells produced higher levels of IFN-when primed with Nrf2-/- vs. 
Nrf2+/+ DC (Fig.6a). 2D2 TH cells from Nrf2+/+ or Nrf2-/- mice produced similar levels 
of IFN- in response to priming by Nrf2+/+ vs. Nrf2-/- DC (Fig.6a and Suppl. Fig.10a).  
 
 
Figure 5. Nrf2 inhibits IL-12 and promotes IL-6 and TNF expression in DC. (a) Expression of Il12/23p40 
analyzed by qRT-PCR in sorted (CD11c+MHCII+TCR-IgM-CD19-) splenic DC from Nrf2+/+ or Nrf2-/- C57BL/6 
mice cultured in presence (+) or absence (-) of LPS (100 ng/ml; 4h). Data is shown as mean ± STD from four 
independent experiments, with similar trend (n=3-4 pooled mice/genotype/experiment). (b) Concentration of 
IL-12/23p40, in cell culture supernatants of sorted splenic DC stimulated with LPS (+; 100 ng/ml), Poly(I:C) 
(+; 50 g/ml) or CpG (+; 0.1M) for 24h. Data is shown as mean ± STD from 5 (LPS and PolyI:C) or 3 wells 
(CpG) in one experiment representative of at least two independent experiments with similar trend (n=3-4 
pooled mice/genotype/experiment). (c) Expression of Il12p35 analyzed by qRT-PCR in sorted splenic DC as 
in (a). Data is shown as mean ± STD from three independent experiments, with similar trend (n=3-4 pooled 
mice/genotype/experiment). (d) IL-12p70, (e) IL-6 and (f) TNF in cell culture supernatants of sorted splenic 
DC stimulated with LPS (+; 100 ng/ml; 24h) as in (b). Data is shown as mean ± STD from one representative 
experiment performed in sixtuplicate out of two (TNF and IL-6) or three (IL-12p70) independent experiments 
with similar trend (n=3-4 pooled mice/genotype/experiment). 
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Nrf2 expression in DC or TH cells had no effect on the production of other cytokines, 
such as IL-17A (Fig.6b), TNF (Suppl. Fig.10d and 11a), IL-2 (Suppl. Fig.10e and 
11b), IL-10 (Suppl. Fig.10f and 11c), GM-CSF (Suppl. Fig.10c and 12a) or IL-13 
(Suppl. Fig.10g and 12b). These observations suggest that expression of Nrf2 in 
DC inhibits the priming of naïve MOG35-55-reactive TH cells towards IFN--producing 
TH1 cells. Of notice, 2D2 TH cells from Nrf2+/+ vs. Nrf2-/- mice produced higher levels 
of IL-4 when primed by Nrf2+/+ DC (Suppl. Fig.10h). 
3.6. Nrf2 inhibits the encephalitogenic effect of IFN- produced by myelin-
reactive TH1 cells 
We reasoned that if inhibition of TH1 cell priming is functionally involved in the 
protective effect of Nrf2 against EAE, this effect should be abrogated in mice in 
which the biologic activity of IFN- is suppressed. To test this hypothesis, 
 
Figure 6. The protective effect of Nrf2 is mediated via inhibition of IFN- production by myelin-reactive 
TH1 cells. Concentration of (a) IFN- and (b) IL-17A in cell culture supernatants of TH cells from naïve 
2D2Nrf2+/+ or 2D2Nrf2-/- mice cultured with MOG35-55-pulsed splenic DC from Nrf2+/+ or Nrf2-/- mice (96h). When 
indicated (+), DC were stimulated with LPS (100 ng/ml). Cytokine production was assessed 48h after re-
stimulation with an anti-CD3 (2.5 g/ml) mAb. Data is shown as mean ± SEM pooled from at least three 
independent experiments with similar trend, each performed at least in quintuplicate. (c) Mean EAE score ± 
SEM in Ifngr1-/- mice adoptively transferred with leukocytes isolated from MOG35-55-immunized 2D2Nrf2+/+ 
(white; n=9) or 2D2Nrf2-/- (black; n=9). Results were pooled from two independent experiments with similar 
trend. (d) Disease incidence in the same mice as (c). (e) Mortality in the same mice as (c). 
61 
 
leukocytes from MOG35-55-immunized 2D2Nrf2+/+ and 2D2Nrf2-/- mice were 
adoptively transferred into recipients that do not express the IFN- receptor (Ifngr1-/-
). Consistent with previous reports46, adoptive transfer of leukocytes into naïve 
Ifngr1-/- mice led to the development of an atypical axial-rotatory form of EAE. 
Severity of EAE was similar in Ifngr1-/- recipient mice receiving 2D2Nrf2+/+ vs. 
2D2Nrf2-/- leukocytes, as revealed by mean disease scores (Fig.6c) and incidence 
of disease (Fig.6d). Onset of mortality was slightly delayed in Ifngr1-/-, receiving 
leukocytes from 2D2Nrf2-/- vs. 2D2Nrf2+/+ mice (Fig.6e). These observations 
suggest that the protective effect of Nrf2 against EAE is mediated via a mechanism 
involving the inhibition of IFN-production by myelin-reactive TH1 cells. 
 
3.7. Nrf2 controls TH1 encephalitogenicity via inhibition of IL-12 production in 
DC 
Given that Nrf2 inhibits the expression of IL-12 in DC, we asked whether this effect 
would be sufficient to impair myelin-reactive TH cell priming towards IFN--
producing TH1 cells. Inhibition of IL-12 activity using a neutralizing anti-IL-12/23p40 
mAb restored the levels of IFN- produced by TH cells primed in vitro with MOG35-55-
pulsed splenic Nrf2-/- DC to those of TH cells primed in vitro with MOG35-55-pulsed 
splenic Nrf2+/+ DC (Fig.7a). This effect was not observed using an isotype-matched 
control mAb (Fig.7a). This suggests that expression of Nrf2 in DC inhibits the 
differentiation of encephalitogenic TH1 cells via a mechanism that relies on the 
inhibition of IL-12 production by DC. Production of IL-17A was not modulated by the 
anti-IL-12/23p40 neutralizing mAb, as compared to an isotype-matched control mAb 
(Fig.7b). 
We then tested whether neutralization of IL-12 in vivo reduces EAE severity 
in 2D2Nrf2-/- mice. Administration of an anti-IL-12/23p40 neutralizing mAb to 
2D2Nrf2-/- mice suppressed the onset of EAE in response to PTx administration, as 
compared to an isotype-matched control mAb (Fig.7c-e). This is revealed by a 
reduction in mean disease scores (Fig.7c), incidence of disease (Fig.7d) and 
mortality (Fig.7e). A similar effect was observed in 2D2Nrf2+/+ mice (Suppl. Fig.13). 
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This reveals that the onset of EAE in 2D2 mice receiving PTx is strictly controlled by 
IL-12 and/or IL-23, suggesting that inhibition of IL-12 contributes to the protective 
effect of Nrf2 against autoimmune neuroinflammation. 
3.8. The protective effect of Nrf2 is not mediated via the expression of HO-1 in 
DC 
Nrf2 controls the expression of HO-1 in several cell types29, including DC (Fig.4i). 
Given that expression of HO-1 inhibits the pathological outcome of EAE31,32,47, we 
reasoned that the protective effect of Nrf2 against EAE might act via a mechanism 
involving the induction of HO-1 expression in DC. Expression of IL-12p70 was 
higher in both naïve and LPS-stimulated splenic Hmox1-/- vs. Hmox1+/+ DC, as 
assessed in vitro (Fig.8a). This indicates that Nrf2 inhibits the expression of IL-
 
Figure 7. The protective effect of Nrf2 is mediated via inhibition of IL-12/23p40 production. Concentration 
of (a) IFN- and (b) IL-17A in cell culture supernatants of TH cells from naïve 2D2Nrf2+/+ or 2D2Nrf2-/- mice co-
cultured with MOG35-55-pulsed splenic DC from Nrf2+/+ or Nrf2-/- mice (96h). When indicated (+), DC were 
stimulated with LPS (100 ng/ml) and an anti-IL-12/23p40 neutralizing antibody (IL-12; 20 g/ml) or an isotype-
matched control antibody (IgG2a; 20 g/ml) were added to the cell culture. Cytokine production was assessed 
48h after re-stimulation with an anti-CD3 (2.5 g/ml) mAb. Data is shown as mean ± STD of one experiment 
representative of two independent experiments with similar trend, performed at least in quintuplicate. (c) Mean 
EAE score ± SEM in 2D2Nrf2-/- treated with an anti-IL-12/23p40 neutralizing antibody (IL-12; black; n=8) vs. an 
isotype-matched control antibody (IgG2a; white; n=9). Data is pooled from three independent experiments with 
similar trend. (d) Disease incidence in the same mice as (c). (e) Mortality in the same mice as (c). 
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12p70 in DC most probably via a mechanism involving the expression of one of its 
target genes, namely Hmox1. 
In a similar manner to Nrf2 (Suppl. Fig.9a), HO-1 failed to regulate the 
expression of MHC class II (IAd) and costimulatory molecules, regulating DC 
immunogenicity, including CD40, CD80 and CD86, as assessed in vitro in 
unstimulated or LPS-stimulated GM-CSF bone marrow-derived DC from Hmox1-/- 
vs. Hmox1+/+ mice (Suppl. Fig.14) or in vivo in splenic DC from naïve or LPS-
stimulated Hmox1-/- vs. Hmox1+/+ mice (Suppl. Fig.15). This indicates that when 
expressed under physiologic conditions in DC, HO-1 does not regulate DC 
maturation, as assessed by the expression of MHC class II and costimulatory 
molecules. 
In a similar manner to Nrf2 (Fig.3a,b,d), expression of HO-1 in DC also 
failed to regulate T cell proliferation, as assessed in leukocytes isolated from OVA-
immunized Hmox1+/+ vs. Hmox1-/- mice, re-challenged with OVA in vitro (Fig.8b). 
This is in keeping with our previous finding48, showing that when expressed under 
physiologic conditions HO-1 does not regulate TH cell proliferation. 
We then asked whether expression of HO-1 regulates naïve TH cell priming 
towards an IFN--secreting TH1 phenotype. Leukocytes from OVA-immunized 
Hmox1-/- vs. Hmox1+/+ mice produced similar levels of IFN- when re-stimulated with 
OVA in vitro (Fig.8c). This indicates that Nrf2 inhibits TH1 cell differentiation via a 
mechanism that does not involve HO-1. 
Finally, we asked whether expression of HO-1 in DC contributes to the 
protective effect of Nrf2 against autoimmune neuroinflammation. EAE severity was 
slightly but not significantly higher in MOG35-55-immunized C57BL/6 Hmox1lox/lox 
mice, carrying a functional Hmox1 allele flanked by LoxP sites, as compared to 
CD11c-Cre/Hmox1 mice in which the Hmox1lox/lox allele is deleted by the 
expression of Cre recombinase under the control of the CD11c promoter49. This is 
revealed by the mean disease scores (Fig.8d), incidence of disease (Fig.8e) and 
mortality (Fig.8f). Hmox1 deletion in splenic DC from CD11c-Cre/Hmox1 vs. 
Hmox1lox/lox was confirmed by qRT-PCR (Suppl. Fig.16). These experiments reveal 
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that Hmox1 deletion in DC is not sufficient per se to impact on the pathologic 
outcome of EAE, suggesting that the protective effect of Nrf2 against autoimmune 
neuroinflammation is not mediated by the induction of HO-1 expression in DC. 
4. Discussion 
DC play a central role in the initiation of both protective and pathologic TH cell 
responses, including those involved in the pathogenesis of autoimmune 
neuroinflammation50,51. Presumably, this pathologic effect is related to the inherent 
capacity of DC to activate naïve myelin-reactive TH cells50 in the periphery as well 
as to reactivate primed TH cells thereafter in the CNS52. Expression of IL-12 by DC, 
 
Figure 8. The protective effect of Nrf2 is not mediated by expression of HO-1 in DC. (a) Splenic DC from 
BALB/c Hmox1+/+ or Hmox1-/- mice were stimulated in vitro with LPS (+; 100 ng/ml). Supernatants were collected 
24 hours thereafter and IL12p70 measured by ELISA. Data is pooled from 5 independent experiments performed 
in sixtuplicate and shown as mean ± SEM. (b) Proliferation of LN leukocytes from BALB/c Hmox1+/+ (n=6) or 
Hmox1-/- (n=6) mice harvested eight days after footpad immunization with OVA, emulsified in CFA (2 mg/ml; 50 
l of emulsion/footpad). Cells were re-stimulated in vitro with OVA (10, 50, 250 g/ml) for 72h and [3H]-thymidine 
incorporation was measured. Data is shown as mean ± STD (n=6 mice/group) from two independent 
experiments with similar results. (c) IFN- production by LN leukocytes isolated from BALB/c Hmox1+/+ (n=9) or 
Hmox1-/- (n=9) mice 8 days after footpad immunization with OVA emulsified in CFA. Leukocytes were re-
stimulated in vitro with OVA (10, 50, 250 g/ml) for 72h and IFN- was measured in cell culture supernatants by 
ELISA. Data is shown as mean ± STD (n=9 mice/group) from three independent experiments with similar results. 
(d) Mean EAE score ± SEM in Hmox1lox/lox (white; n=17) vs. CD11c-Cre/Hmox1∆/∆ (black; n=15) C57BL/6 mice 
immunized with MOG35-55 plus CFA and receiving PTx. Data was pooled from three independent experiments 
with similar results (e) Disease incidence in the same mice as (e). (f) Mortality in the same mice as (e). 
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is necessary and sufficient to drive the differentiation of naïve myelin-reactive TH 
cells towards the encephalitogenic TH1 phenotype9,10. That IL-12 contributes in a 
critical manner to the pathogenesis of autoimmune neuroinflammation is supported 
by the observation that polymorphisms in the human IL12A (IL12p35), IL12B 
(IL12/23p40) and IL12RB1 genes act as genetic risk factors contributing to the 
pathogenesis of MS53. Presumably therefore, regulatory mechanisms inhibiting the 
production of IL-12 in DC should restrain the priming of naïve myelin-reactive TH 
cells towards a TH1 phenotype and as such, prevent the pathogenesis of 
autoimmune neuroinflammation. As demonstrated herein, the transcription factor 
Nrf2 acts in such a manner. 
EAE severity is exacerbated in Nrf2-/- vs. Nrf2+/+ mice, as assessed both 
when EAE is induced by active immunization in C57BL/6 mice (Fig.1b-d) or without 
active immunization in transgenic 2D2 mice (Fig.1e-f). This suggests that the 
protective effect of Nrf2 against autoimmune neuroinflammation can act under 
pathophysiologic conditions, i.e. without active immunization, such as those 
associated with the pathogenesis of MS. In keeping with this notion is the finding 
that Dimethylfumarate, a synthetic pharmacological molecule that activates Nrf2, 
affords protection against EAE54 as well as MS55. Given the above, understanding 
the mechanism of action of Nrf2 should be relevant for the treatment of MS. 
Nrf2 is a transcription factor that provides cellular metabolic adaptation to 
oxidative stress24. While protective against autoimmune neuroinflammation36,37 
(Fig.1b-g), the mechanism underlying the salutary effect of Nrf2 does not seem to 
operate in resident cells of the CNS. Instead, Nrf2 exerts an immunoregulatory 
effect that restrains the capacity of DC to prime naïve myelin-reactive TH1 cells 
involved in the pathogenesis of autoimmune neuroinflammation. This notion is 
supported by the following observations. First, adoptive transfer of leukocytes from 
MOG35-55-immunized Nrf2-/- mice elicits a more severe form of EAE, as compared to 
adoptive transfer of Nrf2+/+ leukocytes (Fig.2a-c). The reverse is not true, in that 
adoptive transfer of leukocytes from MOG35-55-immunized mice elicits similar EAE 
severity in Nrf2+/+ or Nrf2-/- recipient mice (Fig.2d-e). Second, expression of Nrf2 in 
DC inhibits the production of IL-12p70, as demonstrated in Nrf2+/+ vs. Nrf2-/- DC 
66 
 
(Fig.5d). Third, Nrf2 prevents the differentiation of naïve myelin-reactive TH cells 
towards an encephalitogenic TH1 phenotype (Fig.6a), an effect determined solely 
by the expression of this transcription factor in DC, as demonstrated using Nrf2+/+ 
vs. Nrf2-/- DC (Fig.6a). Fourth, inhibition of TH1 cell differentiation using an IL-
12/23p40 neutralizing antibody (Fig.7c-e) or inhibition of TH1 cell effector function in 
Ifngr1-deficient mice (Fig.6c-e) ablates the pathogenic effect associated with Nrf2 
deletion. These findings provide a mechanism of action for the protective effect of 
Nrf2 against autoimmune neuroinflammation36,37, contributing to explain how 
therapeutic molecules, such as Dimethylfumarate, act via this signal transduction 
pathway to prevent the pathogenesis and/or progression of MS. 
Expression of Nrf2 inhibits IL-12 (Fig.5a-d), while promoting IL-6 and TNF 
(Fig.5e,f) expression in DC. This effect should not only inhibit the differentiation of 
naïve myelin-reactive TH cells towards a TH1 phenotype, but also promote TH17 
differentiation. This appears to be the case for TH1 cells, as demonstrated by the 
observation that blocking IL-12/23p40 in vitro is sufficient to reverse the TH1 bias 
associated with deletion of the Nrf2 allele in DC (Fig.7a). However, the observation 
that Nrf2 does not regulate the number of IFN--producing TH1, or of TH17 cells 
infiltrating the CNS of mice undergoing EAE is difficult to conciliate with this notion 
(Suppl. Fig.1 and 2). It is possible that this immunoregulatory effect is masked in 
the CNS by the conversion of infiltrating TH17 cells into IFN--producing TH cells 
that become a major source of IFN- in the CNS during EAE56. Presumably, Nrf2 
prevents the priming of IFN--producing TH1 cells, while not affecting the later 
conversion of TH17 cells into IFN--producing TH cells. It should be noted that the 
number of TH17 cells in the CNS of Nrf2-/- mice is reduced as compared to Nrf2+/+ 
mice undergoing EAE (Suppl. Fig.1f), which is consistent with the reduction of IL-6 
production by DC. 
Presumably, the molecular mechanism via which Nrf2 controls the 
expression of IL-12 in DC is mediated via the expression of immunoregulatory 
genes controlled by Nrf2. One of the Nrf2-responsive genes that could contribute to 
this effect is Hmox1 (Fig.4i), which encodes an enzyme that catabolizes free heme 
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into labile iron and biliverdin, while producing carbon monoxide (CO)57. The 
observation that Hmox1-/- DC produce higher levels of IL-12p70 in vitro, as 
compared to Hmox1+/+ DC (Fig.8a), suggests that Nrf2 inhibits the expression of IL-
12 via the induction of HO-1 expression in DC (Fig.4i). This notion is in keeping with 
the observation that CO suppresses the pathogenesis of autoimmune 
neuroinflammation31 and inhibits IL-12p70 production by DC58. Moreover, the 
protective effect of Dimethylfumarate against EAE also acts via a mechanism 
involving the expression of Nrf236 and HO-1, which inhibits the production of IL-
12/23p40 and IL-12p70 in DC54. 
However, deletion of the Hmox1 allele fails to modulate the differentiation of 
naïve TH cells towards a TH1 phenotype (Fig.8c), suggesting that this effect is 
mediated via other Nrf2-regulated genes. Moreover, specific deletion of the Hmox1 
allele in DC has only a minor, if any, impact in EAE severity (Fig.8d-f). This 
suggests that expression of Nrf2 in DC inhibits myelin-reactive TH1 cell priming and 
confers protection against EAE via a mechanism not mediated exclusively by HO-1. 
Candidate Nrf2-responsive genes include Mt1 and Mt242. 
Several studies have suggested that expression of HO-1 in DC exerts 
immunosuppressive effects that limit the pathological outcome of immune-mediated 
inflammatory diseases47, including autoimmune neuroinflammation31,32. It should be 
noted however, that most of these studies are based on pharmacologic modulation 
of HO activity31,44,58, using pharmacologic molecules that can act irrespectively of 
HO-159, which questions the physiologic relevance of these findings. This is in 
keeping with the observation that when HO-1 is expressed under physiologic 
conditions in DC, it fails to regulate DC maturation (Suppl. Fig.14 and 15) or T cell 
proliferation (Fig.8b). However, HO-1 can inhibit the expression of IL-12 in DC 
(Fig.8a), suggesting that it can exert immunoregulatory effects via its expression in 
DC. 
In conclusion, we demonstrate that the transcription factor Nrf2 exerts 
immunoregulatory effects in DC that limit the progression of a prototypical TH1-
driven immunopathology, such as demonstrated for autoimmune neuroinflammation 
in mice. This protective effect is mediated only partially via the expression of HO-1. 
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Given that pharmacologic inducers of Nrf2 act therapeutically against MS, these 
findings should be relevant for the treatment of MS. 
 
5. Methods 
Mice. Mice were maintained under specific pathogen-free conditions at the Instituto 
Gulbenkian de Ciência and all experimental protocols were approved by the 
“Instituto Gulbenkian de Ciência animal care committee” and by the “Direção Geral 
de Veterinária (DGV)” of the Portuguese Ministry of Agriculture, Rural Development 
and Fisheries (License 018831-2010-09-03). C57BL/6 Nrf2-/-25 and Hmox1LoxP60 
mice were generated by the laboratory of Dr. Masayuki Yamamoto (Tohoku 
University Graduate School of Medicine) and obtained through the RIKEN 
BioResource Center (Nrf2 knockout mouse/C57BL6J and B6J.129P2-
Hmox1<tm1Mym>). Nrf2-/- mice were bred at Instituto Gulbenkian de Ciência from 
Nrf2+/- breeding pairs and genotyped by PCR from genomic DNA using the 
following primers: Nrf2-5’ 5’-TGGACGGGACTATTGAAGGCTG-3’, Lacz 5’-GCGGATTG 
ACCGTAATGGGATGG-3’, AS 5’-GCCGCCTTTTCAGTAGATGGAGG-3’. C57BL/6CD11c-
Cre49 mice were generated by the laboratory of Dr. Boris Reizis (Columbia University 
Medical Center) and obtained through the Jackson Laboratory (B6.Cg-Tg(Itgax-
cre)1-1Reiz/J). CD11c-Cre/Hmox1∆/∆ mice were produced at the Instituto 
Gulbenkian de Ciência from CD11c-Cre/Hmox1lox/lox x Hmox1lox/lox mice. CD11c-
Cre/Hmox1∆/∆ and Hmox1lox/lox mice were genotyped by PCR from genomic DNA 
using the following primers: CD11c-Cre transgene forward 5’-
ACTTGGCAGCTGTCTCCAAG-3’, CD11c-Cre transgene reverse 5’-GCGAACATCTTCA 
GGTTCTG-3’, CD11c-Cre internal control forward 5’-CAAATGTTGCTTGTCTGGTG-3’, 
CD11c-Cre internal control reverse 5’-GTCAGTCGAGTGCACAGTTT-3’, Hmox1 
forward 5’-CTCACTATGCAACTCTGTTGGAGG-3’, Hmox1 wt reverse 5’-GTCTGTAATC 
CTAGCACTCGAA-3’ and Hmox1 flox reverse 5’-GGAAGGACAGCTTCTTGTAGTCG-3’. 
Deletion of the Hmox1lox/lox allele by the Cre recombinase was assessed in sorted 
splenic DC by qRT-PCR from CD11c-Cre/Hmox1∆/∆ relative to Hmox1lox/lox mice 
using the following set of primers: 5’-AGGAGGTACACATCCAAGCCGAG-3’ and 5’-
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GATATGGTACAAGGAAGCCATCACCAG-3’. BALB/c Hmox1+/- mice61 were generated 
by Dr. Shaw-Fang Yet (Brigham and Women's Hospital). BALB/c Hmox1+/- and 
BALB/c.SCID.Hmox1+/- were bred at the Instituto Gulbenkian de Ciência from 
Hmox1+/- or SCID.Hmox1+/- breeding pairs and genotyped as described 
elsewhere62. Ifngr1-/-63 mice were generated by the laboratory of Dr. Michel Aguet 
(Swiss Institute for Experimental Cancer Research) and MOG35-55 TCR transgenic 
mice (2D2)43 by Dr. Vijay Kuchroo (Brigham and Women's Hospital), both obtained 
through the Jackson Laboratory (B6.129S7-Ifngr1tm1Agt/J and C57BL/6-
Tg(Tcra2D2,Tcrb2D2)1Kuch/J). 2D2Nrf2+/- mice were bred from hemizigous 
2D2Nrf2+/- x Nrf2+/- mice and interbred to produce 2D2Nrf2+/+ and 2D2Nrf2-/- mice. 
2D2Nrf2+/+ and 2D2Nrf2-/- mice were genotyped by PCR, using the following 
primers: 2D2 forward 5’-CCCGGGCAAGGCTCAGCCATGCTCCTG-3’ and 2D2 reverse 
5’-GCGGCCGCAATTCCCAGAGACATCCCTCC-3’. Food and water were provided ad 
libitum. Breeding pairs and progeny were maintained under RM3 diet (Lillico) at the 
exception of the progeny of 2D2Nrf2+/- x Nrf2+/- and Nrf2+/- x Nrf2+/- that was kept 
under AIN-76A diet after weaning (Harlan Teklad and TestDiet), as previously 
described64. Mice were used at 6 to 12 weeks of age and littermates were used as 
controls. 
Reagents. Murine MOG35-55 (MEVGWYRSPFSRVVHLYRNGK; Biopolymers 
Laboratory of Harvard Medical School and Caslo Laboratory) and OVA (Grade V; 
Sigma) were dissolved in PBS at 2 mg/ml and 10 mg/ml, respectively. CFA was 
prepared by grinding and re-suspending Mycobacterium tuberculosis HR37 (4 
mg/ml) in incomplete Freund’s adjuvant (Difco; BD Biosciences). PTx (List 
Biological Laboratories) was dissolved in PBS (100 ng/l). Phorbol 12-myristate 13-
acetate (PMA; Sigma) and inonomycin (Calbiochem) were dissolved in Dimethyl 
sulfoxide (DMSO; 2.5 mg/ml). Brefeldin A (Epicenter technologies) was dissolved in 
pure ethanol (1 mg/ml). Anti-CD3 (145-2e11) antibody and IL-23 were purchased 
from eBioscience. Anti-IL12/23p40 neutralizing antibody (C17.15; kind gift from Dr. 
Giorgio Trinchieri, National Cancer Institute) and rat isotype IgG2a controls (YKIX-
302; anti-canine CD4; a kind donation from Prof. Herman Waldmann, Oxford 
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University) were produced in house from hybridoma cell culture supernatants and 
purified on a Protein G column. 
EAE. Nrf2+/+ and Nrf2-/- mice or CD11c-Cre/Hmox1∆/∆ and Hmox1lox/lox were 
immunized with MOG35-55 (100 g) emulsified in CFA (100 l) subcutaneously on 
each side of the belly and received PTx intravenously (200 ng in PBS; 100 l) after 
immunization (i.e. 4h and 2 days). 2D2Nrf2+/+ and 2D2Nrf2-/- mice received PTx 
intravenously (200 ng in PBS; 100 l) twice at 48h interval. Clinical signs of EAE 
were evaluated daily for 40 days and scored as follows. For classical EAE: 0 - 
normal; 1 - limp tail; 2 - partial paralysis of the hind limbs; 3 - complete paralysis of 
the hind limbs; 4 - hind-limb paralysis and forelimb weakness; 5 - moribund or 
deceased. For axial-rotatory atypical EAE: 0 - normal; 1 - head turned slightly 
(ataxia, no tail paralysis); 2 - head turned more pronounced; 3 - inability to walk on 
a straight line; 4 - laying on side; 5 - rolling continuously unless supported, 
moribund or deceased. 
Adoptive transfer: MOG35-55-immunized 2D2Nrf2+/+ and 2D2Nrf2-/- mice (s.c.; 200 
μg in CFA; 100 l on each side of the belly) received PTx (i.p.; 200 ng in PBS; 100 
l) at the time of immunization and leukocytes were isolated from spleen and 
draining LN (inguinal and aortic), 7 days after immunization. Single-cell 
suspensions (8x106 cells/ml) in supplemented RPMI 1640 (100 U/ml penicillin, 100 
μg/ml streptomycin, 10% FCS, 50 μM-mercaptoethanol, 10 mM HEPES and 1 
mM sodium pyruvate; 2 mM L-glutamine; Invitrogen and Sigma) were re-stimulated 
with MOG35-55 (20 g/ml) and recombinant mouse IL-23 (20 ng/ml) for 48h (37°C; 
5% CO2, 95% humidity). Cells were washed in PBS and transferred (1.5x107 
cells/mouse; i.p in 500 l of PBS) into 10-12 week-old gender-matched wild type, 
Nrf2-/- or Ifngr1-/- mice, 20h after sub-lethal irradiation (550 rad; Gammacell 2000; 
Mølsgaard Medical). EAE was monitored for 40 days and scored as described 
above. 
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IL-12/23p40 neutralization in vivo. 2D2Nrf2+/+ and 2D2Nrf2-/- mice received PTx 
intravenously (200 ng in PBS; 100 l) twice with a 48h interval. At day -1 and 6 
post-PTx administration, mice received either anti-IL12/23p40 neutralizing antibody 
(C17.15, 1 mg/mouse) or a rat isotype-matched IgG2a control antibody (YKIX-302; 
1mg/mouse) i.p. dissolved in PBS. 
Antigen re-stimulation in vitro. Draining LN (inguinal and popliteal) cells were 
harvested 8 days after footpad immunization (50 g/per paw of MOG35-55 or OVA 
emulsified in CFA) and homogenized into single-cell suspensions. Cells were plated 
in 96-well flat bottom microtiter plates (2.5x105 cells/well) in supplemented RPMI 
1640 (200 l) and re-stimulated with MOG35-55 (1, 10 and 100 g/ml) or OVA (10, 50 
and 250 μg/ml) for 72 hours (37°C; 5% CO2, 95% humidity). Supernatants were 
analyzed by ELISA for detection of IFN- IL-17A, TNF, IL-10, GM-CSF and IL-13 
according to the manufacturer’s instructions (eBioscience). 
Cell proliferation. Draining LN (inguinal and popliteal) cells were isolated 8 days 
after footpad immunization (50 g of MOG35-55 or 100 g of OVA emulsified in CFA 
per paw). Cells were plated in 96-well flat bottom microtiter plates (2.5×105 
cells/well) in 200 l of supplemented RPMI 1640 (Invitrogen) and exposed to 
MOG35-55 (1, 10 and 100 g/ml) or OVA (10, 50 and 250 g/ml) for 72 hours (37°C, 
5% CO2, 95% humidity). For Nrf2+/+ and Nrf2-/- as well as Hmox1+/+ and Hmox1-/- 
cells, proliferation was assessed by [3H]-thymidine incorporation (1 μCi/well; Perkin 
Elmer) during the last 6 hours of culture evaluated in a scintillation counter (Tomtec; 
Pharmacia). 2D2Nrf2+/+ and 2D2Nrf2-/- cell proliferation was assessed by 
carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) staining. Briefly, cells 
were re-suspended in HBSS (2.5x106 cells/ml), incubated with CFSE (5 M; 5 min.) 
and stained for flow cytometry. Cell numbers were assessed by flow cytometry, 
using a fixed number of latex beads (Beckman Coulter) co-acquired with a pre-
established volume of the cellular suspensions. 
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Isolation of splenocytes and LN cells. Spleen and LN cells were harvested and 
homogenized into a single-cell suspension in PBS 2% FCS. Splenocytes were 
subjected to erythrocyte lysis in 3 ml of a hypotonic red blood cell lysis buffer (155 
mM NH4Cl, 10 mM NaHCO3, 0.1 mM EDTA) while centrifuging (375g, 5 min., 4ºC). 
Cells were washed twice in 15 ml PBS 2% FCS (375 g, 5 min., 4ºC). For 
intracellular cytokine staining, cells were cultured in supplemented RPMI 1640 
containing 50 ng/ml PMA, 500 ng/ml ionomycin and 10 g/ml brefeldin A for 4h at 
37°C (5% CO2, 95% humidity). Surface and intracellular stainings were analyzed by 
flow cytometry. 
CNS-infiltrating leukocytes. Brain and spinal cord were harvested from 
transcardially perfused mice (20 ml cold PBS). Single-cell suspensions were 
prepared in HBSS (Invitrogen) containing Collagenase VIII (0.2 mg/ml; Sigma) by 
homogenizing the tissue between two glass slides, digesting (30 min.; 37°C; 5% 
CO2, 95% humidity) and filtering (100-m; BD Falcon). After centrifugation (375g, 5 
min., 4ºC) in PBS, leukocytes were separated on a discontinuous 30% percoll 
gradient (Sigma) by centrifugation (1041g, 30 min., RT) erythrocytes were lysed in 
hypotonic red blood cell lysis buffer (5 min., RT). For intracellular cytokine staining, 
cells were cultured in supplemented RPMI 1640 with PMA, ionomycin and brefeldin 
A as described above. Surface and intracellular stainings were analyzed by flow 
cytometry. 
Splenic DC isolation. Spleens were harvested and perfused with Collagenase D 
(2 mg/ml; Roche) in HBSS, cut into small pieces and incubated at 37°C for 30 min. 
(5% CO2, 95% humidity). The single-cell suspensions were filtered (70-m) and DC 
in these suspensions were isolated using anti-CD11c positive magnetic selection 
according to the manufacturer’s instructions (Miltenyi Biotech) and sorted as 
CD11c+MHCII+TCR-IgM-CD19- cells using a MoFlo cell sorter (Beckman Coulter). 
DC purity was routinely higher than 98% (Fig 4a-d). 
Flt3L-derived bone marrow DC. Bone marrow cells were isolated and cultured (10 
days, 37ºC; 5% CO2, 95% humidity) in supplemented RPMI 1640 medium in 6-well 
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plates (3-5x106 cells/well) with 5% of cell culture supernatant containing murine 
Flt3L produced by the CHO-Flt3L cell line (kind gift from Dr. Caetano Reis e Sousa, 
Imperial College, London, UK). The CHO cell line was originally provided as a kind 
gift by Dr. Nic Nicola (The Walter and Eliza Hall Institute). The CHO-Flt3L cell 
culture supernatant was produced as follows: murine Flt3L was expressed in CHO 
cells transfected with a soluble Flt3L/FLAG peptide in the mammalian expression 
plasmid pEF-BOS65. CHO-Flt3L cells were grown in RPMI 1640 media containing 
5% FCS and 400 g/ml geneticin (G418; Sigma) for 7 days. Supernatant was 
collected, centrifuged (375g, 5 min., 4ºC), filtered (22-m) and stored at -20ºC until 
use. 
GM-CSF-derived bone marrow DC. Bone marrow cells were isolated and cultured 
(6 days, 37ºC; 5% CO2, 95% humidity) in supplemented RPMI 1640 medium with 
1% GM-CSF-conditioned medium in 6-well plates (1x106 cells/well). Medium was 
replaced every 48h until day six. GM-CSF-conditioned medium was prepared from 
the J558 plasmacytoma (kind gift from Dr. Brigitta Stockinger, National Institute for 
Medical Research) as follows. Cells were cultured in D-MEM: F12 supplemented 
with 10% FBS, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine 
(Sigma), 50 M-mercaptoethanol and 1 mg/ml Geneticin (G418; all from 
Invitrogen and Sigma). Confluent cells were transferred and grown in 50 ml of 
medium without Geneticin for 3 days. The cell suspension was collected, 
centrifuged (200g, 10 min., 4ºC) and supernatant filtered through 0.22-m and 
stored at -20ºC until use. 
DC stimulation. DC were plated in 96-well round bottom microtiter plates (0.5x105 
(IL12/23p40 and IL-6) or 2.0x105 cells/well (IL-12p70 and TNF)) in supplemented 
RPMI 1640 medium (250 l) and stimulated with LPS (100 ng/ml; E.coli O127:B8; 
Sigma), Poly(I:C) (50 g/ml; Invivogen) or CpG (0.1 M, Invivogen) for qRT-PCR 
analysis for 1h (Il23p19) or 4h (others) and for ELISA 24h. Flt3L-derived bone 
marrow DC were plated (0.5x105 cells/well) in supplemented RPMI 1640 medium 
(250 l) and stimulated with LPS (starting at 1.25x104 ng/ml and diluted sequentially 
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1:5; E.coli O127:B8; Sigma), Poly(I:C) (starting at 50 g/ml and diluted sequentially 
1:5; Invivogen) or CpG (starting at 2 M and diluted sequentially 1:5; Invivogen). 
Cells were incubated for 24h (37°C; 5% CO2, 95% humidity) and supernatants 
analyzed by ELISA for IL-12/23p40 (BD biosciences) according to manufacturer’s 
instructions. 
CD4+ T cell purification and antigen-presenting assays. Spleen and LN cells 
were homogenized into single-cell suspensions, as described above. Naïve CD4+ T 
cells were sorted from 2D2Nrf2+/+ or 2D2Nrf2-/- as CD4+CD62LhighCD25-CD11c- cells 
in the presence of EDTA to disrupt DC-T cell complexes (MoFlo cell sorter; 
Beckman Coulter). Purity was routinely higher than 98%. For antigen-presenting 
assays, splenic Nrf2+/+ vs. Nrf2-/- DC were plated in 96-well round bottom microtiter 
plates (1x104 cells/well) in supplemented RPMI 1640 and pulsed with MOG35-55 
(100 ng/ml) for 1h in presence of LPS (100 ng/ml) (37 °C; 5% CO2, 95% humidity). 
After centrifugation (666g, 2 min., 4ºC), supernatants were removed and T cells 
(1x105 cells/well) added (250 l) in supplemented RPMI 1640 medium with LPS 
(100 ng/ml). Cells were cultured for 96h (37°C; 5% CO2, 95% humidity). After 
centrifugation (666g, 2 min., 4ºC) cells were re-stimulated (48h) with plate-bound 
anti-CD3 mAb (2.5 g/ml; PBS; 1h; 37°C). Anti-IL-12/23p40 neutralizing mAb 
(C17.15; 20 g/ml) was used to suppress IL-12/23p40 activity during DC pulsing 
and in the following 96h of co-culture with T cells. Rat IgG2a (YKIX-302; 20 g/ml) 
mAb was used as control. Supernatants were analyzed by ELISA for IFN- IL-17A, 
TNF, IL-10, GM-CSF, IL-13 (all from eBioscience), IL-2 and IL-4 (BD Biosciences) 
according to the manufacturer’s instructions. 
Flow cytometry and antibodies. The following mAb were used: FcIII/II receptor 
(2.4G2), anti-CD4 (GK1.5-8 and RM4-5), anti-CD11b (M1/70), anti-CD25 (PC 61), 
anti-IgM (R33.24.12), anti-TCR(H57-597). anti-CD11c (HL3), anti-CD40 (3/23), 
anti-CD45 (30-F11), anti-CD80 (16-10A1), anti-CD86 (GL1), anti-Ly6G (RB6-8C5), 
anti-CD19 (MB19-1), anti-CD62L (Mel 14) (prepared in house from hybridoma 
culture supernatants), anti-MHC class II (AF6-120.1; BD Biosciences and M5/114; 
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eBioscience) and anti-F4/80 (CI:A3-1; Serotec). The following antibodies were used 
to sort DC, anti-CD11c (HL3), anti-MHC class II (M5/114), anti-TCR (H57-597), 
anti-CD19 (MB19-1) and anti-IgM (R33.24.12), and naïve T cells were sorted with 
the antibodies against CD4 (GK1.5-8), CD25 (PC 61), CD62L (Mel 14) and CD11c 
(HL3). Antibodies were directly conjugated to FITC, Alexa488, PE, PerCP, APC, 
Cy5, Alexa467 or APC-Cy5. 
For surface staining (flow cytometry and sorting), cells were incubated with 
anti-FcIII/II receptor antibody (2.4G2) in PBS 2% FCS (20 min., 4°C). Surface 
staining was performed in PBS 2% FCS (20 min., 4°C). After washing and 
centrifugation (666g, 2 min., 4ºC) cells were incubated with streptavidin-
allophycocyanin for (20 min., 4°C) to detect biotinylated antibodies. For flow 
cytometry analysis of surface stainings dead cells were excluded using propidium 
iodide (1.7 g/ml). 
For intracellular cytokine staining cells were fixed (2% paraformaldehyde; 30 
min., RT) and permeabilized (0.5% saponin in PBS 2% FCS, i.e. permeabilization 
buffer)(10 min., RT). Cells were incubated with anti-IFN- (XMG1.2; BD 
Biosciences) or anti-IL-17 (eBioTC11-18H10.1; eBioscience) mAb in 
permeabilization buffer (20 min., 4°C). For intracellular Foxp3 staining, cells were 
stained with anti-mouse Foxp3 conjugated (FJK-16s; eBioscience) with PE using 
the Foxp3 detection set (eBioscience) according to the manufacturer’s instructions. 
Cell numbers were assessed by flow cytometry, using a fixed number of 
latex beads (Beckman Coulter) co-acquired with a pre-established volume of the 
cellular suspensions. 
Flow cytometry detection was done in the FACSCalibur (BD Biosciences), 
using the cellquest software (BD Biosciences) for acquisition. Post-acquisition 
analysis was performed with FloJo software (Treestar). 
RNA isolation and qRT-PCR. For mRNA analysis of Nrf2-dependent genes in the 
CNS, spinal cords from individual mice were harvested, snap-frozen in liquid 
nitrogen, grinded and resuspended in TRIzol (Invitrogen). RNA was extracted with 
chloroform and purified with the RNeasy Mini Kit (Qiagen). For mRNA analysis of 
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Nrf2-dependent genes in splenic DC, cells from at least 3 spleens were pooled, 
sorted, stimulated in vitro and RNA was extracted with the RNeasy Mini Kit 
(Qiagen). cDNA synthesis was performed from 2 g (spinal cord) or 0.3-0.5 g (DC) 
of RNA using random hexamer primers (0.3 g/reaction; Invitrogen), dNTPs (0.5 
mM/reaction; Invitrogen)(5 min., 65°C). 5x First Strand buffer (Invitrogen) was 
added in the presence of DTT (10 mM/reaction; Invitrogen) and RNAse Out 
recombinant ribonuclease inhibitor (40 U/reaction; Invitrogen)(2 min., 42°C). 
SuperScriptII reverse transcriptase (200 U/reaction; Invitrogen) was added 
completing a final volume of 20 l (50 min., 42°C; 15 min., 70°C). cDNA was diluted 
1:25 (spinal cord) or 1:5 (DC) and (1 l) used for PCR reactions (10 l) using the 
Power SYBRGreen PCR master mix (Applied Biosystems) and optimal primer 
concentrations (previously determined for each transcript). PCR products were 
detected by qRT-PCR (ABI-7900HT; Applied Biosystems)(2 min., 50°C, 10 min., 
95°C, and 40 cycles of 15 sec at 95°C, 1 min., 60°C). Primers used to amplify 
mouse mRNA transcripts were designed using the Primer3 software (Whitehead 
Institute for Biomedical Research, Steve Rozen and Helen Skaletsky) according to 
the specifications of the ABI-7900HT equipment (Applied Biosystems) and are 
listed below: Nrf2 5’-TAGATGACCATGAGTCGCTTGCCC-3’ and 5’-ATAGCTCCTGCCA 
AACTTGCTCC-3’, Nqo1 5’-CCGAACACAAGAAGCTGGAAGCTG-3’ and 5’-AGGCAAATC 
CTGCTACGAGCAC-3’, Hmox1 5’-AAGGAGGTACACATCCAAGCCGAG-3’ and 5’-GATAT 
GGTACAAGGAAGCCATCACCAG-3’, Fth1 5’-ATGCCGAGAAACTGATGAAGCTGC-3’ 
and 5’-TGCACACTCCATTGCATTCAGCC-3’, Gstt1 5’-AGCCATTCTCAACTACATCGCCA 
C-3’ and 5’-GGGGGACATAATACCAATTGCCCAATC-3’, Gpx 5’-TCGGTTTCCCGTGCAA 
TCAGTTC-3’ and 5’-CCTTCTCACCATTCACTTCGCACTTC-3’, Gsr 5’-ACCATGATTCCA 
GATGTTGACTGCC-3’ and 5’-CCCTTTTCATCCGTCTGAATGCCC-3’, Mt1 5’-ACGTGCTG 
TGCCTGATGTGACGAACAG-3’ and 5’-TAGACTCAAACAGGCTTTTATTATTAACG-3’, 
Mt2 5’-CAACTGCTCCTGTGCCTCCG-3’ and 5’-ACGGCTTTTATTGTCAGTTACATGCTTT 
AT-3’, Prdx1 5’-CAAGGAGGATTGGGACCCATGAAC-3’ and 5’-GCCCCTGAAAGAGATA 
CCTTCATCAGC-3’, Cat 5’-ACCCCTATTGCCGTTCGATTCTCC-3’ and 5’-TTGTTTCCCA 
CAAGATCCCAGTTACC-3’, Sod2 5’-TAAGGGTGGTGGAGAACCCAAAGGAG-3’ and 5’-
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TTATTGAAGCCAAGCCAGCCCCAG-3’, Trn1 5’-GGACCTTGCAAAATGATCAAGCCCTT 
C-3’ and 5’-AGCAACATCCTGGCAGTCATCCAC-3’, Gclm 5’-GCCACCAGATTTGACTGC 
CTTTG-3’ and 5’-TGCTCTTCACGATGACCGAGTACC-3’, Gclc 5’-ACATCTACCACGCAG 
TCAAGGACC-3’ and 5’-CTCAAGAACATCGCCTCCATTCAG-3’, Cd36 5’-GATGACGTGG 
CAAAGAACAG-3’ and 5’-TCCTCGGGGTCCTGAGTTAT-3’, Il12p35 5’-CCACCCTTGCCC 
TCCTAAAC-3’ and 5’-GTTTTTCTCTGGCCGTCTTCA-3’, Il12p40 5’-GGAAGCACGGCAG 
CAGAATA-3’ and 5’-AACTTGAGGGAGAAGTAGGAATGG-3’, Il23p19 5’-TGCTGGATTG 
CAGAGCAGTAA-3’ and 5’-GCATGCAGAGAT TCCGAGAGA-3’ and Glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) 5’-AACTTTGGCATTGTGGAAGG-3’ and 5’-
ACACATTGGGGGTAGGAACA-3’. All other transcripts were analyzed using a 
TaqMan Gene Signature Mouse Immune Array (Applied Biosystems) according to 
the manufacturer’s instructions. Transcript number was calculated from the Ct of 
each gene using a 2−ΔΔCT method (relative number) and normalizing results to 
Gapdh. 
Statistics. EAE severity was analyzed daily with the Nonparametric Mann-Whitney 
U test. Disease incidence was analyzed by the Fisher test and survival by Log-rank 
analysis. Statistical analysis of IL-12/23p40 levels in Flt3L-derived bone marrow DC 
was performed by linear regression analysis where the dependent and independent 
variables are the concentration of IL-12/23p40 and the dose of stimulus, 
respectively. All other statistical analysis were performed using the Nonparametric 
Mann-Whitney U test, when sample size was smaller than 5, or did not follow 
normal distribution, and when it did Unpaired Student’s t-test for unequal variances 
was used. Normal distributions were assessed using the Kolmogorov-Smirnov test. 
p<0.05 was considered statistically significant. 
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8. Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1. Relative level of expression of Nrf2-dependent genes in naïve wild type mice. 
Data is shown as the inverse of the average Ct multiplied by a factor of 100 (1/ average Ctx100). Ct is the 
difference between the threshold cycle (Ct) of the gene of interest and the Ct of Gapdh. Data was pooled from at 
least three independent experiments. 
 
Supplementary Table 2. Mortality associated with OVA plus CFA immunization in EAE induction. Nrf2+/+ 
(n=17) and Nrf2-/- (n=16) mice were immunized with OVA (100 g) emulsified in CFA (100 l) subcutaneously on 
each side of the belly and received PTx intravenously (200 ng in PBS; 100 l) after immunization (i.e. 4h and 2 
days). Data is shown as the percentage of mice that died over the course of 40 days post-immunization and was 
pooled from three independent experiments. 
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Supplementary Figure 1. Nrf2 does not modulate leukocyte infiltration into the CNS during EAE. Flow 
cytometry analysis of brain and spinal cord leukocyte infiltrates in MOG35-55-immunized Nrf2+/+ (n=17) and Nrf2-/- 
(n=6) mice receiving PTx, analyzed at the onset of EAE (day 13). Number of (a) macrophages (CD45hiCD11b+) 
and (b) microglia (CD45lowCD11b+). Mean intensity of fluorescence (MFI) of MHC class II expression in (c) 
macrophages and (d) microglia. Number of (e) TH1, (f) TH17 and (h) TREG cells (CD4+CD25+Foxp3+). (g) Ratio of 
TH1/TH17 cells calculated as Log10 (number CD4+IFN-+/number CD4+IL-17A+). Circles correspond to single mice 
and lines to the average of the group. Data was pooled from two independent experiments. 
 
Supplementary Figure 2. Nrf2 does not modulate leukocyte infiltration into the CNS during EAE. Flow 
cytometry analysis of brain and spinal cord leukocyte infiltrates in 2D2Nrf2+/+ (n=4) and 2D2Nrf2-/- (n=3) mice 
displaying symptoms of EAE (day 22 post-PTx administration). Number of (a) of macrophages (CD45hiCD11b+) 
and (b) microglia (CD45lowCD11b+). MFI of MHC class II expression in (c) macrophages and (d) microglia. 
Number of (e) TH1, (f) TH17 and (h) TREG cells. (g) Ratio of TH1/TH17 cells calculated as Log10 (number CD4+IFN-

+/number CD4+IL-17A+). Circles correspond to single mice and lines to the average of the group. Data was 
pooled from two independent experiments. 
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Supplementary Figure 3. Expression of Nrf2 does not modulate the expression of immune-related genes 
in the CNS during EAE. Transcripts were quantified by qRT-PCR in the spinal cord of Nrf2+/+ and Nrf2-/- mice, 
before and at the onset of EAE (day 13). (a, b) Data is shown as the mean of the fold change in mRNA 
expression relative to wild type naïve mice ± STD. (c, d) Data is shown as mean fold change of mRNA 
expression relative to wild type mice undergoing EAE ± STD. Data was pooled from 4 independent experiments 
(n=12 pooled in sets of 3 mice). 
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Supplementary Figure 4. Nrf2 does not modulate macrophage or TH cell activation in the spleen during 
EAE. Flow cytometry analysis of the splenic populations in Nrf2+/+ (n=17) and Nrf2-/- (n=6) mice at the onset of 
EAE (day 13). (a) Total number of macrophages, (b) neutrophils, (c) dendritic cells, (d) TH1, (e), TH17 and (f) 
TREG cells. Each data point corresponds to a mouse and the line is the average of the group. Data is shown as 
the pool of two independent experiments. 
 
Supplementary Figure 5. Nrf2 inhibits leukocyte encephalitogenicity. (a) Mean EAE score ± SEM of Nrf2+/+ 
or Nrf2-/- mice adoptively transferred with leukocytes from MOG35-55-immunized 2D2Nrf2+/+ (white; n=21) or 
2D2Nrf2-/- leukocytes (black; n=12) mice, respectively. (b) Disease incidence in the same mice as (a). (c) 
Mortality in the same mice as (a). (d) Mean EAE score ± SEM in Nrf2+/+ (white, n=9) or Nrf2-/- mice (black; n=12) 
adoptively transferred with leukocytes from MOG35-55-immunized 2D2Nrf2-/- mice. (e) Disease incidence in the 
same mice as (d). (f) Mortality in the same mice as (d). Data was pooled from five independent experiments with 
similar results. The mice are the same as in Figure 2. (*) p<0.05. 
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Supplementary Figure 6. Nrf2 does not modulate the expression of IL-17A, TNF, IL-10, GM-CSF and IL-13 
in C57BL/6 mice. Concentration of IL-17A, TNF, IL-10, GM-CSF and IL-13 in supernatants from leukocytes 
isolated from MOG35-55-immunized Nrf2+/+ (n=9) or Nrf2-/- (n=7) mice and re-challenged in vitro with MOG35-55 (100 
g/ml; 72h). Data is shown as mean ± SEM from three independent experiments with similar trend (n=2-3 
mice/group ), each performed in triplicate. 
 
Supplementary Figure 7. Nrf2 inhibits the production of IL-12/23p40 in Flt3L-derived bone marrow DC. 
Concentration of IL-12/23p40 in cell culture supernatants from Flt3L-derived DC generated from the bone 
marrow of Nrf2+/+ or Nrf2-/- C57BL/6 mice stimulated with (a) LPS, (b) Poly(I:C) and (c) CpG. Data is shown as 
mean ± STD from one experiment representative of two independent experiments, performed in triplicate. 
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Supplementary Figure 9. Nrf2 does not modulate the expression of MHC class II or costimulatory 
molecules in DC. (a) MFI of MHC class II, CD80, CD86, CD70 and CD40 in splenic DC (CD11c+) from Nrf2+/+ 
(n=6) and Nrf2-/- (n=6) mice, receiving or not LPS in vivo (10 g/mouse; 6h). Data is shown as mean ± STD from 
individual mice (n=6) pooled from two independent experiments. (b) Percentage and total number of CD11c+ 
cells in the spleen of Nrf2+/+ (n=6) and Nrf2-/- (n=6) mice at the onset of EAE (day 13) (c) MFI of MHC class II, 
CD40, CD80 and CD86, gated in CD11c+ cells in the spleen of Nrf2+/+ (n=6) and Nrf2-/- (n=6) mice at the onset of 
EAE (day 13). Each data point corresponds to a mouse and the line is the average of the group. Data is shown 
from two pooled independent experiments. 
 
Supplementary Figure 8. Nrf2 expression in DC does not affect IL-23p19 production. mRNA expression of 
Il23p19 analyzed by qRT-PCR in splenic DC from Nrf2+/+ or Nrf2-/- C57BL/6 mice. When indicated (+) DC were 
stimulated in vitro with LPS (100 ng/ml; 1h). Data is shown as mean fold change of mRNA expression relative to 
wild type unstimulated cells ± STD from two independent experiments, with similar trend. 
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Supplementary Figure 10. Effect of Nrf2 expression on cytokine production by TH cells. Concentration of 
(a) IFN-, (b) IL-17A, (c) GM-CSF, (d) TNF, (e) IL-2, (f) IL-10, (g) IL-13 and (h) IL-4 by TH cells from naïve 
2D2Nrf2+/+ or 2D2Nrf2-/- mice, co-cultured with Nrf2+/+ MOG35-55-pulsed (100 g/ml) splenic DC (96h). When 
indicated (+) DC were stimulated with LPS (100 ng/ml). TH cells were re-stimulated with an anti-CD3 mAb (2.5 
g/ml) and cytokines were measured in cell culture supernatants by ELISA. Data is shown as mean ± SEM from 
at least three independent experiments, each performed in quintuplicate. 
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Supplementary Figure 11. Nrf2 expression in DC does not affect TNF, IL-2, and IL-10 production by TH 
cells. Concentration of (a) TNF, (b) IL-2 and (c) IL-10 in cell culture supernatants of CD4+ TH cells from naïve 
2D2Nrf2+/+ or 2D2Nrf2-/- mice co-cultured with MOG35-55-pulsed splenic DC from Nrf2+/+ or Nrf2-/- mice. When 
indicated (+), DC were stimulated with LPS (100 ng/ml). Cytokine production was assessed 48h after re-
stimulation with an anti-CD3 (2.5 g/ml) mAb. Data is shown as mean ± SEM pooled from at least three 
independent experiments, each performed at least in quintuplicate. 
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Supplementary Figure 12. Nrf2 expression in DC does not affect GM-CSF, IL-13 or IL-4 production by TH 
cells. Concentration of (a) GM-CSF, (b) IL-13 and (c) IL-4 in cell culture supernatants of CD4+ TH cells from 
naïve 2D2Nrf2+/+ or 2D2Nrf2-/- mice co-cultured with MOG35-55-pulsed splenic DC from Nrf2+/+ or Nrf2-/- mice 
(96h). When indicated (+), DC were stimulated with LPS (100 ng/ml). Cytokine production was assessed 48h 
after re-stimulation with an anti-CD3 (2.5 g/ml) mAb. Data is shown as mean ± SEM pooled from at least three 
independent experiments, each performed at least in quintuplicate.  
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Supplementary Figure 14. Expression of Hmox1 does not modulate the maturation of GM-CSF-derived 
bone marrow DC in vitro. Histogram comparing surface expression of (a) MHC class II, (c) CD40, (e) CD80 
and (g) CD86 in GM-CSF-derived CD11c+ DC generated from the bone marrow of Hmox1+/+ (left) and Hmox1-/- 
(right) mice, stimulated (back line) or not (grey) with LPS in vitro (100 ng/ml; 24h). Each line represents cells 
from a single mouse, in one out of 3 independent experiments with similar results (n=1-4 mice/group). MFI of (b) 
MHC class II, (d) CD40, (f) CD80 and (h) CD86 in GM-CSF-derived CD11c+ DC generated from the bone 
marrow of Hmox1+/+ and Hmox1-/- mice, stimulated (+) or not with LPS in vitro (100 ng/ml; 24h). Data is shown as 
mean ± SEM from three pooled independent experiments, with similar results. 
 
Supplementary Figure 13. EAE induced by PTx in 2D2 mice is mediated by IL-12/23p40 production. (a) 
Mean EAE score ± SEM in 2D2Nrf2+/+ treated with an anti-IL-12/23p40 neutralizing antibody (IL-12; 20 g/ml; 
black; n=8) vs. an isotype-matched control antibody (IgG2a; 20 g/ml; white; n=15). Data is pooled from three 
independent experiments with similar trend. (b) Disease incidence in the same mice as (a). (c) Mortality in the 
same mice as (a). 
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Supplementary Figure 15. Expression of Hmox1 does not modulate the maturation of splenic DC in vivo. 
Histogram comparing surface expression of (a) MHC class II, (c) CD40, (e) CD80 and (g) CD86 in splenic DC 
(CD11c+) from severe combined immunodeficiency (SCID).Hmox1+/+ (left) and SCID.Hmox1-/- (right) mice, 
stimulated (open black line) or not (filled grey) with LPS in vivo (10 g/mouse; 6h). Each line represents cells 
from a single mouse, in one out of two independent experiments with similar results. MFI of (b) MHC class II, 
(d) CD40, (f) CD80 and (h) CD86 in splenic CD11c+ DC from SCID.Hmox1+/+ (n=5) and SCID.Hmox1-/- (n=3) 
mice, stimulated (+) or not with LPS in vivo (10 g/mouse; 6h). Data is shown as mean ± STD from two 
independent experiments with similar results (n=2-3 mice/experiment). 
 
Supplementary Figure 16. DC from CD11c-Cre/Hmox1∆/∆ mice do not express Hmox1. Hmox1 mRNA 
analyzed by qRT-PCR in sorted splenic DC from Hmox1lox/lox (n=2 pooled) vs. CD11c-Cre/Hmox1∆/∆ (n=2 
pooled) C57BL/6 mice with EAE (after day 40). Data is shown as percentage of the mean fold change of mRNA 
expression relative to Hmox1LoxP/LoxP DC from one experiment. 
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1. Abstract 
Heme oxygenase-1 (HO-1, encoded by HMOX1) dampens inflammatory reactions 
via the catabolism of heme into CO, Fe, and biliverdin. We report that expression of 
HO-1 dictates the pathologic outcome of experimental autoimmune 
encephalomyelitis (EAE), a model of multiple sclerosis (MS). Induction of EAE in 
Hmox1-/- C57BL/6 mice led to enhanced CNS demyelination, paralysis, and 
mortality, as compared with Hmox1+/+ mice. Induction of HO-1 by cobalt 
protoporphyrin IX (CoPPIX) administration after EAE onset reversed paralysis in 
C57BL/6 and SJL/J mice and disease relapse in SJL/J mice. These effects were 
not observed using zinc protoporphyrin IX, which does not induce HO-1. CoPPIX 
protection was abrogated in Hmox1-/- C57BL/6 mice, indicating that CoPPIX acts via 
HO-1 to suppress EAE progression. The protective effect of HO-1 was associated 
with inhibition of MHC class II expression by APC and inhibition of TH and CD8 T 
cell accumulation, proliferation, and effector function within the CNS. Exogenous 
CO mimicked these effects, suggesting that CO contributes to the protective action 
of HO-1. In conclusion, HO-1 or exposure to its end product CO counters 
autoimmune neuroinflammation and thus might be used therapeutically to treat MS. 
 
2. Introduction 
MS is a presumed autoimmune disorder that targets the CNS1. Neuroinflammatory 
lesions associated with MS progression are triggered upon interaction of activated 
pathogenic TH cells with APC within the CNS. This leads to the generation of a pro-
inflammatory response that causes irreversible oligodendrocyte injury, neuron 
demyelination, and eventually axonal loss, the main pathologic hallmarks of MS2-4.  
The clinical course of MS is, in most cases, associated with transitory 
episodes of remission2, suggesting that regulatory mechanisms must operate to 
counter neuroinflammation and/or to promote neuron regeneration. Such 
mechanisms may involve, but are most probably not limited to, the participation of 
regulatory T cells5,6. We hypothesized that expression of “protective genes”5,7 might 
also promote MS remission. One candidate is heme oxygenase-1 (HMOX1/HO-1), 
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a prototypical cytoprotective and anti-inflammatory stress-responsive gene 
(reviewed in5,8) expressed in the CNS during the course of MS9 and EAE10, a well-
established model of MS11. 
Under inflammatory conditions, HO-1 becomes the rate-limiting enzyme in 
the catabolism of heme, yielding equimolar amounts of CO, free Fe, and 
biliverdin12, which is subsequently reduced into bilirubin by biliverdin reductase 
(reviewed in13). Induction of HO-1 by metal protoporphyrins has been shown to 
have salutary effects in a variety of experimental inflammatory conditions (reviewed 
in8,14). The observation that in most cases, exposure to CO can mimic the protective 
effects of HO-1 (reviewed in8,15) would suggest that HO-1 acts in a protective 
manner via the generation of CO. It is likely, however, that other end products of 
HO-1 activity such as biliverdin16 and/or free Fe (by up-regulating heavy chain 
ferritin expression17; or cellular Fe efflux pumps18) may exert similar effects. 
Whether HO-1 modulates the pathogenesis of autoimmune 
neuroinflammation remained to be established, because both protective19 and 
deleterious20 effects of chemical HO-1 modulators have been demonstrated in EAE. 
Using HO-1-deficient (Hmox1-/-) mice, we demonstrate that expression of HO-1 
inhibited inflammation, demyelination, and paralysis, preventing mortality 
associated with the development of EAE. We also provide evidence that induction 
of HO-1 using protoporphyrins modulated ongoing autoimmune neuroinflammation, 
thereby reverting paralysis and leading to disease remission in mice with previously 
established EAE. Exogenous CO mimicked this effect, which suggests that this end 
product of heme degradation contributes to the protective action of HO-1. 
Suppression of EAE was associated with inhibition of (a) leukocyte accumulation in 
the CNS, (b) MHC class II expression by CNS APC, and (c) pathogenic TH cell 
proliferation and effector function. 
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3. Results 
3.1. Expression of HO-1 counters the pathogenesis of EAE 
Given that HO-1 expression in the CNS is associated with the development of both 
EAE and MS10,19,20, and based on the well-established protective effect of HO-1 
(reviewed in5,8), we hypothesized that HO-1 might modulate the pathogenesis of 
EAE. When immunized with the myelin oligodendrocyte glycoprotein peptide 35-55 
(MOG35-55), Hmox1-/- C57BL/6 mice developed a more severe form of EAE than did 
wild-type (Hmox1+/+) C57BL/6 mice (Fig.1a and Table 1), with 75% mortality in 
Hmox1-/- mice compared with 19% mortality in Hmox1+/+ controls (P = 0.0024; Table 
1).  
 
 
 
 
Figure 1. HO-1 and CO suppress EAE progression. EAE was induced, and 
disease severity was scored daily thereafter. Clinical scores are shown as 
mean ± SEM. (a) Progression of EAE in C57BL/6 Hmox1+/+ (open circles; n = 
21) versus Hmox1-/- (filled circles; n = 8) mice. (b and c) C57BL/6 (b) or SJL/J 
(c) mice, randomized 2 days after EAE onset, were treated daily with PBS 
(open squares; n = 10-15), CoPPIX (filled squares; n = 10-14), or ZnPPIX (grey 
squares; n = 10-14). (d) C57BL/6 Hmox1+/+ mice were treated as in (b). Hmox1 
mRNA and protein expression in the CNS were assessed by quantitative RT-
PCR and Western blotting, respectively. Hmox1 mRNA expression is shown as 
mean number of Hmox1 per HPRT mRNA molecules ± SD. (e) EAE was 
induced in C57BL/6 Hmox1+/+ (open circles; n = 12) and Hmox1-/- (filled circles; 
n = 3) mice treated with CoPPIX as in (b). (f) EAE was induced in C57BL/6 
Hmox1+/+ mice, randomized 10-12 days after immunization, and exposed to 
CO (450 ppm; dark grey squares; n = 20) or not (light gray squares; n = 22). 
Shaded areas indicate periods of designated treatment. *P < 0.05; **P < 0.01. 
a b c 
d e f 
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We tested whether induction of HO-1 by metal protoporphyrins would arrest 
EAE progression in Hmox1+/+ C57BL/6 mice. Induction of HO-1 expression and 
function by administration of cobalt protoporphyrin IX (CoPPIX) after EAE onset 
(i.e., disease incidence, 37%; mean clinical score, 0.7 ± 0.1) reversed paralysis and 
led to complete disease remission in 66.6% of mice compared with controls treated 
with vehicle (PBS) or zinc protoporphyrin IX (ZnPPIX) (Fig.1b and Table 2). To 
address whether similar effects would occur in other mouse strains, EAE was 
induced in SJL/J mice by immunization with the proteolipid protein peptide 139-151 
(PLP139-151). Induction of HO-1 by administration of CoPPIX after EAE onset in 
SJL/J mice (disease incidence, 40%; mean clinical score, 0.8 ± 0.2) reversed 
paralysis and led to complete disease remission in 75% of afflicted mice (Fig.1c and 
Table 2). Moreover, disease relapse was also suppressed in SJL/J mice treated 
with CoPPIX (Fig.1c and Table 2). That CoPPIX induced HO‑1 expression in 
C57BL/6 mice with established EAE was confirmed at the mRNA and protein levels 
(Fig.1d). CoPPIX induced a 3‑fold increase in Hmox1 mRNA expression in the 
CNS compared with PBS‑treated controls (P < 0.01; Fig.1d). Hmox1 mRNA was 
not significantly induced upon ZnPPIX administration (Fig.1d). Expression of HO-1 
protein was confirmed using protein extracts from the CNS (Fig.1d). 
When used at the same dose and schedule shown to arrest EAE 
progression in Hmox1+/+ C57BL/6 mice (Fig.1b), CoPPIX failed to arrest EAE 
progression in Hmox1-/- C57BL/6 mice (Fig.1e), confirming that the protective effect 
of CoPPIX requires the expression of HO-1. 
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We have previously shown that exogenous CO can mimic the protective 
effects of HO-1 in several inflammatory conditions21 (reviewed in8). To determine 
whether this was the case in EAE, C57BL/6 mice were exposed to CO via 
inhalation (EAE incidence, 17%; mean clinical score, 0.3 ± 0.1). CO arrested EAE 
progression and paralysis when compared with air inhaled under similar flow 
conditions (Fig.1f and Table 2). We asked whether expression of HO-1 during the 
course of EAE prevented CNS demyelination, the main cause of paralysis 
associated with EAE (reviewed in2-4). CNS demyelination was more pronounced in 
Hmox1-/- versus Hmox1+/+ C57BL/6 mice as assessed 60 days after the induction of 
EAE (Suppl. Fig.1a-f). Induction of HO-1 after EAE onset in SJL/J mice prevented 
CNS demyelination compared with ZnPPIX‑ or PBS-treated controls (Fig.2a-c), an 
effect consistent with reduction of paralysis (Fig.1a-c). Taken together, these 
observations suggest that the ability of HO‑1 to revert paralysis during the 
progression of EAE is associated with inhibition of CNS demyelination. 
 
3.2. HO-1 modulates the effector function of pathogenic TH cells 
Inhibition of EAE progression and relapse in SJL/J mice treated with CoPPIX was 
associated with a 87.2% ± 20% (P = 0.0033) and 62.4% ± 40% (P = 0.013) 
reduction of inflammatory foci in the CNS parenchyma and meninges, respectively,  
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compared with vehicle‑treated controls (Fig.2d-g). ZnPPIX, a protoporphyrin that 
inhibits HO enzymatic activity, increased by 2.3-fold the total number of 
inflammatory foci (i.e., parenchyma and meninges) compared with vehicle‑treated 
controls (P = 0. 0003), suggesting again that endogenous HO‑1 activity counters 
neuroinflammation associated with EAE progression (Fig.2d-g). However, this effect 
was not reflected by an increase in the clinical scores of the disease (Fig.1c).  
 
Figure 2. Induction of HO-1 prevents CNS demyelination and formation of 
inflammatory foci. SJL/J mice, randomized 2 days after EAE onset, were treated daily 
with PBS (a and d), CoPPIX (b and e), or ZnPPIX (c and f). Representative Luxol fast 
blue (a-c) and hematoxylin and eosin (d-f) spinal cord stainings with adjacent peripheral 
nerve root are shown 40 days after disease induction. Original magnification, ×160. Note 
the presence of some edema of myelin (a) and meningeal inflammation (d) in PBS-
treated controls, intact myelin (b) and mild meningeal inflammation (e) in CoPPIX-treated 
mice, and demyelination (c) and marked meningeal and parenchymal inflammation (f) in 
ZnPPIX-treated mice. (g) The number of inflammatory foci in the meninges and 
parenchyma as well as the total (meninges plus parenchyma) were quantified and are 
shown as mean ± SD (n = 8-10 per group). **P < 0.01. 
d e f 
g 
a b c 
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The ability of HO-1 induction to reduce the formation of inflammatory foci in 
the CNS (Fig.2g) was paralleled by a similar reduction in the total number of 
leukocytes detected within the CNS. Significant numbers of leukocytes (CD45high) 
were detected in the CNS of C57BL/6 mice with EAE (Suppl. Fig.2). These were 
composed primarily of CD4+ TH cells, CD8+ T cells, and CD45highCD11b+ 
macrophages (Mø; Fig.3a and Suppl. Fig.2). Induction of HO‑1 by CoPPIX 
decreased by 80% ± 6% the total number of leukocytes within the CNS compared 
with PBS‑treated controls (P < 0.001; Fig.3a). This decrease was reflected by an 
83% ± 7% decrease in TH cells (P < 0.001) and a 67% ± 17% decrease in CD8+ T 
cells (P < 0.001) compared with PBS‑treated controls (Fig.3a). These data 
demonstrate that HO‑1 induction after EAE onset significantly decreases the 
number of CNS leukocytes and the formation of inflammatory foci within the CNS. 
We tested whether HO-1 interfered with the activation, proliferation, and/or 
acquisition of effector function by CNS-infiltrating TH cells. Induction of HO-1 by 
CoPPIX reduced by 57% ± 2% the frequency of TH cells undergoing cell cycle 
progression (BrdU+; P = 0.028) and by 51.5% ± 34% that of TH cells expressing IL-2 
(P < 0.01), compared with vehicle‑treated controls (Fig.3b and Suppl. Fig.3a). This 
suggests that induction of HO-1 suppresses TH cell proliferation within the CNS, an 
effect that should contribute to suppressing EAE progression. 
The pathogenic function of CNS-infiltrating TH cells was also modulated by 
up-regulation of HO‑1 in that HO‑1 targeted specifically the expression of IFN- in 
TH cells. Control‑treated mice with EAE had 24% ± 4% CNS‑infiltrating TH cells 
expressing intracellular TNF- and IFN- (Suppl. Fig.3b). Induction of HO-1 by 
CoPPIX reduced by 60% ± 3% the frequency of TH cells expressing IFN- but failed 
to affect TNF- expression in these cells compared with PBS‑treated controls 
(Fig.3b and Suppl. Fig.3b). The frequency of TH cells expressing IL‑10 (Fig.3b) was 
not modulated by HO-1, an effect that should contribute to suppressing EAE 
progression as well. 
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We asked whether the protective effect of HO-1 was associated with 
modulation of regulatory T cells within the CNS. The frequency of forkhead box p3-
positive (Foxp3+) regulatory T cells within the CNS was not modulated by HO-1 
 
Figure 3. Induction of HO-1 reduces the number of TH and CD8
+
 T cells within the 
CNS and suppresses TH cell effector function. C57BL/6 mice, randomized 2 days 
after EAE onset, were treated daily with PBS, CoPPIX, or ZnPPIX. Leukocyte CNS 
infiltrates were analyzed by flow cytometry 20 days after immunization. (a) Number of 
CD45high (leukocytes), CD4+TH, and CD8+ T cells are shown as mean ± SD (n = 4-5 per 
group). (b) Percentages of CNS CD4+ TH cells expressing intracellular BrdU (S phase 
cell cycle progression), IL-2, IFN-, TNF-, IL‑10, and Foxp3 (regulatory T cells). (c) 
Percentage of CNS CD8+ T cells expressing intracellular BrdU, IFN-, and TNF-. Each 
value in (b) and (c) represents an individual animal. Bars indicate mean values of all 
mice analyzed in each group. *P < 0.05; **P < 0.01; ***P < 0.001. 
a 
b 
c 
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induction (Fig.3b and Suppl. Fig.3c), suggesting that the protective effect of HO-1 
may act independently of regulatory T cells. 
We tested whether expression of TH cell activation surface markers, 
including CD69, CD25, CD44, and CD62 ligand (CD62L), were modulated by HO-1 
induction. We found that this was not the case for the frequency of TH cells 
expressing these markers (Suppl. Fig.4) or for their relative level of expression 
(data not shown). 
The frequency of CNS-infiltrating CD8+ T cells undergoing cell cycle 
progression (BrdU+) was reduced by 55% ± 21% when HO-1 was induced 
compared with vehicle‑treated controls (P = 0.028; Fig.3c and Suppl. Fig.3d), an 
effect that should contribute to suppressing EAE progression2-4. Induction of HO‑1 
did not modulate IFN- or TNF‑ expression by CNS‑infiltrating CD8+ T cells 
(Fig.3c). 
 
3.3. HO-1 and CO suppress myelin-reactive TH cell reactivation 
We hypothesized that HO-1 induction might interfere with the reactivation of primed 
myelin-reactive TH cells that occurs in the CNS during the development of EAE and 
presumably also occurs in MS patients. Induction of HO-1 by CoPPIX reduced 
myelin‑reactive TH cell proliferation by 60.5% ± 3% compared with vehicle- or 
ZnPPIX‑treated controls (P < 0.001; Fig.4a). Moreover, HO-1 induction did not 
affect the proliferative response of draining lymph node TH cells to concanavalin A 
(ConA; Suppl. Fig.5a) nor did it reduce TH cell numbers in draining lymph nodes 
(data not shown). 
In the same experimental system, induction of HO-1 suppressed secretion 
of TNF- by 64% ± 2% (P < 0.001), IFN- by 75% ± 2% (P < 0.001), and IL-
12/23(p40) by 61% ± 16% (P < 0.01) compared with controls (Fig.4b). This 
suggests that HO-1 suppresses the differentiation of primed myelin-reactive TH cells 
toward a pathogenic effector phenotype characterized by the secretion of pro-
inflammatory cytokines. 
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To assess whether suppression of TH cell reactivation in vitro was due to 
defective priming of naïve myelin-reactive TH cells in vivo, draining lymph node TH 
cells (>98% CD4+) were isolated 7 days after immunization and rechallenged in 
vitro with MOG35-55 in the presence of naïve APC (<2% CD4+). Proliferation of 
 
Figure 4. The antiproliferative effect of HO-1 is exerted via APC. Results shown are mean ± 
SD from triplicate samples in 1 of at least 3 independent assays, except for IL-12/23(p40) (1 
assay). (a) C57BL/6 mice were treated as described in Methods. Eight days after immunization, 
proliferation of myelin-reactive TH cells was assessed in vitro 72 hours after addition of MOG35-55 
(10 μg/ml). (b) Cytokines were assayed in the cell culture supernatants (100 μg/ml MOG35-55 for 
72 hours). (c) C57BL/6 mice were exposed to air (n = 3) or CO (450 ppm; n = 3) starting 2 days 
prior to immunization. TH cell proliferation was assayed as in (a). (d) Mice were treated as in (c), 
and cytokines were assayed as in (b). (e-h) C57BL/6 mice were treated as in (a). (e) TH cells 
(>98% CD4+) from PBS-, CoPPIX-, or ZnPPIX-treated mice (n = 5) were cocultured with APC 
(<98% CD4+) from immunized but otherwise untreated mice. TH cell proliferation was measured 
as in (a). TH cells from untreated immunized mice were cocultured with (f) APC (<2% CD4+), (g) 
DC (>98% CD11c+), or (h) B cells (>98% B220+) from PBS-, CoPPIX-, or ZnPPIX-treated 
immunized mice (n = 5). TH cell proliferation was measured as in (a). **P < 0.01; ***P < 0.001. 
a b 
c d 
e f g h 
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myelin-reactive TH cells from CoPPIX-treated mice was similar to that of control 
mice (Suppl. Fig.5a), suggesting that HO-1 induction did not interfere with priming 
of naïve myelin-reactive TH cells in vivo. 
Exposure of C57BL/6 mice to CO inhibited by 71% ± 5% the proliferative 
response of myelin‑reactive TH cells compared with control mice exposed to air 
under similar flow conditions (P = 0.0016; Fig.4c). In the same experimental setting, 
CO inhibited TNF- secretion by 40% ± 2% (P = 0.0029) but failed to inhibit IFN‑ 
secretion (Fig.4d). This suggests that the immunomodulatory effect of CO may be 
more restricted than that of HO-1 induction. 
 
3.4. HO-1 expression in APC inhibits myelin-reactive TH cell proliferation 
We reasoned that inhibition of TH cell proliferation could result from induction of HO-
1 expression in TH cells22,23 and/or in APC24. To test the first possibility, TH cells 
were purified from MOG35-55-immunized mice in which HO-1 was induced. 
Proliferation of TH cells from CoPPIX-treated mice was not significantly inhibited in 
the presence of APC isolated from immunized but otherwise untreated mice 
compared with PBS- or ZnPPIX-treated controls (Fig.4e). This suggests that HO-1 
expression in TH cells is not sufficient per se to suppress TH cell proliferation.  
That the anti-proliferative effect of HO-1 is exerted via APC is suggested by 
the following set of observations. Proliferation of purified myelin-reactive TH cells 
from immunized but otherwise untreated mice was inhibited by 65% ± 7% in the 
presence of purified APC from immunized mice treated with CoPPIX compared with 
control APC isolated from PBS- or ZnPPIX‑treated immunized controls (P < 0.001; 
Fig.4f). TH cell proliferation was inhibited by 59% ± 3% (P < 0.01) by DC (>98% 
CD11c+; Fig.4g) but not by B cells (>98% CD19+; Fig.4h) isolated from CoPPIX- 
treated immunized mice compared with DC or B cells isolated from control PBS‑ or 
ZnPPIX‑treated immunized mice, respectively. 
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Figure 5. CoPPIX induces HO-1 expression in DC in vivo and in vitro. (a) C57BL/6 mice 
were randomized 2 days after EAE onset and treated daily with PBS, CoPPIX, or ZnPPIX. HO-1 
and CD11c (DC) expression in spinal cords was detected by immunocytochemistry 7 days after 
beginning treatments and analysed by confocal microscopy. Shown are HO-1 (left panels), 
CD11c (middle panels) and CD11c plus HO-1 (right panels). Original magnification, ×240. Arrows 
indicate positive staining. (b) Unsorted bone marrow-derived DC (approximately 80% CD11c+) 
were exposed to CoPPIX or ZnPPIX, and Hmox1 mRNA and protein expression were assessed 
by quantitative RT-PCR and Western blotting, respectively. Hmox1 mRNA is shown as mean 
number of Hmox1 per HPRT mRNA molecules ± SD (n = 3 per group). (c) Bone marrow-derived 
DC were purified (>98% CD11c+) and exposed to CoPPIX (50 μM for 16 hours) as in (b). HO-1 
(green) and CD11c (red) were detected as in (a). Original magnification, ×400. (d) Expression of 
HO-1 was detected by Western blot in purified DC shown in (c). **P < 0.01; ***P < 0.001. 
a 
b 
c d 
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Administration of CoPPIX to C57BL/6 mice after EAE onset induced high 
levels of HO-1 expression in CNS-infiltrating DC (CD11c+) compared with PBS‑ or 
ZnPPIX‑treated controls (Fig.5a). Similar effects were observed in vitro: CoPPIX 
induced a 64-fold increase in Hmox1 mRNA expression in bone marrow-derived DC 
(approximately 80% CD11c+) compared with vehicle-treated controls (Fig.5b). While 
Hmox1 mRNA expression was also induced by ZnPPIX, this effect was significantly 
less pronounced than that of CoPPIX (Fig.5b). These observations are consistent 
with the notion that ZnPPIX can induce HO-1 expression moderately while inhibiting 
its activity strongly, thus acting as a potent HO-1 inhibitor25. In the same 
experimental setting, CoPPIX induced HO-1 protein expression while ZnPPIX failed 
to do so (Fig.5b). To ensure that CoPPIX induced HO-1 expression specifically in 
DC and not in a putative contaminating cell population, bone marrow-derived DC 
were further purified (>98% CD11c+). That CoPPIX induced HO-1 expression 
specifically in CD11c+ cells was shown by immunocytochemistry (Fig.5c) and 
Western blot (Fig.5d). These data demonstrate that CoPPIX, but not ZnPPIX, 
induces HO‑1 expression in DC, a finding concordant with those of others24. 
 
3.5. HO-1 suppresses MHC class II expression in activated APC 
To evaluate further the impact of HO-1 in APC function, draining lymph node DC 
from immunized C57BL/6 mice were analyzed by flow cytometry. Induction of HO-1 
by CoPPIX reduced by 39% ± 12% MHC class II expression in DC (CD11c+) 
compared with controls (P < 0.001; Fig.6a). This effect was specific to MHC class II, 
as expression of CD40, CD80, and CD86 were not significantly affected (Suppl. 
Fig.6a). Induction of HO-1 did not alter the frequency or total number of DC in the 
draining lymph nodes of immunized mice (data not shown). Exogenous CO 
inhibited by 24% ± 8% MHC class II expression in DC compared with air-treated 
controls (P = 0.0011; Fig.6b). This effect was again specific to MHC class II, as CO 
failed to inhibit the expression of CD40, CD80, or CD86 (Suppl. Fig.6b). 
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To test whether HO-1 and/or CO would affect other APC populations 
involved in the pathogenesis of EAE26,27, MHC class II expression was analyzed in 
microglia (CD45lowCD11b+) and CNS-infiltrating Mø (CD45highCD11b+) of C57BL/6 
mice with established EAE. Induction of HO-1 starting 2 days after disease onset 
(approximately 40% EAE incidence) reduced MHC class II expression by 44% ± 
13% in microglia (P < 0.05; Fig.6c) and by 47% ± 24% in CNS-infiltrating Mø (P < 
0.05; Fig.6d) compared with controls. 
MHC class II-expressing cells in the CNS of mice with established EAE was 
confined to the perivascular area and associated primarily with CNS-infiltrating 
leukocytes, i.e., Mø (Fig.6e,f). Low level MHC class II expression was also detected 
in the parenchyma, presumably associated with microglia (data not shown). 
Induction of HO-1 by CoPPIX reduced MHC class II expression in both perivascular 
 
Figure 6. Induction of HO-1 and exposure to CO inhibit MHC class II expression in APC. 
(a) C57BL/6 mice were treated daily with PBS, CoPPIX, or ZnPPIX (n = 4-6) starting 2 days 
prior to footpad immunization. Draining lymph node cells were isolated, and surface MHC class 
II expression was analyzed in DC (CD11c+) by flow cytometry 8 days after immunization. 
Representative histograms and quantifications (mean intensity of fluorescence; MIF) are shown 
as mean ± SD. (b) C57BL/6 mice were exposed to air (n = 6) or CO (450 ppm; n = 7) starting 2 
days prior to immunization and continuously thereafter. Draining lymph node cells were isolated, 
and surface MHC class II expression was assessed in DC (CD11c+) as in (a). Representative 
histograms and quantification are shown as mean ± SD. (c and d) C57BL/6 mice, randomized 2 
days after EAE onset, were treated daily with PBS, CoPPIX, or ZnPPIX (n = 9 per group). MHC 
class II expression in (c) microglia (CD45lowCD11b+) and (d) CNS-infiltrating Mø 
(CD45highCD11b+) was analyzed by flow cytometry 20 days after immunization, when controls, 
i.e., ZnPPIX and PBS, reached maximal disease severity. Representative histograms and 
quantifications are shown as mean ± SD. (e and f) EAE induction and treatments were 
performed as in (c and d). MHC class II expression was detected by immunocytochemistry and 
counterstained. Original magnification, ×10 (e); ×40 (f). White arrows indicate MHC class II 
expression. *P < 0.05; **P < 0.01. 
c a 
b d 
e f 
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leukocytes and microglia (Fig.6e,f), confirming similar observations made by flow 
cytometry. 
To address further the mechanism by which HO-1 suppressed MHC class II 
expression in CNS APC, we tested whether induction of HO-1 in microglial BV2 
cells would inhibit MHC class II expression. When stimulated in vitro with IFN-, 
microglial BV2 cells up-regulated the expression of MHC class II (Fig.7a,b). 
Induction of HO-1 by CoPPIX inhibited by 27% ± 7% MHC class II expression 
compared with controls (P < 0.05; Fig.7a). Exposure to CO mimicked this effect, 
inhibiting by 20% ± 7% MHC class II expression compared with air‑treated controls 
(P < 0.05; Fig.7b). Induction of HO-1 or exposure to CO had no effect on CD40, 
CD80, or CD86 expression in BV2 cells (data not shown). Induction of HO-1 
inhibited IFN--driven phosphorylation of STAT-1 without affecting STAT-1 
expression (Fig.7c). Induction of MHC class II transcription activator (CIITA) mRNA 
expression by IFN- was inhibited by 30% ± 11% compared with controls (P < 0.05; 
Fig.7d). Given the central role of STAT‑1 phosphorylation and CIITA expression in 
the transcriptional regulation MHC class II expression in APC28 (reviewed in29), the 
inhibitory effect of HO-1 over MHC class II expression in these cells might be 
explained by its ability to suppress STAT-1 phosphorylation and CIITA expression.  
 
 
 
Figure 7. HO-1 inhibits STAT-1 phosphorylation and CIITA expression in CNS APC. (a) 
and b) Expression of MHC class II in microglial BV2 cells was monitored by flow cytometry. 
When indicated (+), BV2 cells were exposed to CoPPIX (50 M) or CO (250 ppm) 6 or 16 
hours, respectively, before IFN- stimulation (50 U/ml for 24 hours). MHC class II expression is 
shown as fold induction versus untreated cells ± SD (n = 3 - 7). (c) Phosphorylated STAT-1, 
total STAT-1, HO-1, and -tubulin were detected by Western blot in BV2 cells treated as in (a). 
(d) Expression of CIITA mRNA was quantified by real-time PCR in BV2 cells treated as in (a). 
Results are shown as mean fold induction versus untreated cells ± SD (n = 3). *P < 0.05. 
a b c d 
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4. Discussion 
There are several genes that can limit the deleterious effects of inflammation and 
thus counter the pathogenesis of inflammatory diseases5,7. We refer to those genes 
as protective7 and hypothesized that the protective gene HO‑1 may control the 
pathologic outcome of EAE, a well‑established model of MS. We provide evidence 
that endogenous HO‑1 suppressed both the severity and the mortality associated 
with the development of this neuroinflammatory disease (Fig.1a and Table 1). 
Upregulation of HO-1 by CoPPIX acted therapeutically to reverse paralysis 
(Fig.1b,c and Table 2). That the therapeutic effect of CoPPIX is exerted via HO-1 is 
demonstrated by the observation that (a) CoPPIX induces the expression of HO-1 
in the CNS of mice with EAE (Fig.1d) and (b) the protective effect of CoPPIX is 
abrogated in Hmox1-/- mice (Fig.1e). 
CO contributes to the protective effects of HO‑1, as exposure of Hmox1+/+ 
mice to CO mimicked the protective effects of HO‑1 (Fig.1f, Fig.4c,d, Fig.6b, and 
Fig.7b). One would expect, however, that other end products of heme degradation, 
e.g., biliverdin, may act in a similar manner30. However, biliverdin does not 
suppress myelin-reactive TH cell proliferation, nor does it suppress EAE progression 
(Suppl. Fig.7). One possible explanation may be that the protective effect of HO-1 is 
exerted within the CNS, which biliverdin cannot enter because of its exclusion by 
the blood-brain barrier.  
Our data suggest that the mechanism underlying the protective effect of HO-
1 is associated with a profound inhibition of leukocyte accumulation (Fig.2g and 
Fig.3a) and reactivation (Fig.3b,c) within the CNS. This is suggested by the 
observation that HO-1 induction by CoPPIX administration after EAE onset reduced 
the number of inflammatory foci (Fig.2g) as well as the total number of CNS TH 
cells, CD8+ T cells, and Mø (Fig.3a) and in addition suppressed the proliferation of 
the remaining TH and CD8+ T cells (Fig.3b,c) infiltrating the CNS. 
The anti-proliferative effect of HO-1 was shown in vitro to be strictly 
dependent on DC (Fig.4g) that express high levels of HO-1 (Fig.5b,c). That a 
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similar effect may occur in vivo to arrest EAE progression is suggested by the 
observation that DC expressing high levels of HO-1 were detected in the CNS of 
CoPPIX-treated mice in which EAE progression was arrested (Fig.5a). 
Induction of HO-1 leads to specific inhibition of MHC class II in APC, 
including DC (Fig.6a,b), microglia (Fig.6c), and CNS-infiltrating Mø (Fig.6d). 
Induction of HO-1 expression in microglia suppressed STAT-1 phosphorylation as 
well as CIITA expression, two critical events for MHC class II expression in APC28 
(reviewed in29) as well as in the reactivation of myelin-reactive TH cells in the CNS31. 
This effect is likely to contribute to the overall protective effect of HO-1 induction, as 
MHC class II expression in microglia is thought to be involved in EAE pathogenesis 
and progression (reviewed in32,33). 
That inhibition of MHC class II accounts for the protective effect of HO-1 is 
supported by the association between certain human MHC class II locus alleles and 
MS susceptibility (reviewed in34). Moreover, peptides that interfere directly with 
MHC class II-mediated antigen presentation to myelin-reactive TH cells are very 
efficient in arresting EAE progression35 (reviewed in2), suggesting again that 
inhibition of MHC class II expression by APC is probably sufficient to explain the 
protective effects of HO-1 observed herein. Another possibility would be that HO-1 
promotes the accumulation of regulatory T cells and/or their activity within the CNS. 
This would be consistent with widespread evidence that regulatory T cells can 
control the pathogenesis of EAE6,36-38 as well as with the hypothesis that HO-1 
expression may control regulatory T cell function39. However, we observed that 
despite its ability to suppress ongoing EAE, induction of HO-1 failed to modulate the 
number of CNS‑infiltrating regulatory T cells (Fig.3b). Furthermore, we also found 
that the number and function of regulatory T cells was unaffected in naïve Hmox1-/-
mice compared with Hmox1+/+ controls, suggesting that HO-1 does not influence 
regulatory T cell development and/or function40. Taken together, these data suggest 
that the protective effect of HO-1 in EAE does not act via modulation of regulatory T 
cells. 
That HO-1 exerts its protective effects via APC, including CNS microglia 
(Fig.6c,d), is relevant for its mechanism of action if one considers that 
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immunomodulation within the CNS is probably required to arrest MS progression. 
This may explain the relative lack of efficiency in treating MS by controlling 
exclusively peripheral antigen presentation, which is probably not as relevant, 
whereas prevention of effector TH cell reactivation by CNS APC almost certainly 
is26,31. Our finding that induction of HO-1 after EAE onset suppressed TH cell 
reactivation and effector function within the CNS (Fig.4b) may explain why this 
approach was effective in suppressing disease progression (Fig.1b,c and Table 2).  
Our present data suggest that upon induction of HO-1 in APC, the effector 
function of myelin-reactive TH cells in the CNS is modulated in a manner that 
suppresses their pathogenicity. This is supported by the suppression of 
neuroinflammatory, i.e., IFN‑, but not neuroprotective, i.e., IL‑1041 and TNF-42, 
cytokine expression by CNS‑infiltrating TH cells (Fig.3b). Presumably, inhibition of 
high-level IFN- expression by CNS‑infiltrating TH cells should promote 
oligodendrogenesis and thus aid to EAE remission43. It should be noted, however, 
that while inhibition of IFN- expression in CNS‑infiltrating TH cells is likely to 
contribute to EAE regression44, this remains to be formally established as EAE is 
exacerbated in IFN‑-deficient mice45. 
One possibility not excluded by the present study is that HO-1 may prevent 
EAE progression not only by immunomodulation but also by its cytoprotective 
properties46,47 in the CNS, i.e., oligodendrocytes or neurons48. Such an effect would 
be consistent with the observed arrest of EAE progression49 as well as with our 
previous observation that cytoprotection afforded by HO-1 can prevent the rejection 
of transplanted organs50. 
Even with the caution necessary for extrapolating from EAE to MS, there are 
several independent lines of evidence suggesting that HO-1 expression affects the 
clinical outcome of MS. First, HO-1 is expressed in the CNS of MS patients9. 
Second, HO‑1 prevents the deleterious effects of inflammation in humans51. Third, 
a (GT)n microsatellite polymorphism in the human HMOX1 promoter controls HO‑1 
inducibility and dictates the incidence of several inflammatory diseases (reviewed 
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in52). Additional studies are needed to determine whether HO‑1 functions to prevent 
MS progression or promote its remission. 
In conclusion, we found that HO-1 suppresses the pathologic outcome of 
autoimmune neuroinflammation associated with the development of EAE. This 
effect is mediated at least in part by CO, which acts on APC to inhibit the 
expression of MHC class II and presumably the reactivation of pathogenic TH cells 
within the CNS. We suggest that modulation of HO-1 expression or administration 
of CO may be a useful therapeutic strategy to treat MS patients. 
 
5. Methods 
Animals. C57BL/6 and SJL/J mice were maintained under specific pathogen-free 
conditions approved by the Animal User and Institutional Ethical Comities of the 
Instituto Gulbenkian de Ciência and the Beckman Center for Molecular Medicine. 
Mice were used between 6 and 8 weeks of age. Hmox1+/- mice were originally 
generated by S.-F. Yet (Brigham and Women’s Hospital, Boston, Massachusetts, 
USA53). Littermate Hmox1+/- and Hmox1+/+ mice were used as controls. 
Cells and reagents. Microglial BV2 cells, obtained from E. Blasi (University of 
Modena and Reggio Emilia, Modena, Italy), were cultured essentially as described 
previously54. Recombinant mouse IFN- (PeproTech) was used to induce MHC 
class II expression in BV2 cells. MOG35-55 was synthesized at the Biopolymers 
Laboratory of Harvard Medical School. PLP139-151 was synthesized at the PAN 
Facility of the Beckman Center for Molecular and Cellular Medicine. CoPPIX, 
ZnPPIX (Frontier Scientific Inc.), and biliverdin hydrochloride (MP Biomedicals) 
were dissolved in 0.2 N NaOH, neutralized with 0.2 N HCl, adjusted to 1 mg/ml 
(CoPPIX and ZnPPIX) and 10 mM (biliverdin) with distilled water, and sterilized by 
filtration. 
Cytokine assays. Cell culture supernatants were used to measure TNF-, IFN-, 
and IL-12/23(p40) concentrations by ELISA according to the manufacturer’s 
indications (OptEIATM; BD Biosciences - Pharmingen). 
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CNS leukocyte infiltration. Leukocytes were isolated from the CNS as described 
previously55. The total number of CD45high, CD11b+, CD4+, and CD8+ T cells in the 
CNS was assessed by flow cytometry, using a fixed number of latex beads 
(Beckman Coulter) coacquired with a pre-established volume of the cellular 
suspensions. 
DC. Bone marrow from naïve mice was flushed, and single-cell suspensions were 
cultured (37ºC; 5% CO2, 95% humidity) in RPMI 1640 (Invitrogen), 2 mM L-
glutamine (Sigma-Aldrich), 100 U/ml penicillin, 100 g/ml streptomycin (all from 
Invitrogen), and 1% GM-CSF conditioned medium. Medium was replaced every 48 
hours until day 6 of culture, after which CD11c cells were purified as described 
above or remained untreated. 
EAE induction and protoporphyrin treatment. Briefly, C57BL/6 and SJL/J mice 
were immunized subcutaneously with MOG35-55 or PLP139-151 (200 g), respectively, 
emulsified in CFA (BD Diagnostics) supplemented with Mycobacterium tuberculosis 
(400 g; BD Diagnostics). C57BL/6 mice received Pertussis toxin (200 ng i.v.; 
Sigma-Aldrich) at the time of immunization and 2 days thereafter. Clinical signs of 
EAE were evaluated daily and scored as follows: 0, normal; 1, limp tail; 2, partial 
paralysis of the hind limbs; 3, complete paralysis of the hind limbs; 4, hind-limb 
paralysis and forelimb weakness; 5, moribund or deceased. Protoporphyrins were 
administered daily (200 l i.p., 5 mg/kg). Biliverdin was administered at 5 M/kg 
every 12 hours. 
Flow cytometry and antibodies. Surface markers and intracellular cytokines were 
detected essentially as described previously55. Purified anti-mouse CD4 (RM4-5), 
CD8 (YTS169.4), CD11b (M1/70), CD11c (HL3), CD40 (3/23), CD45 (30-F11), 
CD80 (16-10A1), CD86 (GL1), B220 (RA3-6B2), I-Ab (AF6-120.1), IL-2 (JES6-
5H4), IL-10 (JES5-16E3), TNF-(MP6-XT22), and IFN- (XMG1.2; all BD 
Biosciences - Pharmingen) were used. Anti-FcIII/II receptor mAbs were prepared 
in house from hybridoma (2.4G2) culture supernatants. Antibodies were directly 
conjugated to PE, allophycocyanin, or FITC. 
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In vivo BrdU incorporation. Mice received BrdU (50 g/g body weight i.p. 
administered 4 times every 2 hours; BD Biosciences - Pharmingen). CNS leukocyte 
infiltrates were isolated as described above, and nuclear BrdU was detected using 
the FITC-labeled anti-BrdU Flow Kit according to the manufacturer’s indications (BD 
Biosciences - Pharmingen). 
Leukocyte isolation and purification. Draining lymph nodes were homogenized 
into single-cell suspension. CD4+ and CD11c+ cells were purified using single-step 
anti-CD4 (L3T4) and anti-CD11c (N418) MicroBeads, respectively (Miltenyi Biotec). 
CD8+ and CD19+ cells were purified by two-step labeling consisting of FITC-labeled 
anti-CD8 (SK1) and anti-CD19 (4G7) mAb (BD) followed by anti-FITC-conjugated 
MicroBeads (Miltenyi Biotec). Cells were separated using a MidiMACS magnetic 
isolation system (Miltenyi Biotec), and purity was assessed by flow cytometry. 
MOG35-55-reactive TH cell proliferation. Draining lymph node cells were isolated 
from PBS-, CoPPIX-, or ZnPPIX-treated animals 8 days after footpad immunization 
(MOG35-55 plus CFA). Cells were plated in 96-well microtiter plates (5×105 cells per 
well) in RPMI 1640 (Invitrogen), 2 mM L-glutamine (Sigma-Aldrich), 100 U/ml 
penicillin, 100 g/ml streptomycin, 10% FCS, 50 M 2-mercaptoethanol (2-ME), 10 
mM HEPES, and 1 mM sodium pyruvate (all from Invitrogen) and exposed to 
MOG35-55 (10 g/ml) or concanavalin A (2 g/ml; Sigma-Aldrich) for 72 hours at 
37ºC (5% CO2, 95% humidity). Cell proliferation was assessed by [3H]-thymidine (1 
Ci/well; GE HealthCare) incorporation during the last 6 hours of culture evaluated 
in a scintillation counter (Tomtec; Pharmacia). 
Immunocytochemistry. Purified bone marrow-derived DC were plated in glass 
coverslips (Paul Marienfeld GmbH & Co.) and fixed in acetone (10 minutes at -
20ºC). Rabbit anti-HO-1 polyclonal antibody (SPA895; Stressgene 
Biotechnologies), PE-labeled anti-CD11c mAb (HL3; BD Biosciences - Pharmingen) 
and FITC‑labeled goat anti‑rabbit polyclonal antibody (Sigma-Aldrich) were used. 
Slides were mounted in Vectashield (Vector Laboratories), and fluorescence was 
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detected by confocal microscopy (Leica Spectral TCS-SP2; Leica Microsystems). 
Images were acquired using Leica confocal software (version 2.61). 
Histology. Mice were perfused with PBS followed by 10% formalin. Brain and 
spinal cord sections were embedded in paraffin and stained with hematoxylin and 
eosin or with Luxol fast blue stains, and inflammatory foci were enumerated in 
meninges and parenchyma as described previously56. 
Immunohistology. Mice were perfused with PBS, and their spinal cords were 
harvested, embedded in Tissue-Tek OCT (Sakura), and snap-frozen in liquid 
nitrogen. Spinal cord sections (10 m) were fixed in acetone, and antigen detection 
was performed essentially as described previously. Rabbit anti-HO-1 polyclonal 
antibody (SPA895; Stressgene Biotechnologies), biotin-labeled anti-MHC class II 
mAb (AF6-120.1; BD Biosciences - Pharmingen), PE-labeled anti-CD11c mAb 
(HL3; BD Biosciences - Pharmingen), and FITC‑labeled goat anti‑rabbit (Sigma-
Aldrich) polyclonal antibody were used. HRP-conjugated streptavidin and 
Vectastain Elite ABC kit were used according to the manufacturer’s instructions 
(Vector Laboratories). HRP stainings were revealed using 3,3-diamenobenzidine 
(Sigma-Aldrich), and tissues were counterstained with Harris hematoxylin (Sigma-
Aldrich). Images were acquired using a Leica (DM.LB2) microscope (Leica 
Microsystems) equipped with an Evolution MP5.0 color camera (MediaCybernetics) 
and free‑GIMP 2.2.10 software (http://portableapps.com/apps/graphics_pictures 
/gimp_portable). Fluorescence staining was detected and processed as described 
above. 
CO exposure. Mice were placed in a plexiglass gastight 60-l capacity chamber and 
exposed continuously to CO as described previously47. Cells (37ºC, 95% humidity) 
were exposed to CO (250 ppm in air, 5% CO2) in a plexiglass gastight 10-l chamber 
(2 l/min). CO concentration was monitored using a CO analyzer (Interscan 
Corporation). Air controls were maintained in a similar chamber without CO. 
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Western blots and antibodies. Western blots were performed as described 
previously46,47 using anti-HO-1 (SPA896; Stressgene Biotechnologies), anti-STAT-1 
(Upstate USA Inc.), and anti-phospho-STAT-1 (Upstate USA Inc.) rabbit polyclonal 
antibodies as well as anti--tubulin (Sigma-Aldrich) and anti--actin (Sigma-Aldrich) 
mouse mAbs. HRP-labeled goat anti-rabbit (31460; Pierce Biotechnology) or goat 
anti‑mouse (31439; Pierce Biotechnology) polyclonal antibodies were used to 
detect the primary antibodies. HRP activity was revealed using ECL. Images were 
acquired using a Kodak 440CF image station. 
Real-time PCR. Total RNA was extracted using RNeasy Protect MiniKit (Qiagen) 
according to the manufacturer’s instructions and reverse transcribed as described 
previously22. HO-1 (5′-TCTCAGGGGGTCAGGTC-3′ and 5′-GGAGCGGTGTCTGGGATG-
3′), CIITA (5′-CTCTACCACCTCTATGACC-3′ and 5′-GCTTCTGTCCTGCTTCTAC-3′), and 
hypoxanthine-guanine phosphoribosyl transferase (HPRT; 5′-GTTGGATACAGGCCA 
GACTTTGTTG-3′ and 5′-GATTCAACCTTGCGCTCATCTTAGGC-3′) PCR products were 
detected using LightCycler realtime quantitative PCR (Roche Diagnostics) as 
described previously22. 
Statistics. Significance of clinical scores was examined by the Mann-Whitney test. 
Significance of Hmox1-/- versus Hmox1+/+ mouse survival was examined by the log-
rank test. Fisher’s exact test was used for analyses of disease remission. All other 
statistical analyses were performed using ANOVA with Bonferroni’s correction for 
multiple comparisons. P < 0.05 was considered significant in all tests. 
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8. Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 1. HO-1 prevents CNS demyelination. Representative Luxol fast blue staining of spinal 
cord sections are shown for naïve C57BL/6 mice (a) versus C57BL/6 Hmox-1+/+ (b) and Hmox-1-/- (c) mice, 60 
days after EAE induction. Magnifications in (a-c) are 40x. Dashed rectangles in (a-c) are magnified (400x) in (d-f), 
respectively. Arrows indicate demyelination. 
 
Supplementary Figure 2. CNS leukocyte infiltrates during EAE. Leukocyte infiltrates were analyzed by flow 
cytometry in (a) naïve C57BL/6 mice (n=2) or (b) 20 days after immunization. Representative plots are shown 
with relative percentages of CD45+, CD11b+, CD4+ and CD8+ cells ± standard deviation. 
a b c 
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Supplementary Figure 3. HO-1 modulates TH cell effector function within the CNS. EAE was induced in 
C57BL/6 mice, randomized two days after disease onset and treated daily with PBS, CoPPIX or ZnPPIX. CNS 
leukocyte infiltrates were analyzed by flow cytometry, 20 days post-immunization. When indicated, mice 
received BrdU. Representative plots are shown with mean percentages ± standard deviation (n=3-10 animals 
per staining). (a) Staining for intracellular BrdU versus surface CD4 and intracellular IL-2 versus surface CD4. 
(b) Staining for intracellular TNF- versus intracellular IFN- is shown in CD4+ TH cells. (c) Staining for 
intracellular Foxp3 versus surface CD4. (d) Staining for intracellular BrdU versus surface CD8. 
d 
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Supplementary Figure 4. Induction of HO-1 does not modulate the expression of activation markers in 
TH cells within the CNS. EAE was induced in C57BL/6 mice, randomized two days after disease onset and 
treated daily with PBS, CoPPIX or ZnPPIX. Leukocyte infiltrates in the CNS were analyzed by flow cytometry, 
20 days post-immunization. Each value represents an individual animal. Relative percentage of CD69+/CD4+ TH 
cells, CD25+/CD4+ TH cells and CD62L+/CD4+ TH cells are shown. For CD44 the mean florescence intensity of 
CD44 is shown in CD4+ TH cells. Bars indicate mean value of all mice analyzed under each treatment. 
 
Supplementary Figure 5. Induction of HO-1 does not suppress naïve myelin-reactive TH cell priming. 
C57BL/6 mice were immunized in the footpad with MOG35-55 plus CFA and treated daily with PBS (n=3), 
CoPPIX (n=3) or ZnPPIX (n=3). Lymph node cells were isolated 8 days post-immunization. (a) TH cell 
proliferation was measured in vitro by [3H]-Thymidine incorporation, 72 hours after addition of concanavalin A (2 
μg/ml). Results shown are the mean ± standard deviation of one representative assay out of five. (b) Increasing 
numbers of TH cells (>98% CD4+ T cells) from PBS- (white) (n=3), CoPPIX- (black) (n=3) or ZnPPIX- (grey) 
(n=3) treated mice were co-cultured with TH cell-depleted lymph node cells (<98% CD4+ T cells) from 
immunized but otherwise untreated mice. MOG35-55-specific TH cell proliferation was measured as in (a). Results 
shown are the mean ± standard deviation. 
a b 
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Supplementary Figure 6. Induction of HO-1 does not modulate the expression of costimulatory 
molecules in APC. C57BL/6 mice were immunized in the footpad with MOG35-55 plus CFA and (a) treated daily 
with PBS (n=4), CoPPIX (n=6), ZnPPIX (n=6),(b) exposed to air (n=6) or CO (n=7). Draining lymph node cells 
were isolated 8 days after immunization and CD40, CD80 or CD86 surface expression in DC (CD11c+) was 
analyzed by flow cytometry. Quantifications (mean intensity of fluorescence; MIF) are shown as mean ± 
standard deviation. 
 
Supplementary Figure 7. Biliverdin does not suppress EAE progression nor does it suppress the 
proliferation of myelin-reactive TH cells. (a) EAE was induced, mice were randomized two days after disease 
onset and treated daily with biliverdin (black)(n=15) or vehicle (white)(n=15) for the period indicated by the 
shaded area. Daily clinical scores are shown as mean ± standard error of mean. (b) C57BL/6 mice were 
immunized in the footpad with MOG35-55 plus CFA and treated daily with biliverdin (n=3) or vehicle (n=3), starting 
two days prior to immunization. Draining lymph node cells were isolated 8 days post-immunization and myelin-
reactive TH cell proliferation was assessed in vitro by [3H]-thymidine incorporation, 72 hours after addition of 
MOG35-55 (10 μg/ml). Results shown are the mean ± standard deviation from one assay with five independently 
treated animals per group. 
a 
b 
a b 
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Chapter 4 
 
General Discussion 
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Immunity aims at protecting organisms from infection, clearing pathogens and thus, 
allowing a return to homeostasis1. Inflammation is an essential component of the 
immune response, triggered by the recognition of molecular patterns expressed by 
microbes or by molecules released upon tissue injury, by cellular or soluble PRR2. 
While inflammation aims at clearing the source of infection or noxious stimuli, it 
imposes a certain level of tissue damage. Therefore, mechanisms assuring tissue 
protection and/or repair are required for return to homeostasis. Tissue damage 
caused by oxidative stress, in particular, can be very deleterious as it may alter the 
function of macromolecules, lipids and proteins, causing mutations and epigenetic 
modifications, leading eventually to DNA damage157. This highlights the need for 
tight regulation of inflammatory and immune responses, as well as the type, 
magnitude and duration of the response mounted. 
The first line of regulation acts on innate immune cells at the level of their 
activation, determining whether adaptive immunity will ensue. This is particularly 
relevant for DC that bridge innate and adaptive immunity and as such, play a 
central role in mounting protective as well as pathologic TH cell responses, such as 
the one involved in the pathogenesis of autoimmune neuroinflammation65. 
The pathogenesis of autoimmune neuroinflammation is initiated by a break 
of peripheral tolerance, in which immunogenic DC activate naïve myelin-reactive TH 
cells252,253, followed by reactivation of primed TH cells by perivascular DC in the 
CNS254 and CNS invasion65. This leads to activation of resident CNS cells, 
recruitment of macrophages, TH and TC cells, among others, and establishes 
neuroinflammation65. CNS-infiltrating-macrophages and microglia become potent 
APC, boosting the TH cell response and sustaining a pro-inflammatory env\ment in 
the CNS255. Damage caused to oligodendrocytes and neurons underlies the 
neurological symptoms of EAE, and presumably those of MS. In this context, 
mechanisms regulating DC immunogenicity, should contribute to restrain myelin-
reactive TH cell activation and as such, prevent the pathogenesis of autoimmune 
neuroinflammation. As demonstrated in chapter 2 the transcription factor Nrf2 
seems to act in such a manner. 
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As previously shown220,221, Nrf2-deficient (Nrf2-/-) mice have an exacerbated 
EAE severity, when compared to Nrf2+/+ mice in two different EAE models: active 
immunization of C57BL/6 mice with MOG35-55 in CFA (Chapter 2 Fig.1b-d) or PTx-
induced EAE in 2D2 TCR transgenic C57BL/6 mice (Chapter 2 Fig.1e-f). This 
suggests that the regulatory effect of Nrf2 is not specific to a particular experimental 
model of EAE, but rather that it operates via a general mechanism of action with 
impact in autoimmune neuroinflammation. Pharmacologic activators of Nrf2, such 
as Dimethylfumarate, reduce the pathological outcome of EAE221,222 and MS223,224, 
suggesting that further understanding of the mechanism behind the protection 
afforded by Nrf2 in MS could be of high therapeutic value. 
This protective mechanism is likely to rely on the expression of Hmox1 
(Chapter 3)175, Mt1 and Mt2256 genes regulated by Nrf2 that inhibit the pathogenesis 
of EAE. In keeping with this notion, these genes are up-regulated in active MS 
lesions as well as in the CNS of mice developing EAE257 (Chapter 2 Fig.1a and 
Suppl. Table1). Interestingly, at steady state the level of expression of different 
Nrf2-dependent genes in the CNS varies considerably, i.e. Fth is expressed at very 
high levels when compared to any other gene analyzed (Chapter 2 Suppl. Table1). 
The reason for this is not understood, but it is known that oligodendrocytes 
accumulate Fe in the cytoplasm258. As labile Fe can be deleterious, acting as a 
potent pro-oxidant via the Fenton chemistry209, it is likely to be stored safely under a 
less reactive form in the cytoplasm, when bound to FtH259. In addition, 
oligodendrocytes can uptake Fe via soluble FtH260, that binds extracellular Fe and 
transports it via the T cell immunoglobulin and mucin domain-containing protein-2 
receptor into the cytoplasm261. The dependency on FtH for Fe uptake and storage 
in oligodendrocytes could explain the high levels of expression of this protein 
observed in the CNS of naïve mice (Chapter 2 Suppl. Table1). 
Nrf2 is activated by changes in the cellular redox status and restores 
homeostasis by up-regulating a set of stress-responsive genes169. Activation of Nrf2 
has cytoprotective properties via the expression of genes that help cells cope with 
the damaging effects of oxidative stress162. The environment generated in a tissue 
undergoing inflammation, such as the CNS during EAE or MS, contains high levels 
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of ROS and RNS that can cause damage to oligodendrocytes and neurons157,163. 
Hence, activation of the Nrf2 pathway in the CNS should limit the deleterious effects 
of oxidative stress, presumably ameliorating EAE, by providing tissue-damage 
control. Surprisingly however, the mechanism underlying the salutary effect of Nrf2 
against autoimmune neuroinflammation220,221 (Chapter 2 Fig.1b-g) does not involve 
cellular adaptation to oxidative stress in resident cells of the CNS (Chapter 2 
Fig.2d-f). 
Another possible mechanism for the protective effect of Nrf2 against 
autoimmune neuroinflammation might rely on its ability to regulate the expression of 
pro-inflammatory mediators by innate immune cells170. This has been previously 
suggested for several experimental models of inflammatory diseases, including 
EAE220. Higher EAE severity observed in Nrf2-/- vs. Nrf2+/+ mice in the Biozzi genetic 
background, is associated with increased expression of mRNA encoding cytokines 
(Il1b, Tnf, Il12 and Ifng) and chemokines (Cxcl9 and Cxcl13) in the CNS at the 
onset of EAE220. However, in our study, cytokine and chemokine expression in the 
CNS was similar at the onset of EAE in Nrf2-/- vs. Nrf2+/+ C57BL/6 mice (Chapter 2 
Suppl. Fig.3). This apparent discrepancy may reflect differences in EAE 
progression in the two experimental models. While Nrf2 deletion in the Biozzi 
genetic background is associated with increased EAE severity at the onset of 
disease, in the C57BL/6 genetic background this only becomes apparent at later 
stages of disease progression. Thus, it is conceivable that cytokine and chemokine 
expression in the CNS would be observed at later stages of disease progression in 
C57BL/6 mice lacking Nrf2. However, due to the high rate of mortality of Nrf2-/- vs. 
Nrf2+/+ C57BL/6 mice (Chapter 2 Fig.1d) this hypothesis is difficult to test 
experimentally. 
Our data suggests that Nrf2 controls IL-12 production by DC and, therefore, 
restrains the priming of myelin-reactive effector TH1 cells, involved in the 
pathogenesis of autoimmune neuroinflammation. This is suggested by the following 
observations. First, when transferred into syngeneic recipients, leukocytes from 
MOG35-55-immunized Nrf2-/- mice elicit a more severe form of EAE, as compared to 
Nrf2+/+ leukocytes (Chapter 2 Fig.2a-c). The reverse is not true, in that adoptive 
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transfer of leukocytes from MOG35-55-immunized mice elicit similar EAE severity in 
wild type Nrf2+/+ vs. Nrf2-/- mice (Chapter 2 Fig.2d-f). The adoptively transferred 
leukocytes are not purified activated TH cells, and therefore, we cannot exclude that 
Nrf2+/+ or Nrf2-/- APC are also transferred, but it is unlikely that these cells would 
play a role in TH cell re-stimulation in the CNS of recipient mice as their turnover in 
vivo is approximately 3 days262. Nrf2 expression in DC does not influence TH cell 
proliferation (Chapter 2 Fig.3a,b,d), but does impact on effector TH cytokine 
production (Chapter 2 Fig.3c,e). As the instruction for TH cell lineage differentiation 
is provided during DC/TH cell priming, and not upon TH cell reactivation28, this 
supports further the notion that TH cell priming is the process targeted by Nrf2. 
Depending on the experimental TH cell priming system analyzed, i.e. in vivo 
or in vitro, Nrf2 expression can regulate the differentiation of TH1 (IFN-), TH17 (IL-
17A) and TH2 (IL-13) (Chapter 2 Fig.3c) or just of TH1 cells (Chapter 2 Fig.6a), 
respectively. The apparent discrepancy between these two experimental systems 
probably reflects the relative contributions of different cell populations for TH cell 
priming in vivo or in vitro. While TH cell priming is controlled by DC in vitro, other 
cells can influence TH cell priming in vivo. 
DC-derived IL-12 is necessary and sufficient to drive naïve TH cell 
differentiation towards the TH1 lineage44, while the involvement of DC-derived 
cytokines for TH17 or TH2 cell differentiation is still a matter of debate20. TH17 
differentiation requires IL-6 and TGF-37, while TH2 priming is dependent on IL-437. 
TGF-263 is produced in an autocrin manner by TH cells, while IL-6 can be produced 
by innate immune cells, other than DC264. The cellular source of IL-4, involved in 
TH2 differentiation, is still controversial265-267. Thus, it is possible that other immune 
cell populations producing high levels of IL-6 and IL-4 are responsible for the 
increased production of IL-17A and IL-13 by Nrf2-/- TH cells in vivo (Chapter 2 
Fig.3c), while IL-12 production by DC accounts for the increase in IFN- both in vitro 
and in vivo (Chapter 2 Fig.3c and 6a). 
Regulation of TH1 differentiation by Nrf2 is determined by the expression of 
this transcription factor in DC (Chapter 2 Fig.6a), suppressing IL-12 (Chapter 2 
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Fig.5d), whilst promoting IL-6 and TNF production (Chapter 2 Fig.5e,f). This effect 
should inhibit the differentiation of naïve myelin-reactive TH cells towards a TH1 
phenotype, and possibly promote TH17 differentiation. This appears to be the case 
for TH1 cells, as demonstrated by the observation that blocking IL-12/23p40 in vitro 
is sufficient to revert the TH1 bias observed when Nrf2 expression is absent in DC 
(Chapter 2 Fig.7a). However, the observation that Nrf2 does not regulate the 
number of IFN--producing TH1- or TH17-infiltrating cells in the CNS of mice 
undergoing EAE is difficult to conciliate with this notion (Chapter 2 Suppl. Fig.1 and 
2). Several factors can account for this observation. First, re-stimulation of CNS-
infiltrating leukocytes in vitro with PMA and ionomycin, as performed in our study, 
can promote cytokine production in a manner that does not reflect the profile of 
cytokine production by effector TH cell subsets in vivo134. This can be bypassed by 
antigen-specific re-stimulation of CNS-infiltrating leukocytes in vitro or using anti-
CD3 mAb, which reflect more faithfully the cytokine production of effector CNS-
infiltrating TH cells in vivo134. 
It is possible as well that this apparent discrepancy may reflect a kinetic 
issue, as CNS-infiltrating TH17 cells stop secreting IL-17 and convert to IFN--
producing TH cells, becoming the major source of IFN-during the late phase of 
EAE134. Therefore, elevated levels of IFN-, observed in in vivo and in vitro priming 
systems (Chapter 2 Fig.3c and 6a), may be masked during EAE by the conversion 
of TH17 cells to IFN--producing cells in the CNS. This should not negate that IFN--
producing TH1 cells play a crucial role in the pathogenesis of EAE. 
That the ability of Nrf2 to control the production of IL-12, and subsequently 
the IFN- production by myelin-reactive TH1 cells contributes to the protective effect 
of Nrf2 is revealed by the observation that inhibition of IL-12/23p40 (Chapter 2 
Fig.7c-e) or IFN- (Chapter 2 Fig.6c-e) signaling reduces EAE severity in Nrf2-
deficient mice. IFN- is a pleiotropic cytokine that exerts immunomodulatory effects 
in a variety of immune cells268. These comprise: i) up-regulation of MHC class I and 
II expression in APC and endothelial cells; ii) up-regulation of adhesion molecule 
expression and chemokine secretion by endothelial cells; iii) priming of innate 
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immune cells for the production of pro-inflammatory cytokines, such as IL-1 and 
TNF and iv) the activation and proliferation of TC cells268,269. However, a number of 
immunosuppressive functions have also been assigned to IFN-, including: i) 
inhibition of cell proliferation; ii) induction of TH programmed cell death, iii) inhibition 
of TH2 and TH17 cell differentiation and iv) conversion of activated TH cells into 
TREG268-270. Possibly, as a consequence of this wide range of effects, the results 
obtained when studying the role of IFN- in EAE have been difficult to interpret and 
conciliate with the evidence that IFN--producing TH1 cells are pathogenic in EAE. 
Despite this controversy, it is clearly established that signaling by TH1-derived IFN- 
is necessary and sufficient to determine the localization of the lesions within 
different anatomical compartments of the CNS92,271. The pathogenic effect of IFN- 
produced by TH1 cells acts selectively in the spinal cord while protective in the 
brain, brainstem and cerebellum, as revealed by adoptive transfer of wild type 
encephalitogenic TH1 cells into Ifngr-/- recipients or Ifng-/- TH1 cells into wild type 
recipients. In both cases, adoptive transfer results in the development of atypical 
EAE, with prominent inflammatory infiltrates in the cerebellum and the brain, but not 
in the spinal cord271. 
We propose a mechanism of action underlying the protective effect of Nrf2 
that is somehow distinct from the one proposed by previous studies. While we 
propose that Nrf2 controls IL-12 expression in DC, thus inhibiting TH1 
differentiation, other studies have suggested that Nrf2 expression in DC promotes 
TH2 responses or reverses TH1-reduced immunity. 
Exposure of Nrf2+/+ and Nrf2-/- DC to urban ambient particulate matter 
(APM), a TH2-inducing stimuli, suggested that Nrf2 promotes a TH2-type immune 
response272. This study used GM-CSF-derived bone marrow or pulmonary DC while 
we used splenic DC in our study. This would suggest that Nrf2 may have different 
effects in specific DC populations, and presumably therefore act in a tissue-specific 
manner. Another difference between this study and ours relates to the inflammatory 
agonist used to render DC immunogenic, APM vs. LPS, CpG and Poly(I:C). This 
would suggest that expression of Nrf2 in DC affects TH cell priming in a stimulus-
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specific manner. Presumably, when Nrf2-/- DC are stimulated with a TH1 inducer, 
such as the TLR4 agonist, LPS, a heightened TH1 response is to be expected and 
so is increased severity of TH1-driven pathology, such as the development of EAE 
in response to MOG35-55 plus CFA immunization. Nevertheless, when Nrf2-/- DC are 
exposed to TH2 inducers, such as APM, the TH2 response should be enhanced and 
TH2-driven pathology worsened, as demonstrated for lung inflammation. In both 
cases however, Nrf2 down-modulates TH cell responses by controlling DC 
immunogenicity in a stimulus-dependent manner. In agreement with this, Nrf2 does 
not appear to act on TH cells to control differentiation of specific TH cell lineages. 
Another study revealed that DC treated with compounds that activate Nrf2 
reverse the decreased TH1 immunity observed in aged mice273. However, this study 
cannot be directly compared to ours since again GM-CSF-derived bone marrow DC 
were used, while splenic DC were used in ours. In addition, our study used 2-month 
old mice, while this study used 20-month old mice. Importantly, aged Nrf2-/- mice 
have been described to develop several immune-mediated diseases, such as 
systemic lupus erythrematosus213,214 and immune-mediated hemolytic anemia215 
and as such, the homeostatic state of DC from mice in this study and ours might be 
different. 
The molecular mechanism via which Nrf2 controls the induction of IL-12 
expression in DC, in response to PRR signaling, is not clear at the moment. One 
possibility is that this mechanism would act in a cell-autonomous manner via the 
transcriptional repression of different Il12 gene family members. This notion is 
supported by the observation that induction of Il12/23p40 (Chapter 2 Fig.5a) and 
Il12p35 (Chapter 2 Fig.5c) mRNA expression in response to the TLR4 agonist, 
LPS, is increased in DC lacking Nrf2, as compared to wild type DC. Also in keeping 
with this notion is the finding that Nrf2 inhibits the activation of several transcription 
factors regulating the expression of different Il12 gene family members173,225, 
including NF-B and IRF-3, as demonstrated for TLR4 signaling in mouse 
embryonic fibroblasts217. A similar mechanism could operate in DC given that 
induction of IL-12/23p40 and IL-12p35 expression in response to LPS is driven by a 
mechanism dependent on NF-B activation as well as the activation of different IRF 
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family members274, including IRF-1, -3 and -7 that regulate IL-12p35 expression, 
and IRF-5 that regulates IL-12/23p40 expression or IRF-8 that regulates both IL-
12p35 and IL-12p40 expression274. The mechanism by which Nrf2 would regulate 
the activation of these transcription factors in DC remains unclear, although it has 
been suggested to rely on the regulation of the cellular redox status217, which can 
modulate NF-B activation in response to LPS275,276. In keeping with this notion, 
expression of anti-oxidant genes is impaired in Nrf2-/- vs. Nrf2+/+ DC (Chapter 2 
Fig.4e-i), probably explaining why there is an accumulation of free radicals and a 
redox imbalance in Nrf2-/- vs. Nrf2+/+ DC277, possibly promoting IL-12 expression 
(Chapter 2 Fig.5a,c) via NF-B activation. Nevertheless, induction of Il6278 and 
Tnf279 mRNA expression in response to LPS is also regulated by NF-B, but the 
expression of these genes is reduced in Nrf2-/- vs. Nrf2+/+ DC, arguing for a specific 
mechanism regulating the transcription of Il12 gene family members. 
The increased levels of IL-12p40 observed in Nrf2-/- DC (Chapter 2 Fig.5b), 
compared to wild type DC, in response to TLR3 (Poly(I:C)) stimulation could be the 
result of a combined effect of Nrf2 on NF-B and IRF-3 activation. This is 
suggested by the experimental evidence that Nrf2 also inhibits IRF-3 activity217. 
An alternative hypothesis is that Nrf2 inhibits Il12p35 and Il12/23p40 
expression via directly binding to ARE in the promoter regions of these genes. Both 
genes have sequences of putative ARE in their promoters, where Nrf2 could bind 
(Ana Cunha, unpublished observations). Nevertheless, Nrf2 is a transcriptional 
activator and there is only one study suggesting that a caspase-3-cleaved form of 
Nrf2 can act as a negative regulator of gene transcription280, pointing to the 
unlikeliness of this mechanism. 
Another possible explanation is that Nrf2 regulates de ontogeny of DC 
subsets and thus, the composition of splenic DC subsets, that may differ between 
Nrf2+/+ and Nrf2-/- mice. Splenic DC subpopulations have different abilities to 
promote the differentiation of distinct TH cell lineages. CD8+ DC express high 
levels of CD70 and secrete IL-12, stimulating TH1 responses upon activation, in 
contrast to CD8- DC, which express low levels of CD70 and do not produce 
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significant levels of IL-12, inducing TH2 responses45,47,48,281. It is possible, therefore, 
that there is an over-representation of CD8+ DC in the spleen of Nrf2-/- mice, when 
compared to Nrf2+/+ controls. However, analysis of DC subpopulation composition 
in Flt3L-derived bone marrow DC, which are thought to resemble splenic DC-
derived subsets26, revealed a similar profile between Nrf2+/+ and Nrf2-/- mice (Ivo 
Marguti, unpublished observations), suggesting Nrf2 does not regulate DC subset 
ontogeny. However, this should be further confirmed by comparing splenic DC 
subpopulation composition in Nrf2+/+ and Nrf2-/- mice. 
The molecular mechanism via which Nrf2 controls the expression of IL-12 in 
DC might rely also on the expression of Nrf2-responsive genes that limit the 
accumulation of ROS in innate immune cells217. This notion is supported by the 
observation that Nrf2 can inhibit the accumulation of ROS in a variety of cell types, 
including DC277. Hmox1 is one of such genes (Chapter 2 Fig.4i), a notion supported 
by the observation that when exposed to LPS in vitro, Hmox1-/- DC produce higher 
levels of IL-12, as compared to Hmox1+/+ DC (Chapter 2 Fig.8a). This suggests that 
Nrf2 controls the expression of IL-12 via a mechanism involving the expression of 
HO-1 in DC. This notion is also in keeping with the observation that exogenous 
delivery of CO, a by-product of HO-1 activity, can inhibit the expression of IL-12 in 
DC282. Moreover, a recent study has shown that treatment of DC with an inducer of 
the Nrf2 pathway, Dimethylfumarate, reduces the expression of Il12 gene family 
members in DC via a mechanism that involves inhibition of STAT-1 phosphorylation 
and induction of HO-1 expression222. Silencing of STAT-1 signaling suppresses the 
expression of Il12p35 mRNA, via a mechanism involving IRF-8 inhibition, while  
HO-1 induction inhibits the transcription of Il12/23p40 and Il23p19222. Inhibition of 
IL-23p19 expression relies on the interaction of a nuclear N-terminal truncated 
portion of HO-1 with NF-B binding sites on the Il23p19 promoter, thus inhibiting its 
transcription222. This raises the possibility that HO-1 inhibits the expression of IL-
12/23p40 via the same mechanism, which would be consistent with the observation 
that increased Il12/23p40 expression in Nrf2-deficient DC (Chapter 2 Fig.5a) is 
associated with suppression of HO-1 expression (Chapter 2 Fig.4i), as compared to 
wild type DC. As for the regulation of IL-12p35, it has never been addressed 
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whether STAT-1 phosphorylation would be increased in Nrf2-deficient cells, but this 
is a possibility that could explain why Nrf2-/- DC produce more Il12p35 (Chapter 2 
Fig.5c), as compared to DC that express Nrf2. 
Expression of HO-1 in DC fails to inhibit the differentiation of naïve TH cells 
towards the TH1 lineage (Chapter 2 Fig.8c), suggesting this effect is mediated 
probably via other Nrf2-responsive genes. In addition, the overall protective effect of 
Nrf2 against EAE does not appear to act via a mechanism involving the expression 
of HO-1 in DC. This notion is supported by the observation that specific down-
regulation of the Hmox1 allele in DC has no impact on the pathological outcome of 
EAE (Chapter 2 Fig.8d-f). This suggests that expression of Nrf2 in DC confers 
protection against EAE via a mechanism driven by the expression of HO-1 in 
combination with other Nrf2-responsive genes. The identity of these genes remains 
elusive at the moment, but Metallothioneins (Mt1 and Mt2) are possible candidates, 
as they are Nrf2-regulated genes with a demonstrated role in the inhibition of the 
pathological outcome of EAE256. 
Several studies have suggested that HO-1 inhibits DC maturation, exerting 
immunosuppressive effects that limit the pathological outcome of immune-mediated 
inflammatory diseases185, including autoimmune neuroinflammation174,175. It should 
be noted, however, that most of the studies addressing the ability of HO-1 to 
modulate DC maturation are based on pharmacologic modulation of HO-1174,282,283. 
Given that the pharmacologic molecules used in these studies can inhibit DC 
maturation irrespectively of HO-1284, the physiologic relevance of these findings is 
difficult to assess. This notion is supported by the observation that, when expressed 
under physiologic conditions, HO-1 fails to regulate DC maturation (Chapter 2 
Suppl. Fig.14 and 15 and Appendix 1 Fig.3) as well as T cell proliferation (Chapter 
2 Fig.8b). Although, expression of HO-1 appears to exert immunoregulatory effects 
in DC, i.e. inhibition of IL-12 production (Chapter 2 Fig.8a), these effects do not 
seem to be sufficient to suppress the pathogenesis of autoimmune 
neuroinflammation (Chapter 2 Fig.8d-f). 
Although DC-specific deletion of Hmox1 does not modulate the 
pathogenesis of EAE, systemic (Chapter 3 Fig.1a and Table 1) or myeloid-specific 
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ablation175 have been shown to do so. This suggests that the protective effect of 
HO-1 expression relies on an immunoregulatory effect exerted by myeloid cells, 
other than DC. HO-1 was shown to form a complex with IRF-3 and to be essential 
for IRF-3 activation and subsequent gene expression in response to TLR3/TLR4 
signaling175. Hmox1 deletion leads to defective IFN- production, and thus, 
increased activation of macrophages and accumulation of TH1 and TH17 cells in the 
CNS175, causing an exacerbated form of EAE. Moreover, IFN- has therapeutic 
effects in EAE and MS285. Therefore, by promoting IFN-production in myeloid 
cells, HO-1 might limit the progression of autoimmune neuroinflammation. 
Pharmacological induction of HO-1 expression (Chapter 3 Fig.1d), after the 
onset of clinical disease, suppresses EAE progression (Chapter 3 Fig.1b,c and 
Table2). This effect is independent of the mouse genetic background or peptide 
used to induce EAE (Chapter 3 Fig.1b,c), arguing for a general regulatory 
mechanism. This mechanism requires the expression of HO-1 (Chapter 3 Fig.1e) 
and presumably involves HO-1 activity, as suggested by the observation that 
exogenous CO mimics in part the protective effects of HO-1 (Chapter 3 Fig.1f). 
However, the protective effect of CO is more limited than that of pharmacological 
induction of HO-1, suggesting that other end products of heme catabolism by HO-1, 
i.e. biliverdin and/or Fe, might also contribute to this effect. 
Beneficial effects of biliverdin reductase286 and bilirubin239 administration 
have been reported in the context of EAE. Billirubin is a lipophilic antioxidant239, 
being oxidized to biliverdin, with biliverdin reductase sustaining an amplification 
cycle whereby biliverdin is recycled back into bilirubin286. However, we did not 
observe a salutary effect of biliverdin administration during EAE (Chapter 3 Suppl. 
Fig.7). A possible explanation for this might be that biliverdin does not have the 
same antioxidant power as bilirubin and/or cannot gain access to the CNS 
parenchyma. Thus, bilirubin inhibits EAE possibly due its ability to cross the BBB, 
acting as an antioxidant in the CNS. 
It is also possible that the protective effect of HO-1 against EAE operates 
indirectly via a reduction of the cellular labile Fe pool, thereby limiting its availability 
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to participate in the Fenton chemistry, via the up-regulation of FtH211 and Fe efflux 
pumps210. Several lines of evidence support a pathogenic role of Fe in EAE. First, 
Fe deposits are present in lesions of individuals with MS and in the CNS of mice 
with EAE243,258,287. Second, mice fed a low-Fe diet do not develop EAE288. Third, 
pharmacological Fe chelation reduces EAE severity289. Fe is localized mainly to the 
cytoplasm of oligodendrocytes bound to ferritin (Chapter 2 Fig.1a) and transferrin259 
and therefore, oligodendrocyte injury may release Fe, increasing the labile Fe pool 
during EAE and MS. This hypothesis remains to be formally addressed. 
Several lines of evidence suggest HO-1 modulates T cell reactivation and 
effector function, presumably via regulation of antigen presentation by APC. 
Pharmacological induction of HO-1 is associated with inhibition of both TH1 and TC 
cell accumulation, proliferation and IFN- production within the CNS (Chapter 3 
Fig.3). Since TH1 and TC cells are effectors of damage in the CNS during EAE, 
limiting TH1 and TC CNS-accumulation, might limit CNS damage. It remains to be 
tested if pharmacological induction of HO-1 affects the development and/or function 
of TH17 cells. 
Pharmacological induction of HO-1 is associated with inhibition of TH cell 
proliferation in vitro via a mechanism mediated by APC (Chapter 3 Fig.4f). This 
mechanism does not influence TH cell priming, while limiting TH cell reactivation 
(Chapter 3 Fig.4e and Suppl. Fig.5). Within the APC compartment, DC are sufficient 
to mediate this effect (Chapter 3 Fig.4g). However, a possible contribution of 
macrophages has not been discarded. During EAE, perivascular DC are required to 
reactivate primed encephalitogenic TH cells, allowing CNS invasion254, while CNS-
resident APC reactivate TH cells at later stages once access to the CNS is 
facilitated255. Importantly, pharmacological induction of HO-1 induces expression of 
HO-1 in CNS-associated DC (Chapter 3 Fig.5a). Taking this into account, 
pharmacological induction of HO-1 might inhibit the reactivation of encephalitogenic 
TH cells, via modulation of DC activation, and impact on the initial events leading to 
the establishment of neuroinflammation. Furthermore, by modulating 
microglia/macrophage activation, HO-1 would counter TH cell reactivation and the 
inflammatory milieu established in the CNS. In keeping with this notion, down-
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modulation of encephalitogenic TH cell activation and effector function (Chapter 3 
Fig.3), by pharmacological induction of HO-1 is associated with inhibition of MHC 
class II expression in APC, including DC, infiltrating-Mø and microglia (Chapter 3 
Fig.6a,c,d). Expression of MHC class II by DC is of central importance for the 
activation of naïve TH cells and generation of TH responses, such as the one 
involved in the pathogenesis of EAE65. In addition, MHC class II, expressed on CNS 
APC is crucial for TH cell reactivation within the CNS254,290. 
Expression of MHC class II is regulated mainly at the transcriptional level291 
by nuclear transcription factor Y , CREB and regulatory factor X, that bind 
consensus DNA sequences in the MHC class II gene promoter, forming a 
transcriptionally inactive multiprotein complex291. Recruitment of class II 
transactivator (CIITA) is required to activate MHC class II gene transcription by 
interacting with the basic transcriptional machinery, as well as by altering chromatin 
conformation291,292. CIITA acts as a master regulator of MHC class II expression 
determining whether or not cells express MHC class II293. 
Induction of MHC class II in response to IFN- is strictly dependent on 
CIITA293,294. Ligation of the IFN- receptor triggers a signal transduction pathway 
that activates the Janus kinase (JAK) family, phosphorylating/activating STAT-1295 
that dimerizes and translocates to the nucleus where it binds the CIITA promoter 
and activates its transcription296. Pharmacological induction of HO-1 inhibits STAT-1 
activation and is associated with a reduction in CIITA expression in microglial cells 
(Chapter 3 Fig.7c,d), an effect likely to explain the inhibition of MHC class II 
expression observed in these cells (Chapter 3 Fig.6c). The molecular mechanism 
via which HO-1 or its by-products inhibit STAT-1 phosphorylation remains to be 
established. One study suggests that CO can modulate STAT-1 activation by 
phosphatidylinositol 3-kinase/Akt and p38 MAPK signaling pathways in endothelial 
cells. Whether, the same is true for JAK in APC remains to be tested297. 
Presumably, regulation of CIITA, and consequently of MHC class II 
expression by modulation of STAT1 by HO-1 or CO is not likely to act on DC since 
expression of MHC class II in DC appears to be independent of STAT-1298. 
Nevertheless, down-modulation of MHC class II might limit TH clonal expansion and 
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differentiation towards an encephalitogenic phenotype. However, this effect has 
been shown to require activation of STAT-3, and to act irrespectively of HO-1284. 
This suggests that the protective effects associated with pharmacologic induction of 
HO-1 in EAE could be the result of a combined effect of HO-1-independent, STAT-
3-mediated effects in DC, reducing TH cell reactivation and CNS invasion, and of 
HO-1-dependent mechanisms inhibiting STAT-1 phosphorylation and CIITA 
expression in infiltrating-macrophages/microglia, thus limiting TH cell reactivation 
within the CNS and preventing the consequences of autoimmune 
neuroinflammation. 
Mice with systemic Hmox1 deletion do not show increased expression of 
MHC class II in DC (Appendix 1 Fig.3b,g), macrophages or microglia (Appendix 1 
Fig3b,h and 4c,d,g,h) or increased T cell effector cytokine production (Appendix 1 
Fig.5b,c,f,g and 6b,c,f,g and 7c,d,g,h). This reveals that enforcing 
pharmacologically HO-1 expression at the onset of disease, although salutary, has 
distinct effects to those associated with physiological HO-1 expression during EAE. 
Nevertheless, these effects could be of important clinical relevance. 
The involvement of TREG, a T cell subset critically involved in the control of 
autoimmune and inflammatory responses32,299, in the salutary effects of Nrf2 and/or 
HO-1 also remains to be tested. We found that neither Nrf2 or Hmox1 deletion, nor 
pharmacological induction of HO-1 expression, influenced the frequency or number 
of TREG cells within the CNS of mice undergoing EAE, suggesting that the protective 
effect of HO-1 and Nrf2 does not act via TREG modulation (Chapter 2 Suppl. Fig.1h 
and 2h and Chapter 3 Fig.3b). However, the possibility of a functional interplay 
between Nrf2 and/or HO-1 and TREG activity in EAE cannot be excluded. Several 
observations suggest that TREG can affect DC function300,301, indicating that the 
salutary effects afforded by TREG can be mediated, at least partially by the 
modulation of APC activity. As such, a possible scenario would be that under 
inflammatory conditions TREG would up-regulate the expression of Nrf2 and/or HO-1 
in APC, modulating their activity and controlling TH cell activation. Nonetheless, the 
impact of Nrf2 on TREG function has to the best of our knowledge never been 
analyzed in detail. While it has been suggested that HO-1 expression in DC302 
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and/or TREG303,304 can regulate TREG function305,306, under homeostatic conditions the 
number and function of TREG is similar between Hmox1+/+ and Hmox1-/- mice. 
However, it remains to be tested if the same would be the case under inflammatory 
conditions in vivo, such as during EAE and MS. 
In conclusion, this Thesis reveals that Nrf2 expression and pharmacological 
induction of HO-1 play a previously underappreciated role in innate immune cell 
regulation, with impact on the TH cell response at the core of autoimmune 
neuroinflammation. First, we demonstrate that Nrf2 down-regulates the expression 
of IL-12 in DC, limiting TH1 lineage differentiation and thus modulating the severity 
of autoimmune neuroinflammation. Second, we found that one of the genes 
regulated by the Nrf2 pathway, Hmox1 controls the severity of EAE and its 
pharmacological induction inhibits the expression of MHC class II in APC and thus, 
the T cell response and severity of EAE. Presumably, this effect is mediated via a 
mechanism involving the production of CO. Altogether these data reveals the 
importance of Nrf2 and HO-1 in the control of autoimmune neuroinflammation, via 
the modulation of APC and consequently of adaptive immunity. 
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1. Introduction 
We have demonstrated that Hmox1-deficient mice (Hmox1-/-) mice develop a more 
severe form of EAE than wild type (Hmox1+/+) animals (Chapter 3 Fig.1a). We have 
also shown that pharmacological induction of HO-1, at the onset of disease, 
reduces EAE severity in a HO-1-dependent manner (Chapter 3 Fig.1b,c,e). This 
salutary effect is associated with a reduction of MHC class II expression in APC and 
down-regulation of TH cell reactivation, proliferation and effector function (Chapter 3 
Fig.3 and Fig.4). This raised the hypothesis that HO-1 might down-regulate the 
immune response causing EAE, by acting on APC. To gain more understanding on 
the physiologic role of HO-1 during EAE we characterized the: 1) profile of HO-1 
expression in the CNS and 2) the immune response of Hmox1-/- vs. Hmox1+/+ mice 
undergoing EAE. 
 
2. Results 
2.1. HO-1 is expressed in microglia/macrophages and astrocytes of mice with 
EAE. 
HO-1 had been previously reported to be expressed in lesions of individuals with 
MS and in the CNS during EAE, specifically in infiltrating-macrophages/microglia 
and astrocytes1. In addition, we have demonstrated that HO-1 is also expressed in 
CNS-resident DC (Chapter 3 Fig.5a). To gain further insight into the cellular pattern 
of expression of HO-1 in the CNS, we performed double immunofluorescence 
stainings of HO-1 and CNS cell-specific markers in spinal cord sections of mice at 
the remission phase of EAE. This time point was chosen based on the observations 
that: 1) HO-1 is expressed in this time-point during EAE2 and 2) Hmox1-/- mice 
undergoing EAE fail to remit, consistent with the notion that HO-1 plays a role and 
thus, is expressed at this time point. As others had reported, we observed that HO-
1 expression in the spinal cord is mostly associated with the sites of lesion, where 
abundant cell infiltration is present (Fig1a-d). In addition, HO-1 expression could be 
detected in infiltrating-macrophages or microglia, as assessed by the expression of 
CD11b (Fig.1b-g) or F4/80 (Fig.1h-j) and astrocytes, as assessed by GFAP 
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expression (Fig.1k-m). HO-1 expression was not detected in endothelial cells, using 
CD31 as a marker, or in oligodendrocytes, stained with CNPase (data not shown). 
This suggests that HO-1 could play a regulatory role not only in infiltrating-immune 
cells but also in CNS-resident cells. 
 
 
 
 
Figure 1. HO-1 expression in cells of the CNS during EAE. Immunostaining of (a,e,h,k) HO-1 in PFA-fixed 
CNS sections, of a C57BL/6 mouse immunized with MOG35-55 in the remission phase, and double-labeled with 
(c,f) CD11b, (i) F4/80 and (l) GFAP. Overlay of HO-1 and (d,g) CD11b, (j) F4/80 or (m) GFAP. Data shown is 
from one mouse. Magnifications: (a-d) 4x and (e-m) 40x. 
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Figure 2. HO-1 does not modulate the number of 
cells in the CNS during EAE. Flow cytometry 
analysis of (a) splenocytes and (b) CNS-infiltrating 
cells from MOG35-55-immunized Hmox1+/+ (n=14) and 
Hmox1-/- (n=9) mice receiving PTx, at the peak of EAE. 
Data was pooled from four independent experiments. 
Flow cytometry analysis of (c) splenocytes and (d) 
CNS-infiltrating cells from MOG35-55-immunized 
Hmox1+/+ (n=12) and Hmox1-/- (n=5) mice receiving 
PTx, in the remission phase of EAE. Data was pooled 
from two independent experiments. Circles correspond 
to single mice and lines to the average of the group. 
2.2. HO-1 deletion does not impact in a relevant manner the immune response 
ongoing during EAE. 
We analyzed by flow cytometry innate 
and adaptive immune cell populations 
and their activation status both in the 
periphery and in the CNS of Hmox1-/- vs. 
Hmox1+/+ mice at the peak and 
remission of EAE. At the peak of EAE 
the total number of splenocytes was 
increased in Hmox1-/- vs. Hmox1+/+ mice 
(Fig.2a), but this was no longer 
observed in the remission phase 
(Fig.2c). It should be noted that naïve 
Hmox1-/- mice develop splenomegaly, 
characterized by increased cellularity3-5, 
which might account for this 
observation. Importantly this did not lead 
to an increased accumulation of 
leukocytes in the CNS of Hmox1-/- vs. 
Hmox1+/+ mice (Fig.2b,d).  
Regarding innate immune cells in the periphery, the number of DC, i.e. 
CD11c+ cells, in the spleen of Hmox1-/- vs. Hmox1+/+ mice was similar (Fig.3a,f) at 
the peak and remission phases of EAE. This was also the case for the activation 
status of DC from Hmox1-/- vs. Hmox1+/+ mice at the peak of EAE, as revealed by 
the expression of MHC class II (Fig.3b) and of the costimulatory molecules CD40 
(Fig.3c), CD80 (Fig.3d) and CD86 (Fig.3e). In the remission phase, the same was 
observed for MHC class II (Fig.3g), CD80 (Fig.3i) and CD86 (Fig.3j) but not for 
CD40 that had a modest increase in Hmox1-/- vs. Hmox1+/+ DC (Fig.3h). 
In the CNS, no differences were observed in the number of microglia cells 
(Fig.4b,f) of Hmox1-/- vs. Hmox1+/+ mice at the peak or remission of EAE. The 
number of infiltrating-macrophages (Fig.4a), however, was increased and the  
a b 
c d 
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Figure 3. HO-1 does not modulate the activation status of
 
splenic DC during EAE. Flow cytometry analysis 
of splenocytes from MOG35-55-immunized Hmox1+/+ (n=14) and Hmox1-/- (n=9) mice receiving PTx, at the peak 
of EAE. (a) Number of DC (CD11c+). Mean intensity of fluorescence (MFI) of (b) MHC class II, (c) CD40, (d) 
CD80 and (e) CD86 expression in DC. Data was pooled from four independent experiments. Flow cytometry 
analysis of splenocytes from MOG35-55-immunized Hmox1+/+ (n=12) and Hmox1-/- (n=5) mice receiving PTx, in 
the remission phase of EAE. (f) Number of DC. MFI of (g) MHC class II, (h) CD40, (i) CD80 and (j) CD86 
expression in DC. Data was pooled from two independent experiments. Circles correspond to single mice and 
lines to the average of the group. 
 
 
 
Figure 4. HO-1 does not modulate innate immune cells in the CNS during EAE. Flow cytometry analysis of 
CNS-infiltrating leukocytes from MOG35-55-immunized Hmox1+/+ (n=14) and Hmox1-/- (n=9) mice receiving PTx, 
at the peak of EAE. Number of (a) macrophages (CD45hiCD11b+) and (b) microglia cells (CD45loCD11b+). MFI 
of MHC class II expression in (c) macrophages (CD45hiCD11b+MHCIIhi) and (d) microglia cells 
(CD45loCD11b+MHCIIhi). Data was pooled from four independent experiments. Flow cytometry analysis of 
splenocytes from MOG35-55-immunized Hmox1+/+ (n=12) and Hmox1-/- (n=5) mice receiving PTx, in the remission 
phase of EAE. Number of (e) macrophages and (f) microglia. MFI of MHC class II expression in (g) 
macrophages and (h) microglia. Data was pooled from two independent experiments. Circles correspond to 
single mice and lines to the average of the group. 
 
a b c d 
e f g h 
a b c d e 
f g h i j 
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Figure 5. HO-1 does not modulate TH and TREG cell populations in the spleen during EAE. Flow cytometry 
analysis of splenocytes from MOG35-55-immunized Hmox1+/+ (n=14) and Hmox1-/- (n=9) mice receiving PTx, at the 
peak of EAE. Number of (a) TH (CD4+), (b) TH1 (CD4+IFN+), (c) TH17 (CD4+IL-17A+) and (d) TREG 
(CD4+CD25+Foxp3+). Data was pooled from four independent experiments. Flow cytometry analysis of 
splenocytes from MOG35-55-immunized Hmox1+/+ (n=12) and Hmox1-/- (n=5) mice receiving PTx, in the remission 
phase of EAE. Number of (e) TH , (f) TH1, (g) TH17 and (h) TREG. Data was pooled from two independent 
experiments. Circles correspond to single mice and lines to the average of the group. 
expression of MHC class II both in macrophages and microglia (Fig.4c,d) was 
reduced in Hmox1-/- vs. Hmox1+/+ mice at the peak of EAE, but these differences 
were no longer present in the remission phase (Fig.4e,g,h). 
No differences were observed in the number of TH (Fig.5a,e and 6a,e), TH1 
(Fig.5b,f and 6b,f), TH17 (Fig.5c,g and 6c,g) and TREG (Fig.5d,h and 6d,h) cells in 
the spleen or in the CNS of Hmox1-/- vs. Hmox1+/+ mice undergoing EAE. The same 
is true for CD8+ T cells (Fig.7a,b,e,f), including activated CD8+ T cells (Fig.7c,d,g,h), 
assessed by the production of IFN-. 
This data suggests that Hmox1 deletion does not affect in a significant 
manner innate or adaptive immune cell populations in the periphery or in the CNS 
during EAE in a way that could explain the increased EAE severity observed in 
Hmox1-/- mice compared to Hmox1+/+ animals. 
a b c d 
e f g h 
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Figure 6. HO-1 does not modulate TH and TREG cell populations in the CNS during EAE. Flow cytometry 
analysis of CNS-infiltrating leukocytes from MOG35-55-immunized Hmox1+/+ (n=14) and Hmox1-/- (n=9) mice 
receiving PTx, at the peak of EAE. Number of (a) TH, (b) TH1, (c) TH17 and (d) TREG. Data was pooled from four 
independent experiments. Flow cytometry analysis of splenocytes from MOG35-55-immunized Hmox1+/+ (n=12) 
and Hmox1-/- (n=5) mice receiving PTx, in the remission phase of EAE. Number of (e) TH, (f) TH1, (g) TH17 and 
(h) TREG. Data was pooled from two independent experiments. Circles correspond to single mice and lines to the 
average of the group. 
 
 
 
Figure 7. HO-1 does not modulate CD8
+
 T cells in the CNS during EAE. Flow cytometry analysis of 
splenocytes and CNS-infiltrating leukocytes from MOG35-55-immunized Hmox1+/+ (n=14) and Hmox1-/- (n=9) mice 
receiving PTx, at the peak of EAE. Number of CD8+ T cells (a) in the spleen, (b) in the CNS and of activated 
CD8+ T cells (CD8+IFN-+) (c) in the spleen and (d) in the CNS. Data was pooled from four independent 
experiments. Flow cytometry analysis of splenocytes of MOG35-55-immunized Hmox1+/+ (n=12) and Hmox1-/- 
(n=5) mice receiving PTx, in the remission phase of EAE. Data was pooled from two independent experiments. 
Number of CD8+ T cells (e) in the spleen, (f) in the CNS and of activated CD8+ T cells (g) in the spleen and (h) in 
the CNS. Circles correspond to single mice and lines to the average of the group. 
 
a b c d 
e f g h 
a b c d 
e f g h 
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3. Discussion 
The exacerbated EAE phenotype observed in Hmox1-/- mice, compared to wild type 
controls (Chapter 3 Fig.1a), suggests that HO-1 plays a regulatory role in EAE. HO-
1 is expressed during EAE in cells of the immune system, i.e. infiltrating-
macrophages/microglia (Fig1a-j) and dendritic cells (Chapter 3 Fig.5a), as well as in 
non-hematopoietic CNS-resident cells, e.g. astrocytes (Fig1k-m), suggesting that its 
regulatory role could be exerted in the immune compartment and/or in the CNS. 
Comparative analysis of innate (Fig.3 and 4) and adaptive (Fig.5-7) immune 
cells, in the periphery and CNS of Hmox1-/- and Hmox1+/+ mice undergoing EAE did 
not reveal any major differences. However, Hmox1-/- mice did show a small and 
transient difference in specific immune cell populations, as compared to Hmox1+/+ 
mice. However, these rather modest effects could hardly explain the strong 
protective effect of HO-1 expression during EAE. 
These observations seem conflicting with a recent report demonstrating that 
specific deletion of HO-1 in myeloid cells, including macrophages and neutrophils 
but not DC, results in increased EAE severity due to impaired IFN- production and 
thus, increased activation of macrophages and accumulation of TH1 and TH17 cells 
in the CNS6. Our analysis of macrophage/microglia activation (Fig.4c,d,g,h) and of 
TH1 (Fig5b,f and 6b,f.) and TH17 (Fig.5c,g and 6c,g) accumulation in the CNS of 
mice with global Hmox1 deletion did not reveal the same. The reasons for this 
discrepancy are not clear at the moment. Nevertheless, it should be noted that the 
two animal models differ considerably in that one is deficient for HO-1 systemically 
while the other is a cell-specific Hmox1-deficient mouse. Importantly, systemic 
deletion of Hmox1 results in several immune abnormalities, including splenomegaly 
as early as 6 weeks of age3-5, which is not reported in mice with myeloid-specific 
deletion of Hmox16. Thus, analyzing the immune response during EAE in a mouse 
with systemic deletion of HO-1 might not be comparable to that in a mouse with a 
more specific deletion, as their immune steady state is completely different. 
The pharmacological induction of HO-1 at the onset of EAE decreases EAE 
severity (Chapter 3 Fig.1b,c) in a HO-1-dependent manner, since it is lost when 
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Hmox1-/- mice are used instead of Hmox1+/+ (Chapter 3 Fig.1e). This is associated 
with immunoregulatory effects, i.e. reduction of MHC class II expression in APC 
(Chapter 3 Fig.6a,c,d) and down-regulation of myelin-reactive TH cell-reactivation, 
proliferation (Chapter 3 Fig.3 and 4a,e-h) and effector cytokine production (Chapter 
3 Fig.3b and 4b)7. This data is suggestive that HO-1 could play a down-modulatory 
role in the immune response during EAE. Importantly, Hmox1-/- mice do not show 
increased expression of MHC class II in splenic DC (Fig.3b,g) and APC of the CNS 
(Fig3b,h and 4c,d,g,h), or increased T cell effector cytokine production (Fig.5b,c,f,g 
and 6b,c,f,g and 7c,d,g,h). This data reveals that genetic ablation of HO-1 or its 
pharmacological induction at the onset of disease do not have opposite 
immunoregulatory effects, suggesting that if the pharmacological induction 
approach acts specifically via HO-1 then targeting HO-1 in this manner may have 
therapeutic effects. 
HO-1 does not modulate DC activation during EAE (Fig.3). This is in 
agreement with the observation that HO-1 also does not modulate the maturation of 
DC either in vitro (Chapter 2 Suppl. Fig.14) or in vivo (Chapter 2 Suppl. Fig.15) 
upon LPS-stimulation. Moreover, HO-1-specific deletion in DC does not seem to 
impact EAE severity (Chapter 2 Fig8d-f). This data suggests that the regulatory role 
of HO-1 in EAE is not mediated by expression of physiological levels of HO-1 in 
DC, and that the exacerbated EAE phenotype observed in mice with a myeloid-
specific deletion of HO-16 is probably due to effects of HO-1 in other myeloid cell 
populations, such as macrophages and/or neutrophils.  
The observation that EAE progression is similar between mice with DC-
specific deletion of HO-1 and controls (Chapter 2 Fig.8d-f) raises the possibility that 
the HO-1-dependent reduction observed in EAE severity upon CoPPIX 
administration does not rely on a reduction of MHC class II in DC (Chapter 3 
Fig.6a), but instead in the CNS APC, i.e. macrophages/microglia (Chapter 3 
Fig.6c,d). It has been shown that CoPPIX-mediated reduction of MHC class II 
expression in DC relies on a STAT-3-dependent but HO-1-independent 
mechanism8. Nevertheless, this has been demonstrated only in GM-CSF-derived 
bone marrow DC, which are different from LN node DC, where the effect of CoPPIX 
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was analyzed, in our work. Thus, it would be important to analyze in the future: 1) 
MHC class II expression during EAE in Hmox1-/- vs. Hmox1+/+  LN DC after CoPPIX 
administration and 2) MHC class II expression and the T cell response, after 
CoPPIX administration at the onset of EAE, in a mouse with a specific deletion of 
HO-1 in macrophages/microglia.  
 
4. Methods 
Mice. BALB/c Hmox1+/- mice9 were generated by Dr. Shaw-Fang Yet (Brigham and 
Women's Hospital). BALB/c Hmox1+/- mice were backcrossed into the C57BL/6 
background for ten generations, bred as Hmox1+/- x Hmox1+/- breeding pairs at the 
Instituto Gulbenkian de Ciência and genotyped as described elsewhere7. Food and 
water were provided ad libitum. Littermate Hmox1+/+ mice were used as controls 
and all mice were used for experiments in the C57BL/6 background between 6 - 8 
weeks of age. Mice were maintained under specific pathogen-free conditions and 
all experimental protocols were approved by the “Instituto Gulbenkian de Ciência 
animal care committee” and by the “Direcção Geral de Veterenária (DGV)” of the 
Portuguese Ministry of Agriculture, Rural Development and Fisheries (License 
018831-2010-09-03). 
Reagents. Murine MOG35-55 (MEVGWYRSPFSRVVHLYRNGK) was obtained from 
Biopolymers Laboratory of Harvard Medical School (Boston, MA, USA) and 
dissolved in PBS (1mg/ml). Complete Freund’s adjuvant (CFA) was prepared by 
grinding Mycobacterium tuberculosis HR37 (4mg/ml) and re-suspending it in 
incomplete Freund’s adjuvant (Difco; BD Biosciences). Pertussis toxin (PTx; List 
Biological Laboratories; Campbell, CA, USA) was dissolved in PBS (100 ng/l). 
PMA (Sigma) and inonomycin (Calbiochem) were dissolved in Dimethyl sulfoxide 
(DMSO; 2.5 mg/ml). Brefeldin A (Epicenter technologies) was dissolved in pure 
ethanol (1 mg/ml). 
EAE. Hmox1+/+ and Hmox1-/- mice were immunized with MOG35–55 (100 g) 
emulsified in CFA (100 l) subcutaneously on each side of the belly and received 
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PTx intravenously (200 ng in PBS; 100 µL) after immunization (i.e. 4h and 2 days). 
Clinical signs of EAE were evaluated daily for 40 days and scored as follows. For 
classical EAE: 0 - normal; 1 - limp tail; 2 - partial paralysis of the hind limbs; 3 - 
complete paralysis of the hind limbs; 4 - hind-limb paralysis and forelimb weakness; 
5 - moribund or deceased. 
Isolation of splenocytes. Spleen cells were harvested, homogenized into a single-
cell suspension in PBS 2% FCS and subjected to erythrocyte lysis in 3 ml of a 
hypotonic red blood cell lysis buffer (155 mM NH4Cl, 10 mM NaHCO3, 0.1 mM 
EDTA) while centrifuging (375g, 5 min., 4ºC). Cells were washed twice in 15 ml 
PBS 2% FCS (375g, 5 min., 4ºC). For intracellular cytokine staining, cells were 
cultured in supplemented RPMI 1640 (100 U/ml penicillin, 100 μg/ml streptomycin, 
10% FCS, 50 M-mercaptoethanol, 10 mM HEPES and 1 mM sodium pyruvate; 2 
mM L-glutamine; Invitrogen and Sigma) containing 50 ng/ml PMA, 500 ng/ml 
ionomycin and 10 g/ml brefeldin A for 4h at 37°C (5% CO2, 95% humidity). 
Surface and intracellular stainings were analyzed by flow cytometry. 
CNS-infiltrating leukocytes. Brain and spinal cord were harvested from 
transcardially perfused mice (20 ml cold PBS). Single-cell suspensions were 
prepared in HBSS (Invitrogen) containing Collagenase VIII (0.2 mg/ml; Sigma) by 
homogenizing the tissue between two glass slides, digesting (30 min.; 37°C; 5% 
CO2, 95% humidity) and filtering (100-m; BD Falcon). After centrifugation (375g, 5 
min., 4ºC) in PBS, leukocytes were separated on a discontinuous 30% percoll 
gradient (Sigma) by centrifugation (1041g, 30 min., RT) erythrocytes were lysed in 
hypotonic red blood cell lysis buffer (5 min., RT). For intracellular cytokine staining, 
cells were cultured in supplemented RPMI 1640 with PMA, ionomycin and brefeldin 
A, as described above. Surface and intracellular stainings were analyzed by flow 
cytometry. 
Flow cytometry and antibodies. The following mAb were used: FcIII/II receptor 
(2.4G2), anti-CD4 (RM4-5), anti-CD11b (M1/70), anti-CD25 (PC 61), anti-CD11c 
(HL3), anti-CD40 (3/23), anti-CD45 (30-F11), anti-CD80 (16-10A1), anti-CD86 
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(GL1) (prepared in house from hybridoma culture supernatants), anti-CD8 
(YTS169.4; BD Biosciences) and anti-MHC class II (AF6-120.1; BD Biosciences 
and M5/114; eBioscience). Antibodies were directly conjugated to FITC, Alexa488, 
PE, PerCP, APC, Cy5 or Alexa467. 
For surface staining, cells were incubated with an anti-FcIII/II receptor 
antibody (2.4G2) in PBS 2% FCS (20 min., 4°C). Surface staining was performed in 
PBS 2% FCS (20 min., 4°C). After washing and centrifugation (666g, 2 min., 4ºC), 
cells were incubated with streptavidin–allophycocyanin for (20 min., 4°C) to detect 
biotinylated antibodies. For flow cytometry analysis of surface stainings dead cells 
were excluded using propidium iodide (1.7 g/ml).  
For intracellular cytokine staining cells were fixed (2% paraformaldehyde; 30 
min., RT) and permeabilized (0.5% saponin in PBS 2% FCS, i.e. permeabilization 
buffer)(10 min., RT). Cells were incubated with anti-IFN- (XMG1.2; BD 
Biosciences) or anti-IL-17 (eBioTC11-18H10.1; eBioscience) mAb in 
permeabilization buffer (20 min., 4°C).  
For intracellular Foxp3 staining, cells were stained with anti-mouse Foxp3 
conjugated (FJK-16s; eBioscience) with PE using the Foxp3 detection set 
(eBioscience) according to the manufacturer’s instructions. 
Cell numbers were assessed by flow cytometry, using a fixed number of 
latex beads (Beckman Coulter) co-acquired with a pre-established volume of the 
cellular suspensions. 
Flow cytometry detection was done in the FACSCalibur (BD Biosciences), 
using the cellquest software (BD Biosciences) for acquisition. Post-acquisition 
analysis was performed with FloJo software (Treestar). 
Histology. Mice were perfused with PBS (20 ml) followed by 4% paraformaldehyde 
(PFA) (50 ml) and post-fixed overnight in PFA 4%. Brain and spinal cord were 
extracted from the bone with forceps and spinal cord embedded in 3% agar. 
Sections were prepared in a vibratome (30 m) and hematoxilin-eosin staining 
performed as follows. Briefly, sections were placed in gelatin-coated slides and 
immersed in a hematoxilyn solution for ten minutes, washed with water and 
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immersed in a solution of eosin for 15 minutes. Following, sections were washed 
with water and dehydrated in a bath of alcohols for two minutes in each, according 
to the following order 70% (once), 96% (twice) 100% (twice) ethanol and Xilol. 
Immunofluorescence of the CNS. CNS sections were prepared as described 
above and the following antibodies were used: rabbit anti-HO-1 polyclonal 
(SPA895; Stressgene Biotechnologies), rat anti-CD11b monoclonal (Leinco), rat 
anti-mouse F4/80 monoclonal (Serotec) and rat anti-GFAP monoclonal 
(Calbiochem) antibodies. Secondary antibodies directly coupled to fluorochromes 
used were a goat anti-rabbit Alexa 568 (Invitrogen) to detect HO-1, and an anti-rat 
Alexa 488 (Invitrogen) to detect CD11b, F4/80 and GFAP. Briefly, sections were 
blocked with 10 % normal goat serum (NGS) (Sigma) with 0.5% Triton-X (Sigma) in 
PBS for 10 min., washed with PBS and incubated with the primary antibody diluted 
in 1% NGS with 0,5% Triton-X in PBS for 90 min. at RT or ON at 4ºC. Sections 
were washed again in PBS and incubated with the secondary antibody diluted in 
1% NGS with 0,5% Triton-X in PBS for 90 min. at RT in the dark. At the end of this 
time, sections were washed with PBS, placed in a gelatin-coated slide and mounted 
in the water soluble mounting medium Mowiol (Sigma) with a coverslip on top. After 
30 min. at 4ºC sections were analysed by fluorescence microscopy. 
Statistics. Statistical analysis was performed using the Nonparametric Mann-
Whitney U test, when sample size was smaller than 5, or did not follow normal 
distribution, and when it did Unpaired Student’s t-test for unequal variances was 
used. Normal distributions were confirmed using the Kolmogorov-Smirnov test. p < 
0.05 was considered statistically significant. 
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Abstract 
The heme-catabolizing enzyme heme oxygenase-1 (HO-1; encoded by the Hmox1 
gene) inhibits the pathogenesis of several immune-mediated inflammatory 
diseases. This unusually broad salutary effect is thought to rely on the 
immunoregulatory actions of HO-1, exerted on innate and adaptive immune cells. 
According to this notion, HO-1 ‘dampens’ innate and adaptive immune responses, 
limiting immune-mediated tissue injury and thus suppressing the pathogenesis of 
immune-mediated inflammatory diseases. We will argue that the salutary effects of 
HO-1 are also exerted via its cytoprotective action, which sustains tissue function 
and prevents unfettered immune activation by endogenous pro-inflammatory 
ligands released from injured cells. 
 
The heme-catabolizing enzyme heme oxygenase-1 (HO-1) 
HO-1 is a ubiquitously expressed stress-responsive enzyme that catabolizes iron 
(Fe) protoporphyrin IX (i.e. heme) into equimolar amounts of labile Fe, biliverdin 
and carbon monoxide (CO)1 (Fig.1). In contrast to the Fe contained within the 
protoporphyrin IX ring of heme, which can catalyze the production of free radicals 
via the Fenton chemistry, several Fe metabolic pathways can neutralize the labile 
Fe produced through heme catabolism by HO-1. Among those, the induction of 
ferritin heavy chain (FtH) expression by labile Fe mediates to a large extent the 
protective effects of HO-12 (Fig.1). The biliverdin produced through heme 
catabolism by HO-1 can be converted, by biliverdin reductase, into the 
cytoprotective antioxidant bilirubin3. Moreover, CO is also cytoprotective4 as well as 
anti-inflammatory5 (reviewed in6). Presumably, these end-products of heme 
catabolism can each alone or in combination contribute to the protective effects of 
HO-1 (reviewed in7,8). In addition, heme degradation should be protective per se, as 
it prevents the deleterious (pro-oxidant) effects of free heme. 
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Immunoregulatory effects of HO-1 
The notion that HO-1 is immunoregulatory is supported by the observation that 
Hmox1 deficiency leads, in mice and human(s), to the spontaneous development of 
a chronic inflammatory pathology characterized by increased blood leukocyte 
count, serum IgM, accumulation of polymorphonuclear (PMN) cells, and 
 
 
Figure 1. The heme/HO-1 system. Free heme is highly pro-oxidant, as its Fe atom 
can participate in the Fenton chemistry via which hydrogen peroxide (H2O2) is 
converted into the highly reactive hydroxyl radical (OH˙). This pro-oxidant effect is 
controlled by several mechanisms including heme catabolism by HO-1 (Protein Data 
Base; PDB 1n3u), a reaction assisted by NADPH and Cytochrome P450. Contrary to 
heme-Fe, labile Fe (yellow circles) can be neutralized by FtH (Protein Data Base; 
PDB 1r03). The salutary (cytoprotective) effects of HO-1 are mediated to a large 
extent by this conversion of reactive heme-Fe (that promotes oxidative injury) into 
chelatable labile Fe2. Bv: Biliverdin. 
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monocyte/macrophages (Mø) in the spleen as well as in nonlymphoid tissues and 
widespread oxidative tissue injury9-11. We will review hereby data supporting the 
notion that the immunoregulatory effects of HO-1 are exerted via its expression on 
innate and adaptive immune cells, but perhaps more importantly, by its expression 
in nonlymphoid tissues where it affords cytoprotection against oxidative injury. 
 
Effects of the heme/HO-1 system on innate immunity 
Under homeostasis, heme exists essentially as a prosthetic group in several 
hemoproteins. However, under pathologic conditions noncovalently bound heme 
can be released from those hemoproteins12 (reviewed in13). The free heme 
produced in this manner is recognized by the pattern recognition receptor (PRR) 
toll-like receptor 4 (TLR4), triggering the production of low levels of pro-
inflammatory cytokines by innate immune cells such as Mø14 (Fig.2). However, 
when pre-exposed to free heme, Mø become ‘desensitized’ that is lose the ability to 
respond, to a subsequent challenge by other TLR4 agonists, for example bacterial 
lipopolysaccharide (LPS) (Fig.2)8. This immunoregulatory effect is credited to the 
induction of HO-1 and in particular to the production of CO5. Interestingly, the anti-
inflammatory effect of other immunoregulatory molecules such as IL-1015 and 15-
deoxy-12,14-prostaglandin J2 (15d-PGJ2)16 also appears to be exerted via this 
mechanism, namely the induction of HO-1 in Mø (reviewed in17). While suggestive 
that HO-1 can exert anti-inflammatory effects when expressed in Mø, these studies 
have not demonstrated that those effects occur under physiologic conditions. There 
is evidence however, to suggest that this might not be the case. For instance, 
peritoneal Mø isolated from Hmox1-/- or Hmox1+/+ mice have a similar pro-
inflammatory response to LPS in vitro9, making it unclear whether HO-1 exerts 
immunoregulatory effects when expressed physiologically in Mø. 
Similar to Mø, PMN cells can ‘sense’ free heme, in this case through a yet 
unidentified G-protein-coupled receptor18,19. As such, free heme can act as a PMN 
cell chemoattractant, activating PMN cells to produce reactive oxygen species as 
well as pro-inflammatory cytokines18,19 (Fig.2). Since free heme can act as a potent 
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pro-oxidant catalyst via the Fenton chemistry, this latter effect might exacerbate Mø 
as well as PMN-driven oxidative tissue injury. Therefore, by limiting the availability 
of free heme, HO-1 might inhibit PMN cell chemotaxis and activation, and thus, 
oxidative tissue injury. This notion is supported by the observation that Hmox1 
deficiency, in mice and humans, is associated with widespread PMN cell activation 
and tissue infiltration, as well as with oxidative tissue injury9-11,20. In addition, 
pharmacologic induction of HO-1 inhibits the activity of the p47phox, p67phox, and 
gp91phox subunits of nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, thereby reducing the production of reactive oxygen species by activated 
PMN cells and Mø21,22, contributing further to limit oxidative tissue injury. 
 
 
Figure 2. Regulation of innate immunity by the heme/HO-1 system. (a) Free heme induces a mild 
pro-inflammatory response followed by a regulatory response attributable to the induction of HO-1. (b) 
Free heme can be recognized by mouse Mø, via TLR4, which triggers the production of keratinocyte 
chemokine (KC/IL-8) and TNF14. In addition, free heme induces the expression of HO-1 in Mø, which 
exerts a series of anti-inflammatory effects against a variety of pro-inflammatory agonists (second 
signal). These effects are mediated via the regulation of several signal transduction pathways by CO 
(listed to the right in gray). Free heme is recognized by PMN cells, via an unidentified G-protein-coupled 
receptor that triggers PMN cell migration as well as the production of IL-8 and reactive oxygen species19. 
Heme-driven HO-1 induction inhibits PMN cell activation by reducing the availability of free heme and by 
inhibiting NADPH activity, an effect mediated by CO. 
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Dendritic cells (DC) ‘bridge’ innate and adaptive immune responses, 
migrating upon activation, from tissues into secondary lymphoid organs, as to 
become immunogenic, that is acquire the ability to activate naïve T cells. Mouse 
immature DC express negligible levels of HO-1, inducing its expression upon 
activation23,24. Intriguingly, rat and human immature DC express HO-1 
constitutively, downregulating its expression upon activation25. In any case, 
pharmacologic induction of HO-1 inhibits mouse, rat, and human DC activation and 
immunogenicity25-27 (Fig.3a), an effect mimicked by pharmacologic delivery of CO26 
or biliverdin/bilirubin28 (Fig.3a). This suggests that CO and/or biliverdin/bilirubin 
mediate the immunosuppressive effects associated with pharmacologic modulation 
of HO-1 expression in DC (Fig.3a). However, the physiological relevance of these 
observations is somehow questioned by the recent observation that the 
pharmacologic modulators of HO-1 used in these studies can exert 
immunosuppressive effects in DC, independently of HO-123. Moreover, the 
observation that activation of DC from Hmox1+/+ or Hmox1-/- mice occurs in a similar 
manner in vitro23 questions further the physiological relevance attributed to the 
expression of HO-1 in DC. As discussed below, HO-1 might exert 
immunoregulatory effects on innate immune cells, including DC, via a mechanism 
that does not rely on its expression in these cells. 
Effects of the heme/HO-1 system on adaptive (T cell) immunity 
Several observations in vitro suggest that HO-1 exerts immunoregulatory effects by 
inhibiting T cell activation, proliferation and/or effector function. First, the activation 
of human CD4+ T helper (TH) cells is associated with a significant induction of HO-1 
expression29 (Fig.3b). Second, pharmacologic induction of HO-1 inhibits human TH 
and CD8+ cytotoxic T (TC) cell activation29. Third, CO inhibits TH cell activation29 and 
induces apoptosis in Jurkat T cells30 (Fig.3b). Fourth, biliverdin/bilirubin inhibits 
mouse and human TH cell activation28 (Fig.3b). In keeping with these observations, 
pharmacologic induction of HO-1 in vivo can drive activated TH cells to undergo 
apoptosis via activation induced cell death31 (Fig.3b) and can promote dominant 
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peripheral T cell tolerance against transplanted organs32. This latter effect is 
mimicked by biliverdin/bilirubin28,33, which suppresses T cell-driven inflammatory 
pathologies such as the rejection of transplanted organs33 or autoimmune 
neuroinflammation28. The immunoregulatory effects of biliverdin/bilirubin are 
mediated via inhibition of the transcription factors, nuclear factor of activated T-cells 
(NF-AT) and nuclear factor kappa B (NF-B), which suppresses IL-2 production in 
TH cells28,33. Of notice, both biliverdin and bilirubin are endogenous ligands for the 
aryl hydrocarbon receptor (AHR)34, which regulates the plasticity of TH cell 
phenotype toward an anti-inflammatory regulatory T (TREG) cell or a pro-
inflammatory TH17 effector function35,36. Although speculative, it is possible that the 
immunoregulatory effects of HO-1 might be exerted, to at least some extent, 
through the production of these endogenous AHR ligands. 
HO-1 has been suggested to exert immunoregulatory effects by modulating 
TREG cell function37 (Fig.3c), a notion supported by the following set of observations. 
First, human and mouse TREG cells express HO-1 constitutively38,39 (Fig.3c). 
Second, pharmacologic inhibition of HO-1 suppresses human TREG cell function in 
vitro40. Third, the activity of Hmox1+/+ TREG cells is compromised in vitro by Hmox1-/- 
DC41, a finding we have not been able to reproduce39. While these observations 
suggest that HO-1 regulates TREG cell function in vitro, our finding that TREG cell 
development as well as peripheral maintenance and function are normal in Hmox1-/-
mice39, questions the physiologic relevance of the effects attributed to 
pharmacologic modulation of HO-1 in TREG cells. 
Of interest, free heme can act as a T cell mitogen in vitro42-44, promoting TH 
cell activation, in a major histocompatibility complex (MHC) class II restricted 
manner43. Free heme also promotes the activation and effector function of TC cells 
in vitro, but in this case via a mechanism that is not completely MHC class I 
restricted44. Although the molecular basis for heme recognition by T cells and its 
putative impact on the outcome of immune-mediated inflammatory diseases remain 
unexplored, these observations suggest that HO-1 might regulate T cell activation 
by decreasing free heme availability. 
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Figure 3. Regulation of adaptive immunity by the heme/HO-1 system. Immunoregulatory effects attributed to HO-
1 expression in (a) DC, (b) activated TH cells, and (c) TREG cells. In all three models (panels a, b and c) HO-1 exerts 
immunoregulatory effects via the paracrine action of the end-products of heme catabolism, namely CO, BV/BR, or by 
a yet unidentified mechanism associated with pharmacologic induction of HO-1. AICD: activation induced cell death, 
BV/BR: biliverdin/bilirubin, TEFF: effector T cell (TH or TC). 
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Cytoprotective effects of HO-1 
Many if not all immune-mediated inflammatory diseases are associated with the 
production of free radicals, leading to some level of cellular oxidative stress and 
oxidative tissue injury. If not controlled, oxidative stress can drive cells to undergo 
necrosis, a form of cell death associated with the release of their intracellular 
content, including uric acid45 and high mobility group box 1 (HMGB1)46 (Fig.4). 
These intracellular components can be recognized by PRR expressed in innate 
immune cells, such as Mø and DC, and thus can act as pro-inflammatory and 
eventually immunogenic agonists (reviewed in47). Given the above, mechanisms 
regulating cell death/survival in tissues should exert immunoregulatory effects that 
impact on the outcome of immune-mediated inflammatory diseases48. The 
cytoprotective effect of HO-1might act in such a manner (Fig.4).  
When challenged by a pro-inflammatory agonist such as LPS, Hmox1-/- mice 
succumb to unfettered oxidative stress9,20, associated with widespread oxidative 
tissue injury and end-stage multi-organ failure9,49. This suggests that HO-1 prevents 
the pathologic outcome of inflammatory responses by affording cytoprotection 
against oxidative stress. In subsequent studies, the cytoprotective effect of HO-1 
was associated with protection against many other immune-mediated inflammatory 
diseases50 (reviewed in7).  
Expression of HO-1 or exposure to the by-products of its enzymatic activity 
is cytoprotective against oxidative injury in a wide variety of cells, including 
fibroblasts, vascular endothelial cells, pancreatic -cells, hepatocytes, kidney 
epithelial cells, cardiac myocytes and central nervous system astrocytes and 
neurons, among others (reviewed in7,8,51). This broad cytoprotective effect might 
account for the equally broad protective effects of HO-1 against the development of 
vascular diseases, diabetes, liver dysfunction, kidney failure, myocardial infarction 
as well as diseases of the central nervous system (reviewed in7).  
Presumably, the cytoprotective effect of HO-1 has a dual salutary role, in 
that it sustains tissue/organ function while inhibiting the release of endogenous pro-
inflammatory ligands from injured cells (Fig.4). This latter effect should contribute in 
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a significant manner to prevent unfettered inflammation. In keeping with this notion, 
Hmox1-/- mice produce high levels of circulating endogenous pro-inflammatory 
ligands, for example HMGB1, in response to LPS52, an effect that promotes the 
development of septic shock52,53. Moreover, pharmacologic induction of HO-1 
affords tissue cytoprotection and inhibits the production of extracellular HMGB1 in 
response to LPS54. While expression of HO-1 might inhibit the release of other 
endogenous pro-inflammatory ligands this has not been tested critically. 
Assuming that tissue cytoprotection contributes to the salutary effects of 
HO-1, other cytoprotective genes should also prevent the pathogenesis and/or 
progression of immune-mediated inflammatory diseases. This is likely to be the 
 
 
Figure 4. Cytoprotective effect of the heme/HO-1 system. Activation of innate immune cells, including Mø and 
PMN cells is associated with the production of ROS and pro-inflammatory cytokines, leading to oxidative stress. 
Expression of HO-1 in response to oxidative stress (i.e. Hmox1+/+) is cytoprotective and prevents the release of 
endogenous pro-inflammatory ligands from injured cells, thus promoting the resolution of inflammation and the 
return to homeostasis. When expression of HO-1 is impaired (i.e. Hmox1-/-) oxidative stress leads to widespread 
programmed cell death (cytotoxicity) resulting in impaired tissue function as well as release of endogenous pro-
inflammatory ligands. By engaging PRR in innate immune cells, endogenous ligands sustain the activation of 
innate immune cells (inflammation) and exacerbate tissue injury, an effect that should promote the development 
of immune-mediated inflammatory diseases. 
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case for at least another ubiquitously expressed stress-responsive cytoprotective 
gene, namely Fth (Fig.1). The mechanism underlying the salutary effect of HO-1 
and presumably that of FtH against immune-mediated inflammatory diseases is not 
clear. We speculate that this might be related to our recent finding that free heme 
can sensitize cells in non-hematopoietic tissues to undergo programmed cell death, 
a deleterious effect that should promote the pathogenesis of a number of immune-
mediated inflammatory diseases (E Seixas et al., unpublished observation). 
Expression of HO-1 (E Seixas et al., unpublished observation) as well as FtH (R 
Gozzellino et al., unpublished observation) affords cytoprotection against heme-
driven programmed cell death, which should inhibit the pathogenesis of immune-
mediated inflammatory diseases. 
 
Concluding remarks 
It has been assumed that the broad protective effects of HO-1 are mediated 
essentially through its immunoregulatory effects exerted in cells of the innate (i.e. 
Mø, PMN cells, and DC) or adaptive (i.e. T cells) immune system. We have argued 
hereby that the immunoregulatory effects of HO-1 are exerted to a large extent via 
its cytoprotective effect in tissues, which should have important implications for our 
current understanding of not only the mechanisms of action of HO-1 but also of 
those underlying the pathogenesis of a variety of immune-mediated inflammatory 
diseases. 
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